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ABSTRACT 
Cross-over designs are frequently used in clinical 
trials, usually to compare two treatments. It has long 
been known that the simple two-period cross-over is 
adversely affected by the presence of carry-over effects, 
but it is nevertheless still commonly used. This thesis 
examines the problems caused by carry-over effects in 
detail and considers ways of overcoming these problems, 
either by using a more complex cross-over design, or by 
carrying out a more sophisticated statistical analysis. 
Only designs for comparing two treatments are 
considered, but analysis for continuous and binary 
variables is covered. 
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Chapter 1; Introduction 
1.1 Experimental Pesiin Cgnsiderations 
Science has progressed by proposing hypotheses which 
are then tested in controlled experiments. If a scientist 
wishes to demonstrate that a new procedure or treatment 
has a beneficial effect, an experiment to compare the new 
treatment with other possible treatments will be 
necessary. The simplest such experiment would involve the 
application of the new treatment to a set of experimental 
units, and the comparison of the outcomes for these units 
with those for a set of "controls". These "controls" 
would be another set of experimental units which are 
subjected to exactly the same conditions as the treated 
units except that they do not receive the new treatment. 
Thus the word "controls" in this context implies that 
differences other than the treatment under test are not 
allowed to affect the experiment. Clearly, a possible 
difference which could affect the experiment is 
variability in the experimental units themselves, and a 
desire to control this has lead to the common-sense idea 
of grouping the experimental units in blocks or pairs, 
within which they are as similar as possible. Although 
this works well in many cases, in some circumstances, 
particularly where the experimental units are animals or 
people, the process of identifying similar individuals is 
very difficult, or impossible. For example, in the study 
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of post-operative pain, not only is there great variation 
between individuals in the level of pain experienced, but 
experimenters have been unable to correlate the pain with 
other factors such as age, sex, disease etc., and so 
unable to predict the level of pain in order to match 
individuals. <Keats et al.(1950) For such cases, the idea 
of obtaining the equivalent of a paired comparison, by 
using "the subject as his own control" was devised, 
wherein the test and control treatments alternate in 
successive treatment periods, using the same experimental 
unit repeatedly. An experiment which uses a succession of 
treatments on each experimental unit in this way is 
called a change-over or cross-over design. 
1.2 Application of Cross-over Des1ins 
The purpose of matching or pairing is to increase 
the preciSion of the experiment by reducing the 
variability of the experimental units that are compared. 
Since an alternative way of increasing precision is to 
increase the number of experimental units in the treated 
and control groups, an alternative way of looking at the 
benefit of matching is that the same preciSion may be 
obtained with fewer observations. Cross-over designs have 
an immediate intuitive appeal because, by applying the 
treatments to the same experimental unit, it appears that 
we are ensuring that the experimental units are matched 
as exactly as possible, and that the potential benefits 
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of matching will be maximised. However, it is clear that 
this will only be the case if the treatments do not 
effect any permanent change to the experimental unit, so 
that, when subsequent treatments are applied, the 
experimental unit is in the same state as when the first 
treatment was applied. An example of this, and an early 
application of cross-over trials, is the effect of diet 
on milk yield in dairy cows. <Cochran, et al.[1941]) A 
diet may be expected to influence the milk yield. but 
would not be expected to cause any lasting physiological 
change to the cow. On the other hand. there may be 
external factors. such as the variation in milk yield in 
the cow's lactation cycle. or the natural diminution of 
pain with the passage of time in the case of post-
operative pain, which could affect the result of the 
experiment. In order to control factors such as these. a 
balanced design must be used so that any changes will 
affect each treatment equally. This requirement meant 
that early cross-over designs were based on latin squares 
with rows as treatment periods and columns as 
experimental units. 
1.3 Clinical Trials 
Although cross-over designs have been used in many 
fields of application, they are perhaps most commonly 
used in medical experiments. when comparing palliative 
treatments. One reason for this is the large variability 
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between subjects, and the difficulty in predicting how a 
patient will react to a treatment. Another reason is that 
it has often proved easier to relieve a symptom than to 
understand the underlying cause and cure the disease e.g. 
pain in arthritis, blood pressure in hypertension. 
Because of the importance of cross-over designs to 
clinical trials, this thesis will concentrate on this 
area of application, although the majority of the results 
would apply to cross-over designs generally. 
1,4 Carry-oyer 
Even if the treatments cause no lasting change to 
the experimental units, it is possible that their effect 
will not be confined to the treatment period in which 
they are applied. Thus a treatment may have some residual 
effect which carries over to subsequent treatment 
periods. If this happens then the apparent effect of 
subsequent treatments will be a combination of the direct 
effect of that treatment and any carry-over from previous 
treatments. Since it is likely that, in any future 
application of the treatments, only the best treatment 
will be used, the experimenter will be interested in the 
direct effect of treatments, and will wish to disentangle 
this from any carry-over effects. The possibility of 
carry-over effects is thus a major problem for cross-over 
designs, and will be considered in detail in chapter 2. 
At this stage it is sufficient to note that if carry-over 
4 
effects are present, the ideal of applying each treatment 
to an identical experimental unit cannot be achieved, and 
that,s1nce the potential benefits of cross-over designs 
depend on the approximation to this ideal, the 
consequences of carry-over effects can be far-reaching. 
It is thus important to be able to detect the presence of 
carry-over effects in a cross-over deSign, and to have 
some means of correcting or allowing for the problems 
that such effects can have on the data analysiS. Thus the 
problem of carry-over will be considered in detail 
throughout the thesis. 
1.5 The Two-perod Cross-oyer 
The Simplest cross-over design involves two 
treatments, A and B, and two treatment periods. In it, 
subjects are randomly assigned to one of two possible 
treatment sequences; either treatment A in period one 
followed by treatment B in period two, or the treatments 
in the reverse order. This Simple two-period cross-over, 
or GXG cross-over, has been an extremely popular design 
for clinical trials, and is still comonly used, 
particularly in trials of new therapeutic drugs by the 
pharmaceutical industry. Hills & Armitage[lQ7Q] give a 
simple explanation of the statistical analYSis of this 
design, but it will be n~cessary to consider this in 
greater detail, when it will be seen that carry-over 
effects are particularly difficult to deal with, because 
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it is not possible to estimate the size of such effects 
accurately. 
1.6 Hulti-period Cross-oyers 
In most cases, the statistical analysis of a cross-
over design will involve positing a linear model for the 
responses, in which the response is considered to be the 
sum of effects due to the subjects, periods .treatments 
etc. One reason the two-period cross-over has difficulty 
in coping with carry-over effects is that this model 
becomes too complex for the relatively small number of 
observations. An obvious remedy is to increase the number 
of observations by including extra periods. It is also 
possible to deal with more than two treatments in a 
crass-over design. As the number of periods and/or 
treatments increase, the number of possible treatment 
sequences increases, and it may become impractical to 
obtain observations on all possible sequences. The choice 
of which sequences are to be represented in the design is 
generally influenced by considerations of the balance 
that will be achieved, both in terms of which treatments 
occur in each period. and which treatments precede 
others. These considerations will be dealt with in more 
detail in chapter 3. 
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1.7 Analysis Considerations 
As with any experiment, the response variables used 
to measure the effect of the treatments in a cross-over 
design may be of various forms. They may be continuous, 
binary, categorical, or ordered categorical random 
variables, there may also be a single response variable 
of interest (univariate) or many (multivariate). Each 
type of data will, generally speaking, demand a different 
method of statistical analysis. Still greater diversity 
of methods is possible depending on the basis of the 
analysis method. Broadly, the analysis could employ 
classical parametric methods, non-parametric methods, or 
Bayesian methods. Host of the combinations of variable 
type and analysis method have been considered for the 
two-period cross-over, and Hills & Armitage[1979] refer 
at least briefly to many. A review of methods for binary 
data has been given more recently by Kenward & 
Jones[1987al. This thesis will consider the analysis of 
the two-period cross-over with continuous response 
variables in chapter 4, and the corresponding analyses 
for selected, more complex designs in chapter 5. The 
analysis of the two-period cross-over with binary data 
will be considered in chapter 6, with the corresponding 
analYSis for more complex designs being considered in 
chapter 7. More recently, a Bayesian analysis for the 
two-period cross-over has been given by Grieve[19851, and 
this form of analysis will be considered in chapter 9, 
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which will also consider the use of Gibbs sampling to 
perform a Bayesian analysis. 
1.8 Discussion 
Studies of the literature show that cross-over 
designs are still widely used, especially for clinical 
trials. Jones & Kenward[1989J report that a survey of the 
British Medical Journal between January 1980 and April 
1988 found over 80 reports of cross-over trials, most of 
which used the simple two-period design. They also report 
that a survey of 12 large pharmaceutical companies in the 
USA (Fava & Patel[1986J) identified 72 cross-over trials, 
over half of which used the simple two-period design. 
This confirms that, in clinical trials at least, the two-
period cross-over is still commonly used, in spite of 
of 
criticismsAits short-comings (see for example 
Brown[1980J). The aim of this thesis is firstly to 
consider ways in which the analysis of the two-period 
cross-over can be improved, for example by including 
baseline observations, and secondly to examine 
alternative cross-over designs which are more complicated 
than the two-period cross-over, but which give more 
powerful tests and better estimates of the treatment 
effects. 
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Chapter 2; Carry oyer 
2.1 Introduction 
In the previous chapter, the advantages of using a 
subject as his own control in a cross-over design were 
outlined. It was pointed out, however, that these 
advantages are the result of assumdng that the subject is 
in the same condition at the start of each treatment 
period. This will not be the case if treatments which 
have been applied in previous periods are still having 
some effect on the subject, so that the subject's 
initial condition is being modified by these carry-over 
effects. Thus the presence of carry-over effects can, at 
least partially, negate the apparent advantages of a 
crass-over design. It is certainly true that most of the 
problems associated with cross-over designs arise because 
of the possibility of carry-over effects, and that there 
would be few problems if it was known that carry-over 
effects were impossible. This thesis is concerned with 
ways of dealing with the problems caused by carry-over 
effects, so it is necessary to consider the nature of the 
problems that occur, and the ways in which carry-over 
effects can arise. The problems caused by carry-over 
effects will be illustrated by considering the simple 
two-period cross-over design, and the possible causes of 
carry-over effects will then be examdned. 
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2.2 The Two-period Cross-oyer 
In the two-period cross-over design, subjects are 
randomly assigned to one of two treatment groups. Those 
in the first group receive a period of treatment with 
treatment A, follwed by an equal period of treatment with 
treatment B while subjects in the second group receive 
the treatments in the reverse order (B then A). For the 
purpose of illustrating how the presence of carry-over 
effects alter the analysis, it will be assumed that a 
continuous response variable is measured at the 
conclusion of each treatment period. Then, following 
Hills & Armitage[19791, a linear model for the response 
variable can be set up. For the time being, it will be 
assumed that carry·-over effects are not present ,so that 
the model for YUk, the observation on subject j in group 
i for period k, will involve the following terms: 
~ = the overall mean 
WiJ = the effect of an individual subject 
Kk = the effect of a treatment period 
TL = the effect of a treatment 
and EiJk = the random error. 
wand E will be considered as random effects with 
variances ~i and ~i. The w's and E'S are independent, but 
the two observations on the same subject will be 
correlated, with COV <YlJl' YtJ2) = ~3. All the other terDIB 
are fixed effects, with the usual restrictions that Kl + 
K2 = 0 and TA + T. = O. Because of these restrictions, 
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reference to the presence of one of these fixed effects 
in the model should be taken to imply that there is a 
difference between the two levels of the factor. 
Applying this model gives the following expressions: 
for patient i in sequence 1 i 
period 1 : Yl11 = Jl + w, t + 'Jt, + TA + EU1 (2.2. 1) 
period 2: y112 = Jl + W,1 + 'Jt2 + Te + E 112 <2.2.2) 
for patient j in sequence 2i 
period 1: y2J 1 = Jl + W2,j + 'Jtl + Te + E2Jl <2.2.3) 
period 2: y2J2 = Jl + W2J + 'Jt2 + TA + E2J2 <2.2.4) 
Wri ting D'1 for the difference between the two 
observations on subject i in group one, (Yl1l - Yli2) and 
D2J for the corresponding difference for subject j in 
group two, it can be seen that E(Du ) = ('Jtl - 'J(2) + 
(TA - Te) and E(D2J) = (x, - X2) + (Ta - T,,) with var (D1i) = 
var (D2J) = 20'~ 
Du, D2J are within subject comparisons, being the 
comparison of the two observations on the same subject, 
and as such are less variable than a between subject 
comparison. Since observations on different subjects are 
uncorrelated. a similar between-subject comparison <e.g. 
Y1il - Y1J2) would have a variance of 2 (O'a + O'i). As the 
between subject variation O'a is usually larger than the 
within subject variation O'i, it can be expected that the 
11 
the between-subject comparison will have a variance that 
is more than twice that of the within-subject comparison. 
Clearly, if ~A = ~B, the expected values of O,i and 
D2J are equal, so that a two-sample test comparing the 0 11 
and the D2j gives a test of the hypothesis 'TA = 'Ta. If it 
is assumed that there are ni subjects in group i and that 
- - -Di. = (I:O li )/n, and D2, = (I:02j)!n2 ; ~(O" - 02,) gives an 
estimate of 'TA - 'TB which has a variance of 
2.3 Effect of Carry-oyer on the Kadel 
Carry-over effects are now introduced into the model 
with the term aL denoting the effect of treatment L in 
the period immediately following that in which it was 
applied. aA, a. are fixed effects, so the restriction 
aA + a. = 0 may be used. Once again, this restriction 
implies that, if carry-over effects are present, the 
carry-over effects of the two treatments are different. 
There will be no carry-over effects in the first 
period, so the expressions given above will still apply, 
but the expressions for the observations in the second 
period will now be as follows: 
for patient i in sequence 1 i 
period 2: yli2 = J.l + W,1 + 1£2 + 'T. + aA + E 112 (2.3. 1) 
for patient j in sequence 2j 
period 2: y2J2 = J.l + W2J + 1£2 + 'TA + all + E2J2 (2.3.2) 
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Wi th D, i, D2J defi ned as before, the expectati ons are 
now E (D, i) = (1t, - 1£2) + ('TA - 'T8) - aA and 
E(D2J) = (1t, - 1t2) + ('T8 - 'TA) - a8, so that, even if 'TA = 
'T8, the expectations are not equal and ~(Dl. - D2.) 
estimates (TA - Ta) - ~(aA - as). 
Grizzle[1965J showed by consideration of the least 
squares equations that the only way of testing the 
hypothesis TA = 'Ta, or obtaining an unbiased estimate of 
'TA - T8 is by using the observations from the first 
period only, which are unaffected by carry-over. It can 
be seen that E(YU1) = jJ. + 1[, + TA and E(Y2Jl) = jJ. + 1tl + 'Ta 
so that the two sets of observations have the same mean 
if TA = Te, and a two-sample test comparing the y1l1 and 
the y2Jl will test the hypothesis 'TA = Ta. Also, if y'.1 = 
(EY1il)/n" and Y2., = (IY2Jl)/n2, Yl.l - Y2.1 gives an 
unbiased estimate of TA - Ta with variance 
(O'a + O'i)«l/n,) + (1/n2)}. If the between-subject 
variation 0'3 is larger than the within-subject variation 
O'i, this variance will be more than four times as large 
as the variance of the corresponding estimate obtained by 
using the within-subject comparison when no carry-over 
was present. Hence the introduction of carry-over effects 
into the model prevents the use of each subject as his 
own control, and forces the experimenter to use only the 
first period observations, reducing the cross-over to a 
parallel design. This drawback of the two-period cross-
over has been known for many years, and in 1977 the 
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Biometrics and Epidemiology Methodology Advisory 
Committee (BEMAC) of the U.S. Food and Drug 
Administration produced a report criticising the use of 
the two-period cross-over in clinical trials on the 
grounds that the usual within-subject estimate of the 
difference between treatment effects is biased if carry-
over effects are present. Since there is no benefit in 
using the design if carry-over effects are present, the 
FDA advised that it should only be used if there was good 
reason to believe that carry-over effects would not be 
present. Despite this discouragement, the design has 
still been commonly used, at least in the U.K .. It may be 
that experimenters have disregarded the problem because 
they believe that carry-over effects can be avoided by 
judicious organisation of the experiment, or it may be 
that they have considered that, even if carry-over 
effects are present, useful information can be obtained 
from the first period observations. The belief that 
carry-over can be avoided depends partly on a 
misconception of the nature of carry-over effects, which 
will be discussed later in this chapter, while the 
ability to obtain an unbiased estimate of the difference 
between treatment effects depends on being able to detect 
the presence of carry-over. 
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2.4 Testing for Carryover 
Using the model with carry-over as above, the sum of 
the observations on each subject is calculated. For 
subject i in group one, S1:I = ylll + Y1i2, and for subject 
j in group two, S2J = y2J1 + Y2J2. Using the restrictions 
1t1 + 1t2 = 1'A + 1'. = 0, these have expectations E<Su) = 
2J.l + aA, E<S2J) = 2)J + as, and variances 40'a + 2cd. 
Clearly, S11 and SZJ have the same expectation if a ... = a., 
so that a two sample test comparing the Sll and the SZJ 
gives a test of aA = a •• However, this is clearly a 
between-subject comparison, and due to the large 
variances of S11 and SZ,1, the test will not be very 
powerful. The lack of power is emphasised by noting that 
the corresponding estimate of aA - a., obtained from 5" -
-Sz. where S" = <rS1:I)/nl and Sz, = <rSzJ)/nz, has a variance 
of <40'~ + 20'i) {(l/n,) + (l/nz»). If O'~~ > O'l, this 
variance will be more than three times that of the 
estimate of treatment differences from the first period 
only, and more than twelve times that of the estimate of 
treatment differences obtained from both treatment 
periods. The result of this is that small differences in 
carry-over effects may go undetected, and lead to the use 
of a test which is strictly speaking invalid, and the use 
of estimates for the difference between treatments which 
are biased, being contandnated with the undetected carry-
over effects. 
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It should also be noted that by comparing the sums 
of the observations on subjects in groups one and two the 
groups are in effect being compared. The linear model 
given above did not contain terms for the effect of the 
~ 
groups, although these are implicitly contained in the 
set of individual subject effects. The sum of squares for 
differences between subjects could be split into a sum of 
squares for differences between the groups, and a sum of 
squares for subjects within groups. Should there be a 
systematic difference between the two groups, this will 
be confounded with the carry-over effects. It is usually 
argued that, because subjects are allocated at random to 
the two groups, there should not be any systematic 
difference between them. However, it should not be 
forgotten that the groups are treated differently, by 
being given different sequences of treatments, and this 
might induce a difference between them. Any difference 
between the sequences would of course be confounded with 
differences between the groups, and would be detected by 
the test for carry-over given above. Thus the standard 
test for carry-over in the two-period cross-over is not 
only a weak test, but also a test which is not 
specifically aimed at the carry-over effect. 
2,5 The Nature Of Carry-over Effects 
The name "carry-over" suggests an effect of a 
treatment which is left over from the period in which it 
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was applied. The most obvious such effect would occur if 
a drug which had been applied in a previous period was 
still present in the body, and having some effect, in a 
subsequent period. Such carry-over is usually called 
"pharmacological", and must be very rare. Experimenters 
will as a rule be knowledgeable about the bioavailability 
of any drug they use, and ensure that such 
pharmacological carry-over will not occur. In some cross-
over trials, a wash-out period, in which no treatment is 
applied, is inserted between the treatment periods so 
that all trace of the drug administered previously will 
disappear. Experimenters can thus be confident that 
pharmacological carry-over can be avoided, and it may be 
that some have been too ready to extend this confidence 
to all forms of carry-over. 
If carry-over is not pharmacological in nature, it 
may be psychological. A particularly good, or bad, first 
treatment could change the subject's expectations about 
the second treatment, and subtly change their reaction to 
it. This is most likely to affect the results if the 
response.variable is an assessment by the patient of how 
he feels, but given the effects that can arise from 
placebo treatments, it would be unwise to dismiss the 
possibility of such psychological effects on objectively 
measured response variables. 
Although pharmacological and psychological carry-
over effects are the most straight-forward, they are by 
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no means the only possibilities for effects that can 
disrupt the simple analysis of a cross-over design. Any 
effect which alters the response of a given treatment 
administered at different times will do this. Considered 
thus, it is natural to regard such effects as treatment-
period interactions, and this has become the preferred 
description for researchers who wish to avoid the 
pharmacological and psychological implications of the 
term "carry-over". The more general nature of the term 
"treatment-period interaction" does indeed convey the 
sense that any effect causing differences in response to 
the same treatment at different times is to be included, 
and is more generally applicable to cross-over designs 
with more than two periods or more than two treatments. 
In the simple two-period cross-over, with two treatments 
and two periods, there will be one degree of freedom for 
treatment-period interaction, as there is for carry-over. 
Since these two effects are alternative ways of 
explaining how a treatment can have different effects in 
different periods, it is not surprising that they are 
completely equivalent to one another. For a more complex 
cross-over design with, say, three treatments and three 
periods, there would be four degrees of freedom for 
treatment-period interaction. Each of the three 
treatments could have a "first-order" carry-over effect, 
which would affect the treatment imDediately following, 
but these would only take up two degrees of freedom. The 
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other two degrees of freedom could then be accommodated 
by allowing the three treatments to have second-order 
carry-over effects, which would affect the treatment 
applied in two periods time. Thus first and second order 
carry-over effects together would be equivalent to 
treatment-period interaction. By including higher-order 
carry-over effects in the model in this way, an 
equivalent to treatment-period interaction oan be 
constructed for any cross-over design 
While the name carry-over has led people to think 
in terms of easily avoided pharmacological effects, the 
term treatment-period interaction has also induced a 
particular mode of thinking, leading some authors 
(e. g. Kenward & Jones[1987a]) to worry about breaching 
marginality rules (Nelder[1977, 1982]), by fitting the 
interaction without both of the main effects. If the 
effect is in fact a pharmacological or psychological 
effect which it is reasonable to regard as an effect of 
the previous treatment, there is no reason to consider it 
as an interaction and be worried about marginality. 
In addition, although treatment-period interaction 
seems to be a more general term, there are circumstances 
in which it does not seem appropriate. Consider, for 
instance, an experiment in which a wash-out period is 
inserted between the two treatment periods, and an 
observation is taken at the end of the wash-out period. 
If pharmacological or psychological carry-over is 
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present, this observation will be modified by that 
effect, so that it will be different from a baseline 
observation taken at the end of a run-in period. However, 
it does not seem sensible to talk of a treatment-period 
interaction in this case, because no treatment is applied 
in the wash-out period. 
Considerations such as this have led some authors 
<e.g. Huitson et al[1982]) to talk of both carry-over and 
treatment-period interaction, presumably meaning by 
carry-over those effects which can be thought of as being 
caused by the previous treatment, and by treatment-period 
interaction, any effects which cannot be directly 
ascribed to the treatment. Although it seems reasonable 
to draw a distinction in this way, the two sorts of 
effect are confounded. If the effect of a 
treatment is found to differ in the different periods of 
a cross-over design there will be no way of knowing 
whether this is due to "carry-over" from a previous 
treatment, or less specific treatment-period interaction. 
As it is impossible to differentiate between the two 
types of effect, and both have the same undesirable 
effect on the analysis, it is more usual to use only one 
of the two possible names for these effects, giving rise 
to the possibility of the mdsconceptions that seem to be 
inherent in the two appelations. 
20 
Chapter 3; Higher order Cross ayers 
3.1 Introduction 
In the last chapter, the consequences of carry-over 
effects on the two-period cross-over were examined. These 
were severe, and it is clear that, with carry-over 
effects in the model, the complexities are too great for 
the relatively small number of observations. An obvious 
way of attempting to cope with this problem is to 
increase the number of observations. The simplest way of 
doing this is to add baseline readings, which can be 
quite effective, as will be seen in chapter four. In this 
chapter the more radical alternatives of increasing the 
number of periods, sequences or treatments, or some 
combination of these, will also be considered. 
3.2 Increasini the NYmber Of Seqyences 
Given two treatments and two periods, there are two 
choices of treatment for each period and hence four 
possible sequences; AA, BB, AB and BA. It could be argued 
that only the sequences AB and BA are eligible for 
inclusion in a cross-over trial, because there is no 
change over from one treatment to another in the other 
two sequences. However, this seems unnecessarily 
restrictive. It would be qUite possible to arrange a 
trial with sequences AA and BB to mimic a cross-over 
trial, and, if the usual conditions for blindness were 
21 
met, the subject and physician would believe that the 
treatment in the first and second periods were different. 
It would then seem reasonable to regard such a trial as a 
cross-over trial, and to analyse it as though it were 
one, by using a linear model similar to that given in 
section 2.2. 
Clearly, a trial involving only the two sequences 
AA and BB would effectively be a parallel trial, and so 
is of little interest. However, a trial involving all 
four possible sequences, AA, BB, AB and BA would have 
useful properties. The observations taken at the end of 
the two treatment periods for subjects receiving the 
sequence AA or BB would be expected to be the same, 
except for differences in period effects, and any carry-
over effect. Thus these sequences will give information 
about the carry-over effects which will allow a better 
test of carry-over, and a within-subject comparison for 
treatment effects to be made. This assumes that the 
carry-over effect of a particular treatment is always the 
same, and does not depend on the following treatment in 
any way. The analysis of this design is considered in 
detail in chapter 4. It has been shown by Laska et 
al.[1983J that this deSign, with equal numbers in the 
four sequences, is the optimal two-period design, giving 
unbiased estimators of the treatment difference which 
have minimum variance, when carry-over is present. 
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3.3 Increasing the Number of Treatment Periods 
3.3.1 Introduction 
Even if a clinical trial is comparing two 
treatments, there is no reason why a design with more 
than two treatment periods should not be used. Clearly, 
as the number of treatment periods increases the number 
of pOSSible sequences increases, with 2 p sequences for p 
periods. Although an experiment could be carried out in 
which all possible sequences are represented, it is 
likely that it would be unnecessary or inefficient to do 
this. There is a long history of literature which 
considers the desirable properties of cross-over designs, 
often considering designs with more than two treatments, 
and methods of constructing designs with these desirable 
properties. As mentioned in chapter 1, it is frequently 
the case that the response variable will change with 
time, as with the variation in milk yield over a cow's 
lactation CYCle, or the diminution of post-operative pain 
with the passage of time, so that observations taken in 
different periods could be expected to be different. 
Experimenters realised from the outset that the presence 
of such period effects nec:essitated the use of a 
balanced design, in which each treatment occu~d equally 
often in each of the treatment periods. This could easily 
be achieved by using a latin square design with rows as 
treatment periods and columns as experimental units. 
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Where two treatments are involved, this balance can be 
achieved by using sequences which form complementary 
pairs. In such a complementary pair, one sequence can be 
obtained from the other by interchanging the two 
treatments <e.g. ABAAB and BABBA>. Thus the simple two-
period cross-over consists of a single complementary pair 
of sequences <AB and BA). If equal numbers of subjects 
are allocated to each of the two complementary sequences, 
the design is said to be "dual balanced" <Kat:thews[1987]). 
In general, experimenters will be reluctant to 
consider a large increase in the number of periods, as 
this would increase the length and cost of the 
experiment. Kershner & Federer[19811 have examined most 
of the possible designs with two,three and four treatment 
periods, comparing the variances of the estimates of the 
difference between treatments and first-order carry-over 
effects. Table 1 contains an extract from Kershner & 
Federer's results, giving the leading factors in the 
variances of the unbiased estimates of contrasts between 
the treatment and carry-over effects for various two-
treatment cross-over designs. Because Kershner & Federer 
use a model containing sequence, or group effects, their 
table indicates that estimates of the treatment and 
carry-over differences are not possible with the simple 
tWo-period cross-over. The table shows that the three-
period design with sequences ABB and BAA is particularly 
efficient in giving estimates with a relatively low 
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variance. This design is of particular interest. and will 
be dealt with extensively in this thesis. At this stage 
it is interesting to consider the properties that make it 
efficient. 
Table 1 Leading factors of the variances of unbiased 
estimators of contrasts between treatment and carry-over 
effects for various two-treatment cross-over designs. 
Design 
Sequences 
Leading factor of variance 
Treatments Carry-over 
------------------------------------------------------
AB.BA HE lfE 
AB.BA.AA.BB 8.00 16.00 
AAB.BBA 2.00 8.00 
ABB.BAA 1.50 2.00 
ABA.BAB 6.00 8.00 
AAB.BBA.ABB.BAA 1. 55 3.10 
AAB.BBA.ABA.BAB 3.00 6.00 
ABB, BBA, ABA, BAB 1. 85 2.46 
AAB,BBA,ABB, 
BBA,ABA,BAB 1. 85 3.18 
ABAB,BABA 5.50 8.00 
ABBB,BAAA 1. 38 1. 50 
AABB,BBAA, 
ABBA,BAAB 1. 00 1. 45 
(HE = not estimable) 
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3.3.2 Efficiency of three period Designs 
The eight possible sequences of two treatments 
in three periods form four complementary pairs: AAA,BBB; 
AAB,BBAj ABA,BAB and ABB,BAA. The first of these pairs is 
effectively a parallel design, and will not be 
considered, leaving three possible designs, each 
consisting of one complementary pair. Clearly, each of 
these is unbalanced in so far as each subject does not 
receive an equal amount of time on the two treatments, 
but there is nothing to choose between the three in this 
respect. It is thus necessary to consider how first-order 
carry-over affects the three possible designs. In the 
first pair (AAB,BBA) subjects in sequence one only 
experience carry-over from treatment A while those in 
sequence two only experience carry-over from B. Thus 
carry-over will be confounded with sequences, and, 
because one treatment is more associated with each 
sequence, it could be expected that the tests for carry-
over and treatments would be correlated. This can in fact 
be shown to be the case. 
In the second pair (ABA,BAB) first-order carry-over 
from A & B occurs in each sequence, but carry-over from A 
always acts on B and vice versa, suggesting that, for 
this design also, tests for treatment and carry-over will 
be correlated. This can also .be shown to be true. The 
third pair (ABB,BAA) has neither of these problems, both. 
sequences experiencing carry-over from each treatment, 
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and each carry-over acting on each of the treatments. 
This is the design that is particularly efficient, and it 
can be shown that the tests for treatments and carry-over 
are independent. The analysis of this design will be 
considered in detail in chapters 5,7 and 9. 
3.3.3 Properties of Efficient Designs 
Although it is relatively easy to see that the ABBi 
BAA design is free from the deficiencies of the 
alternatives, it is less easy to see what properties it 
has that are characteristic of efficient designs. In 
one of the earliest papers on cross-over designs, 
Cochran, et al.[1941] not only realised that period 
effects meant that treatments should appear equally often 
in each period, but also that the possibility of carry-
over effects imposed the need for another sort of 
balance, in which each treatment was preceeded by each 
other treatment equally often. The design they employed 
consisted of two 3x3 latin squares giving six sequences: 
ABC, BeA, CAB, ACB, BAC, CBA. It can be seen that, in 
this design, each treatment occurs twice in each of the 
three periods, and is immediately preceeded twice by each 
other treatment. The design allows a correction for 
possible carry-over effects to be made, but the authors 
point out that with two treatments, "to obtain direct 
information on carry-over effects ... it would be 
necessary to include units rec~~ving the sequences AA & 
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BB, as well as units receiving the switch-over sequences 
AB & BA". 
Later authors generally took for granted that the 
two sorts of balance mentioned by Cochran, et al. were 
desirable, and sought to give rules by which designs with 
such balance could be obtained, although some extended or 
specialised the balance requirements. Thus 
Williams[1949,1950J considered designs balanced for pairs 
of residual (i.e. carry-over) effects, while 
Berenblut[1964,1967,1968] considers designs which are 
balanced for the linear component of the carry-over 
effects, for a quantitative factor at equally-spaced 
levels, and more recently, designs for use with 
autocorrelated errors have been considered (Bora[1984J, 
~ews[1987J). 
A typical set of conditions for the construction of 
cross-over designs is due to Patterson[1952J. Patterson 
was considering designs with more than two treatments, 
but it is nevertheless interesting to consider his 
conditions in respect to the three designs outlined 
above. Patterson gave seven conditions, the first three 
of which he considered ne'~essary if carry-over effects 
were not present, with all seven to be used if carry-over 
was present. His conditions are as follows: 
I. Ho treatment occurs in a given sequence more than 
once. 
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II. Each treatment occurs in a given period an equal 
number of times. 
III. Every two treatments occur together in the same 
number of sequences. 
IV. Each ordered succession of two treatments occurs 
equally often. 
V. Every two treatments occur together in the same 
number of curtailed sequences, formed by omitting the 
final period. 
VI. In those sequences in which a given treatment 
occurs in the final period the other treatments occur 
equally often. 
VII. In those sequences in which a given treatment 
occurs in any but the final period, each other treatment 
occurs equally often in the final period. 
Condition I is clearly not met by any of the three 
designs being considered, while conditions II and III 
are met by them all, and would be met by any design 
using sets of complementary sequences. Condition IV also 
appears to be met by all three designs, as, given 
condition I, Patterson clearly meant by "ordered 
succession of two treatments" a succession of two 
different treatments. This reflects the earlier 
requirement of Cochrane et al. for each treatment to be 
preceeded equally often by each other treatment. As noted 
earlier, Cochrane et al. also realised the need for 
sequences AA & BB if carry-over effects are to be 
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estimated, but in spite of this, it was not until the 
paper on extra-period latin sqare designs by Lucas[1957J 
that the advantages of a treatment preceeding itself as 
often as other treatments preceeded it was generally 
appreciated. 
In an extra-period latin square design an extra 
period is added, and the final treatment repeated. With a 
2x2 latin square this results in the design with 
sequences ABB & BAA. Lucas pOints out that first-order 
carry-over effects and treatment effects are then 
orthogonal. This idea was later combined with Patterson's 
rules in a joint paper <Patterson & Lucas[1959]), but it 
is only necessary to interpret Patterson's Condition I 
more liberally, to include any possible ordered pair of 
treatments i.e. AA, BB, AB or BA, to obtain the benefit 
of this insight. The design with sequenc~s ABA & BAB does 
not satisfy the condition as the successions AA & BB do 
not occur. The other two designs do, however, satisfy the 
modified condition. Of these two designs, that with 
sequences AAB & BBA does not satisfy any of Conditions V, 
VI and VII, while the efficient design, with sequences 
ABB & BAA, satisfies all three. The design with sequences 
ABA & BAB, which does not satisfy the modified Condition 
IV also satisfies these last three conditions. Thus it 
seems that, for a design consisting of sets of 
complementary sequences, a good design will satisfy the 
modified Condition IV and Conditions V, VI and VII. It is 
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interesting to note that the design with the four 
sequences AA, BB, AB and BA also satisfies these four 
conditions, except that truncated sequences only consist 
of one period so that condition V is redundant. 
3.3.4 Optimal Desi~ns 
In determining the optimum cross-over designs, 
giving the best <minimum variance> linear unbiased 
estimators of the difference between treatments and 
first-order carry-over effects, Laska et al.[1983], Laska 
& Keisner[1985l also give conditions that will be met by 
optimum designs. These conditions relate to ideas of 
"uniformity" and "balance" that the authors define. A 
design is said to be "uniform on the periods" if, in each 
period, the same number of patients are assigned to each 
treatment; and "uniform on the patients" if, for each 
patient, each treatment appears in the same number of 
periods. A "uniform" design is one which is uniform on 
the periods and on the patients. A design is defined as 
"balanced" if each treatment is preceded by each of the 
other treatments equally often, and "strongly balanced" 
if each treatment is immediately preceded by each of the 
treatments, including itself, equally often. It is then 
stated that a strongly balanced uniform design will be 
optimal whether or not first-order carry-over effects are 
present, and whether or not baseline observations are 
taken. Clearly designs with an odd number of treatment 
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periods cannot be uniform on patients, so that no such 
strongly balanced uniform design exists. However, the 
authors also state that, in these circumstances, if the 
truncated design is a strongly balanced uniform design, 
and the final treatment in each sequence is the same as 
the penultimate treatment, the design will be optimal, 
again, whether or not first-order carry-over effects are 
present and whether or not baseline observations are 
taken. These rules can be used to show that for two 
periods and two treatments the design with the four 
sequences AA, BB, AB and BA is optimal, and that with 
three periods and two treatments, the design with the two 
sequences ABB and BAA is optimal. 
It should be noted that designs consisting of sets 
of complementary pairs of sequences will be uniform on 
periods if the same number of subjects are allocated to 
each sequence in a complementary pair, while the concept 
of strong balance is effectively equivalent to 
Patterson's Condition IV, as modified above. Patterson's 
Conditions V,VI and VII are necessary to cope with 
designs with an odd number of treatment periods, and are 
approximately equivalent to Laska's second rule. It 
should also be remembered that, in a design with more 
than two treatment periods, first-order carry-over alone 
is not equivalent to treatment-period interaction. If 
treatment-period interaction, or the equivalent set of 
higher-order carry-over effects, was included, the rules 
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for optimality might need to be modified. Lucas[1957] 
suggested that "more than one extra period may be called 
for when residual <i.e. carry-over) effects are assumed 
to continue for more than one period" 
3.4 Designs to Cpnsider Further 
In the remaining chapters of this thesis four 
designs have been singled out for detailed examination. 
The first of these is the simple two-period cross-over, 
which is the design that has been most commonly used in 
clinical trials, and is included as a comparison for the 
other designs. The second design is the one identified 
by Laska et al. as the optimum two-period design, with 
four sequences AA. BB. AB and BAi while the third is 
their optimum three-period design, with two sequences ABB 
and BAA. As has already been mentioned, only first-order 
carry-over effects were considered in identifying this as 
the optimum three-period design. and, by analogy with the 
two-period case, it might be expected that the design 
with four sequences AAA, BBB, ABB and BAA, ndght prove 
best if higher-order carry-over is included to obtain 
equivalence with treatment-period interaction, and this 
three-period, four sequence design is included in the 
detailed study. It is also clear that this design, and 
the two-period design with four sequences, are 
effectively a combination of a parallel and a cross-over 
design. It will thus be useful to investigate whether the 
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combination is an improvement over the parallel or cross-
over designs separately. 
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Chapter 4; Classical Analysis for Continuoys Response 
Variables; Two-period Desiins 
4.1 Introdyction 
In the previous chapter, four cross-over designs 
were identified as worthy of further study. These are the 
simple two-period cross-over, included mainly for 
comparison with the other designs, the "complete" two-
period cross-over, consisting of all four possible 
sequences: AA, BB, AB & BA; the three-period design with 
sequences ABB & BAA, identified by Kershner & Federer as 
being efficient; and the three period design with 
sequences AAA, BBB, ABB & BAA, which combines the 
features of this design and the parallel design. In this 
chapter and the next, the analysis of these designs will 
be considered assuming there is a single response 
variable which is a continuous random variable. The 
analysis of the above two-period designs will be 
considered in the present chapter, while the three-period 
designs will be dealt with in chapter 5. Classical, as 
opposed to Bayesian methods are considered in these 
chapters. The tests available in the classical framework 
could be parametric, mainly t-tests, or non-parametric 
eqUivalents to t-tests such as the Mann-Whitney U-test. 
Bayesian methods, and methods for response variables 
which are not continuous, will be considered in later 
chapters. 
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The linear model which will form the basis of the 
analysis in this chapter was introduced in chapter 2, and 
the Simple analysis of the two-period cross-over has also 
been given in that chapter. In the present chapter this 
analysis will be extended to cover the situation where 
baseline observations are available, and corresponding 
analyses will be given for the three other designs. 
4.2 The Simple Two period Cross oyer 
Analysis of the two-period cross-over was considered 
in section 2.1, and will not be repeated here. However, 
it is necessary to consider how the analysis can be 
improved by the inclusion of baseline measurements. The 
term "baseline" is used here to mean an observation taken 
at the start of a clinical trial, before treatment 
begins. It should be noted-that some authors use the term 
in a rather different way. When Kershner & Federer[19811 
compare two-treatment cross-over designs, they consider 
the designs with and without baselines, but take "with 
baselines" to mean that each observa.tion for a treatment 
period is preceded by a "baseline" observation. This is 
also the case in the paper by Kenward & Jones[1987bl 
covering the analysis of the simple two-period cross-over 
when "baseline" measurements are available. In this 
thesis, only the observation preceding the first 
treatment period will be called a "baseline", and an 
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observation between the first and second treatment 
periods will be called a "washout" observation. 
Using the linear model outlined in chapter 2, 
expressions can be written down for the baseline 
observations, Ytjo. As no treatment is applied in the 
baseline periods, these expressions will not involve a 
treatment effect, but only a period effect, labelled ~o. 
a subject effect ~lj, and an error term €tjO. The extra 
information in the baseline observations allows the model 
to be complicated by the introduction of group or 
sequence effects ~, and ~2. The individual subject or 
patient effects Wu must be regarded as deviations from 
the sequence effects, so that the sum of the patient 
effects within each group is zero. The sequence effects 
will be regarded as fixed effects, with the restriction 
~, + ~2 = 0, while the patient effects will again be 
regarded as random effects. Using T~, T. and aA, a. to 
represent the treatment and carry-over effects in the 
model, the expressions for the observations are: 
for patient i in sequence 1i 
baseline: yl to = }l + 'VI + w, t + ~o + € 1 to 
period 1 : y" 1 = }l + 'VI + Wll + X, + TA + € 1t I 
period 2: ylt2 = }l + 'VI + Wll + X2 + T. + a~ + € 1 12 
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for patient j in sequence 2; 
baseline: y'lJO = J.l + 'Y'l + W'lJ + 110 + e'lJO 
period 1: y'lJ 1 = J.l + 'Y2 + W2J + 111 + 'fa + e 2J 1 
period 2: y'lJ2 = J.l + 'Y2 + W2J + 112 + 'fA + a. + e 2J2 
.. 4.2.1 
The expected values of the baseline observations 
for the two sequences differ only in the sequence or 
group parameters, so that using a two sample test to 
compare the two sets of baseline observations will test 
whether there is any systematic difference between the 
two groups, or whether the random allocation of subjects 
to the two groups has been succ~sful in avoiding such a 
difference. This test would probably be the first carried 
out on a data set of this type, since one would normally 
wish there to be no significant difference between the 
groups. The sequence of tests would probably continue by 
testing for carry-over, as the test for treatments will 
depend on whether there is significant carry-over. The 
presence of baseline measurements allows a better test of 
carry-over. The combination E 1J = 2yl.10 - yUl - Y132 has 
expected value <2xo - x, - 112) - aA for sequence 1 and 
<2110 - x, - 111) - a. for sequence 2. Thus a comparison of 
the two sets of combinations Ell and E2J using a two 
sample test will test whether there is any difference in 
the two carry-over effects. The EtJ's are of course 
Within-subject comparisons, from which the individual 
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subject effects have been eliminated, so that this test 
of carry-over will be more efficient than the one given 
in section 2.1. This can be seen by considering the 
variance of the estimate of the difference in carry-over 
effects aA - a. which can be obtained from the EiJ'S. 
-liri ting E,. for the average of the nl Elt values and Ez. 
for the average of the nz EZJ values, Ez. - El. is an 
unbiased estimator of aA - a. with variance 
6~i{1/nl + 1/nz}. It can be seen from table 2 below that 
this is only smaller than the corresponding variance for 
the estimator given in chapter 2 if the within-subject 
variation ~i is smaller than the between-subject 
variation, ~~, but this will normally be the case. 
If there is a significant difference in the carry-
over effects, the data from the second period must be 
discarded, but it is still possible to obtain a within-
subject comparison between the baseline and first-period 
observations which can be used to test for a difference 
between the treatment effects. Writing Fu = y"0 - y111 
and F2J = yZJO - yZJ 1, it can be seen that the expected 
value of Fit is ('Jto - 'Jtl) - 'h, while the expected value 
of FZJ is ('Jto - 'Jtl) - 'T., so that a two sample test 
comparing the two sets of F's will test for difference 
between the treatment effects, while the corresponding 
-
-estimate of 'T" - 'h is F2. - Fl., where Fi. is the mean of 
the ni FiJ values. This estimate has a variance of 
2 ~ i { 1/ n 1 . + 1/ n2} . 
39 
If the test for carry-over is non-significant, so 
that the data from the second treatment period need not 
be discarded, the usual test of treatment differences 
using the contrast of the two treatment periods in the 
two sequences given in 2.1 can be used. It can be seen 
from table 2 that this test yields an estimate of the 
treatment difference that has a variance of one quarter 
of that given by the comparison of the baseline and 
first-period observations. It is thus still very 
benefiCial for there to be no carry-over in the 
experiment, although since the test of carry-over is more 
powerful with baseline data, there will be less 
likelihood of making an error which leads to the use of 
the inappropriate test for treatments. The position is 
still complex, however, as will be seen when the question 
of power is examined in chapter 8. 
If there is no carry-over, the estimate of the 
treatment difference based on the F's is of course still 
valid, and it might seem possible to obtain a still 
better estimator by combining the estimates based on the 
D's and the F's. This is not possible, however, because 
the two estimators are positively correlated, and the 
variance of a combined estimator will be larger than that 
based on the D's only. On the other hand, if carry-over 
is present, the estimator based on the D's will be 
biased, having an expected value of ~A - ~. - ~<aA - a.>. 
Since aA - a. can be estimated from the E's, it might 
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seem possible to correct for the bias in the D-estimator, 
and obtain an unbiased estimator. This would be 
- -* (DI. - D2.) + ~ (E2. - E,.). However, this merely reduces 
to the F-estimator F2. - F,. 
Table 2 variances of estimators for the two-period cross-
over design. 
Estimators of TA - Ta 
Combination Estimator Variance( I) 
---------------------------------------------------------
DI.I = ytJI - ytU M!O'~ (2) 
-Yl.l - Y2.1 
Fu = ytJO - ySJl -Fl. 
Estimators of Ch - a. 
Combination Estimator Variance< 1) 
---------------------------------------------------------
StJ = ySJl + YSJ2 40'i + 20'i 
Eu = 2YtJO - ytJ 1 - YiJ2 6 2 0'. 
Hotes: ( I ) all variances are multiplied by {l/n, + l/n2} 
(2) this estimator is only unbiased if there is no 
difference in carry-over effects 
Although adding baseline observations is a very 
Simple modification of the usual analysis of the two-
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period cross-over design, it nevertheless much improves 
the efficiency of the two period croes-over by allowing a 
within-subject comparison to be used for the test of 
carry-over, and for treatments if carry-over is 
significant. Table 2 gives the variances of estimators 
which may be used with the two-period cross-over, from 
which the improvement gained by the use of baselines can 
be seen. 
Sometimes an experiment is organised with a washout 
period in between the first and second treatment periods 
in order to avoid pharmacological carry-over. The 
opportunity then exists for a second "baseline" 
observation to be taken at the end of the washout period, 
before the second treatment period begins. To avoid 
confusion this will be referred to as the washout 
observation. It is clearly possible to write down an 
expression in the form of a linear model for this washout 
observation, although there is some debate about how the 
effect of carry-over should be parameterised. It seems 
clear that the treatment applied in the first period 
could have some effect on the response recorded as the 
washout observation, so that the model for the washout 
observation should include a carry-over term. It seems 
equally uncontroversial to assume that there will be no 
carry-over from the wash-out period itself to the second 
treatment period, as no treatment is being administered 
in the washout period. However, it may be that the 
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treatment given in the first period could still have an 
effect on the second treatment period, although this may 
well not be the same effect as was observed in the 
washout period, or would have been observed if the second 
treatment period had immediately followed the first. In 
order to allow for this the terms aA and a. will be used 
for carry-over effects from one period to the next i.e. 
from the first treatment period to the washout period, 
and ~A, ~8 for carry-over from the first period to the 
second treatment period, when these are separated be a 
washout period. In order to retain the second treatment 
period as period two, the wash-out period between the two 
treatment periods will be labelled period 1'. The 
expressions for the washout and second treatment period 
observations are then: 
for subject i in sequence 1: 
washout: Yl11' = }! + '¥1 + tl)11 + 1(1' + aA + el11' 
period 2: y1l2 = }! + '¥ 1 + tI)" + 1(2 + Ta + ~A + e HZ 
for subject j in sequence 2: 
washout : yZJ1' = }! + '¥Z + tl)ZJ + 1(1' + a. + eZH' 
period 2: Y2U = }J. + '¥2 + c,.)2J + 1(2 + 'TA + ~a + €ZU .. 4.2.2 
Tests for differences in both types of carry-over in 
the model are possible using within-subject comparisons. 
The test of aA = a. = 0 can be made by means of the 
43 
wi thi n-su bj ect comparison F' tj = YtjO - Ytj 1'. The expected 
value of this comparison for the two sequences is: 
E{F',j} = (1[0 
E{F'2J} = (1[0 
Hence, a two sample test comparing the two sets of F' 
values is a test of aA = a.. Similarly, a test of the 
hypothesis ~A = ~B = 0 can be made by using the within-
subj ect comparison Et.t = 2ytJo - Yi.1l - yua. This has the 
following expected values for the two sequences: 
E{E,j} = (21[0 - 1[, - 1(2) j3A 
E {E2J } = (21[0 - 1[1 - 1[a) - .13. 
So that a two sample test comparing the two sets of E's 
will test the hypothesis ~A = ~B. It is only if this 
second test is significant that the data from the second 
treatment period must be discarded, since only the ~ 
terms feature in the model for the second treatment 
period. However, many experimenters would be inclined to 
regard the carry-over to the second treatment period as a 
diminished version of the carry-over into the washout 
period, i.e. to regard the ~ terms as some unknown 
fraction of the a terms. Given this view, an experimenter 
would tend to be somewhat unhappy about the data from the 
second treatment period if the test for difference in the 
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a's was significant even if the test for the ~'s was not, 
taking this as an indication that carry-over is present 
in the experiment, but cannot be detected in the second 
treatment period data. From table 2, it can be seen that 
the estimate of aA - aa, obtained from the EtJ's, is much 
more precise than the estimate of ~A - ~a, obtained from 
the Fu'sj the variance of the former estimator being one 
third of the latter. This difference in precision will 
also be reflected in the power of the corresponding 
tests, so that a difference in first-order carry-over is 
much more likely to be detected than a difference in 
second-order carry-over. 
4,3 The "Complete" Two-period Cross Oyer 
The design with four sequences AA, BB, AB, BA is 
also one of those considered by Kershner & Federer[19811 
while more recently, Husler & Lienert[1985J have 
considered its merits. The design is, in fact, a special 
case of a class of designs considered by Balaam[1968]. 
Husler & Lienert refer to the design as an "incremental" 
cross-over design to emphasise that the analysis of the 
design involves examining the difference between the 
first and second period observations for the four 
sequences. The parameters used in the linear model for 
the simple two-period cross-over can be employed again to 
write down expressions for the observations in this 
design. The only change will be that there are now four 
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sequences and so four sequence effects ~l, .. , ~,. It 
should perhaps be emphasised that it will be assumed that 
carry-over effects depend only on the treatment in the 
preceding period and not on the treatment in the period 
being affected by the carry-over. Thus the sequences AA 
and AB will experience an identical carry-over effect of 
a" in the second period. 
As is emphasised by HUsler & Lienert's name for the 
design, data analysis is facilitated by considering the 
difference D1J = ytJl - YtJ2 for subjects in each of the 
four treatment sequences. By taking this difference, the 
individual subject effects W1J are eliminated, as well as 
the mean ~ and sequence effects ~1. Defining sequence 1 
to be AA, sequence 2 BB, sequence 3 AB, and sequence 4 
BA, the expressions for the expected value of the 
differences, are: 
,..> - a" 
,..> - a. .. 4.3.1 
-Defining 01, to be the average of the n1 Ou values, 
- -it is clear that E{D3, - Dl,} = ,." - '1'., and 
E{D" - D2 ,} = - ('1'A - ,..>, while E{02, - Dl,) = alii - a •. All 
of these estimators are of the same form, and hence have 
similar variances, the variance of '01, - DJ , being 
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20' i < 11 n 1 + 1/ nJ > • 
It would be natural to combine the two estimators of 
TA - T. in an attempt to obtain an estimator with a 
smaller variance, by forming a weighted average of the 
two estimators, with weights inversely proportional to 
their variances. This yields the estimator 
C = {(1/n2 + l/n .. HDa. - D,.l + (lin, + l/n3)[D2. - D ... ]}/c 
where c = lin, + l/n2 + lin, + lin .. , and the variance is 
var(C) = {2o-~(1/n2 + lin .. > (lin, + l/n3)}/c 
It is interesting to examine how many subjects 
should be allocated to the four sequences to minimise the 
variance. It might be expected that equal allocation to 
each of the four sequences would achieve the minimum 
variance. If n subjects are allocated to each sequence 
<1. e. n, = n2 = n3 = n .. = n) the variance reduces to 
2o-i(1/n). In terms of the total number of subjects, 
N (=4n) , the multiplier of the 2o-j term is 4/N. If the 
same N subjects were allocated equally to sequences 1 
<AA) and 3 (AB) only, i.e. N/2 subjects to each of these 
two sequences, and none at all to sequences 2 and 4, the 
estimator of TA - T. would be D3. - D,., and the DlUl t1plier 
of the 2~j would again be 4/N. As the estimator from 
sequences 2 (BB) and 4 (BA) has the same variance, this 
variance could also be achieved by allocating B/2 
subjects to sequences 2 and 4, and none to sequences 1 
and 3. 
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It is interesting that the allocation of subjects 
considered above gives estimators with the same variance 
as equal allocation to all four sequences even though the 
number of subjects allocated to complementary sequences 
(AA and BB, AB and BA>, are not the same. In fact, if the 
N <=4n) subjects are allocated subject only to the 
restriction that the complementary sequences receive 
equal numbers of subjects, i.e. m subjects on each of the 
sequences AA & BB, (nl = n2 = m) and 2n-m on each of the 
sequences AB and BA, (na = n. = 2n-m) the variance of C is 
2~in/{m(2n-m)} which is always larger than 2~i(4/H) 
unless mFn. 
If the number of subjects in complementary sequences 
is made unequal, with nl (AA) = m, n2 (BB) = 2n-m, n3 (AB) 
= m, n. <BA) = 2n-m, the variance of C is again 2~f(4/N). 
The minimum variance is thus achieved by having equal 
numbers of subjects in sequences 1&3, and 2&4, but, with 
this restriction, it does not matter how the subjects are 
split between these two sets of sequences. It thus 
appears that a design consisting of the two sequences AA 
and AB would be a useful deSign, as it will give a within 
subject comparison for the treatment difference TA - Ta. 
The design will not allow an estimate of the difference 
in carry-over, but this is only a problem if carry-over 
is of interest in its own right, as the estimator of the 
treatment difference is not affected by carry-over. The 
design may seem rather odd, because of its unbalanced 
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nature, but if treatment A is a standard treatment and 
treatment B a new treatment, the design reflects the 
options open to the physician - continue with the 
standard, or change to the new. Although this design 
looks interesting and relatively efficient, it is in fact 
very similar to a standard parallel design, with a tl run-
in" period where both sets of subjects are treated with 
the standard treatment A. 
4.3.1 Baseline Observations 
It was noted in 4.2 that the addition of baseline 
observations to the simple two-period cross-over had a 
beneficial effect on the deSign, and it is thus of 
interest to investigate whether baselines have a similar 
beneficial effect on the complete two-period deSign, or 
on the AA, AB design which is derived from it. As 
before,the linear model will be modified by the 
introduction of a "period zero" effect, lto, and 
expressions for the baseline observations written down. 
As the combination EiJ = 2YiJO - YUl - yiU was useful 
when baselines were present in the simple two-period 
deSign, consideration of this combination for each of 
the four sequences may be beneficial. The expected value 
of the combination in the four sequences is given below: 
E{E1J} = (2xo - Xl X2) - 2'T" - a" 
E{E2J} = (2xo - 1(1 - X2) - 2'TI - a. 
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4.3.1.1 
-Defining E,. as the average of the n, E'J values, it 
is clear that E3, - E" has expected value 2'TA and E" - E2, 
has expected value 2'T.. Since 'TA and 'T. are fixed effects 
with the restriction 'TA + Ta = 0, 2'TA and -2'T8 are 
equivalent to the difference 'TA - Ta. Thus, two new 
estimators of the treatment difference can be obtained by 
using the baseline observations. However, it should be 
noted that the variance of an EiJ combination is 6~~, as 
against 2~i for a D1J combination, so that an estimate of 
the treatment difference based on the D's will have a 
smaller variance than one based on the E's. However, if 
baseline observations are available, two unbiased 
estimators of the treatment difference, based on the D's 
and E's respectively, are possible so that it would make 
sense to combine the estimates. A consideration of the 
co-efficients in the D and E combinations shows that they 
are orthogonal contrasts, since the multipliers of the 
period 0,1 and 2 observations are 0,1,-1 and 2,-1,-1 
respectively. Thus the combination can be expected to 
produce an estimator with reduced variance, unlike the 
situation with the simple two-period design. It can be 
seen from the variances above that the estimator based on 
the E's has a variance which is three times as large as 
that based on the D's, so in combining the two estimates 
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~(D-estimate) + ~(E-estimate) will be used. Since both 
the D's and the E's are linear combinations of the 
observations, it is not surprising that the combination 
of the two estimators can be simplified, to a third 
linear combination GiJ = yiJO + YU1 - 2YlJ2. The expected 
value of this combination for each of the four sequences 
is as follows: 
E{G1J } = <xo + Xl -2X2) - 1"A - 2aA 
E{G2J } = <Xo + Xl -2X2) - 1". 2a. 
21".> 
.. 4.3.1.2 
Gu is clearly a within-subject comparison and has 
a variance of 6cr~. Defining G,. to be the mean 
of the ni GI.,t values, ~<G3. - (}1.> and ~(G2. - G4.> are 
unbiased estimators of the treatment difference 1"A - Ta, 
with variances that depend on the number of subjects in 
each sequence in exactly the same way as the previous 
estimators based on the D's in 4.2. Hence, as with the 
combination of the D-estimators, the combination of the 
two G-estimators will have minimum variance when nl = n3, 
and n2 = n4. Once again, this optimum is reached if only 
the sequences AA and AB are used. If there are N/4 
subjects in each of the four sequences, or N/2 in 
sequences 1 and 3 and none in sequences 2 and 4, the 
variance of the estimator will be (6/N)cr~, compared to 
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(8/N)~j for the estimator based on the D's. 
It is of course possible to test the hypothesis that 
~A = T. by comparing the estimate of the difference with 
the estimate of the variance of the difference via a t-
test. 
4.3.2 Washoyt ObseryatioDs 
As with the simple two-period design, it would be 
possible to insert a washout period between the first and 
second treatment periods, and to take a washout 
observation before the second treatment begins. It is a 
simple matter to extend the model used for the simple 
two-period design to the complete two-period design, with 
the washout period being designated period 1', carry-over 
effects aA, as affecting the washout observations, and ~A, 
~. affecting the observations for the second period. As 
with the simple two-period deSign, the washout 
observations are of little use apart from allowing the 
estimation of aA - a., which is unlikely to be of 
interest, except as an indication that carry-over is 
present in the experiment. The estimation of TA - T. is 
affected by the ~'s. 
Except for ensuring the absence of pharmacological 
carry-over, and providing a way of checking whether 
carry-over is present in the experiment by testing for 
first-order carry-over (a's), there seems little point in 
taking washout observations. 
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4.4 Reyiew and Preview 
It has been seen that the addition of a single 
baseline observation, before the first treatment begins, 
is extremely beneficial in two-period cross-over designs. 
This fact does not seem to have been widely publicised, 
and many authors have concentrated instead on the 
situation where a "baseline" observation is taken before 
each treatment period (i.e. a combination of "baseline 
and "washout" observations in the terminology used here). 
This strategy has been seen to be less helpful, and 
possibly even detrimental, as it makes the interpretation 
and modelling of carry-over more awkward. The "complete" 
two-period cross-over has also received relatively little 
attention in the literature, even though it is simple, 
and a marked improvement on the standard two-period 
cross-over. The author is not aware of any literature on 
the two sequence AA AB design derived from this 
"complete" design, even though this appears to be useful. 
Certainly, if a standard and new treatment are to be 
compared, this design seems a likely candidate, 
deSignating the standard treatment as treatment A. It 
could be argued that the design is effectively a parallel 
design with a run-in period, although this has less force 
if the first period is preceded by a baseline 
observation. In any case by treating it as a cross-over 
design, the analysis will almost inevitably be different 
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from that which would be applied to a parallel design. 
and arguably, more informative. 
In the next chapter the two three-period designs 
which appear to be useful will be considered in a similar 
way to the above. 
54 
Chapter 5; Classical Analysis for Continuous Response 
Variables; Three Period Designs 
5.1 Introduction 
Analysis of the two two-period designs of interest 
was considered in chapter 4, including consideration of 
the effects of baseline and washout observations on the 
analysis. In this chapter, the analysis of certain three-
period deSigns 1s considered. 
5.2 The TWO Sequence Desi~n Without Baselines 
In this section the design with two sequences ABB 
and BAA will be considered when baseline observations are 
not available. It has already been noted in section 3.3.1 
that Kershner & Federer(19811 have shown that this design 
is effiCient in estimating the difference in both the 
treatment and first-order carry-over effects. The design 
has also been considered by Ebbutt[19841 and 
Korrey[19841. The linear model with parameters as before 
will be employed, i.e. ~ = overall mean, ~l = sequence 
effect, ~IJ = subject within sequence effect, ~k = period 
effect, ~L = treatment effect, aL = carry-over effect, 
and EUk = error term. wand E are random effects with 
variances ~i and ~l respectively, while all the others 
are fixed effects with restrictions as before. 
Ebbutt[19841 uses essentially the same model, although 
without specific sequence effects, but gives expressions 
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for the estimates of treatment and carry-over differences 
in terms of the quantities TL, RL and SL, which are 
respectively, the sum of observations on treatment L, the 
sum of observations in periods preceded by treatment L, 
and the sum of all observations for those subjects who 
receive treatment L in the last period. It seems simpler 
to write down the linear model for each observation with 
a different combination of sequence and period, and show 
how linear combinations of these can be combined to 
obtain the required estimates. 
Hence, using the linear model, the following 
expressions may be obtained: 
for subject i in sequence 1 i 
period 1 : Ylll = }J. + 'tl + W1i + 1(, + '1'" + € Ii 1 
period 2: yl t2 = }J. + '¥1 + Wli + 1(a + '1'. + a" + E 112 
period 3: Yll3 = }J. + ~, + w" + 1(3 + '1'. + a. + E 1 t3 
for subject j in sequence 2i 
period 1: y2J 1 = }J. + '¥a + Ci)2J + 1(, + '1'. + Ean 
period 2: YU2 = }J. + '¥a + Ci)ZJ + 1(2 + '1'" + a. + Ezu 
period 3: Y2n = }J. + ~z + W2J + 1(3 + '1'" + a" + EaJ3 .. 5.2.1 
It should be emphasised that the error terms in the 
above model are assumed to be independent, so that, given 
the model parameters, the observations are independent. 
Because the models for observations on the same subject 
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in dif£erent periods contain the same subject effect, 
these observations will nevertheless be positively 
correlated, and the unconditional likelihood will contain 
covariance terms. If the errors cannot be regarded as 
independent, a multivariate treatment of the data will be 
necessary. 
The within-subject comparison Hu = 2YiJl - ylJ2 - YlJ3 
has expected value (2Kl - K2 - K3) + 2(TA - T.> for a 
subject in sequence 1, and (2Kl - K2 - K3) - 2(TA - T.> 
for a subject in sequence 2. Thus a two-sample test 
comparing the Hit and HZJ values gives a test of TA = Ta. 
An estimate of the treatment difference can be obtained 
by defining Hi, as the average of the n. HiJ values and 
taking ~<iil. - Hz.), giving an unbiased estimate of TA - T. 
which has variance ~~{l/nl + l/nz}. 
For estimating or testing the difference in carry-
over effects, the wi thin-subject comparison Ku = YiJZ -
ytU can be used. For a subject in sequence 1 this has 
expectation <X2 - X3) + <aA - aa), while for a subject in 
sequence 2 the expectation is (xz - K3) - (~ - a.). Thus, 
a two-sample test comparing the KIl and the KZJ will test 
for equality of carry-over effects, and, if Kt, is the 
average of the ni Ku values, ~<K\, - K2.) gives an 
unbiased estimate of aA - a. with variance 
~O'i{l/nl + l/nz}. 
Ebbutt makes two criticisms of the ABB BAA design. 
Firstly, he states that the estimators of treatment 
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difference and first-order carry-over are only orthogonal 
if there are equal numbers of subjects in the two 
sequences. This is incorrect, as can be seen from a 
consideration of the comparisons within a single subject 
used to obtain the two estimates. The estimator of the 
treatment difference uses HIJ = 2YUl - YlJ2 - ytJ3, while 
the estimator of carry-over uses KiJ = ytJ2 - YtJ3. the 
coefficients of the three observations in these two 
contrasts are 2, -1, -1 for Hand 0, 1, -1 for K, so that 
the two contrasts are orthogonal. Since the contrasts 
within each subject are orthogonal, the estimators based 
on them will be orthogonal, no matter how many subjects 
are in each sequence. 
Ebbutt's second criticism is that blindness may be 
difficult to maintain if it is known that the treatments 
in the last two periods are the same. Although this 
obviously has some force, it would seem possible to 
maintain blindness, if only by the subterfuge of 
pretending that there are three treatments involved in 
the trial. A further problem is the possibility of 
second-order carry-over effects. If the effect of the 
treatment administered in the first period carries over 
to the third period, second-order carry-over effects ~A, 
~., must be introduced into the model. These will appear 
only in the expressions for the third period 
observations, and will then be as much of a nuisance in 
this design as first-order carry-over is in the simple 
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two-period cross-over. With the addition of these second-
order carry-over effects, the expected value of the 
-estimator of the treatment difference ~<H,. - H2. > is (TA 
- Te> - ~(~A - ~8>i and the expected value of the 
estimator of the difference in first-order carry-over 
~(Kl. - K2.> is «(XA - (Xs> - ~<~A - ~s>. In addition, it is 
not possible to test for difference in second-order 
carry-over effects using a within-subject comparison. The 
combination 2YlJl + yiJ2 + yiJ3 must be used, which has 
in sequence 1, and 4~ + 4~2 + <2nl + n2 + n3> +~. for a 
subject in sequence 2. Thus a comparison of the two sets 
of combinations will only test the hypothesiS ~A = ~e if 
there is no systematic difference between the subjects in 
the two sequences (i.e. ~, = ~2)i and even if this is the 
case the test will be inefficient because the subject 
variation is still present in these combinations. Thus 
the introduction of second-order carry-over effects into 
the model has re-introduced all the problems that were 
present in the simple two-period cross-over. 
At this point, it is worth considering whether 
second-order carry-over effects are really necessary in 
the model. As mentioned in chapter 2, there are two main 
ways of viewing carry-over effects. The simplistic view 
is that carry-over is some pharmacological or 
psychological effect of the previous treatment that still 
affects the patient in subsequent periods. Taking this 
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view, it is reasonable to believe that the carry-over 
effect will diminish with time, and that second-order 
carry-over effects will be some fraction of the first-
order carry-over effects, so that if there is no 
difference in first-order carry-over effects, there will 
not be a difference in second-order carry-over either. 
The more complex view of carry-over is that it is 
some treatment-period interaction. If this view is taken, 
the "carry-aver- can be modelled in the standard way that 
an interaction is entered into a linear model, rather 
than introducing carry-over effects. However, in the 
simple two-period cross-over, first-order carry-over and 
treatment-period interaction will be aliased and 
indist~,uishable. Similarly, in the three-period design 
first and second-order carry-over together are equivalent 
to treatment-period interaction, taking up the same two 
degrees of freedom in the model. Thus, taking this more 
complex view of carry-over, first-order carry-over is a 
component of the total treatment-period interaction. It 
is difficult to believe that, if some non-specifiC 
treatment-period interaction exists its effect would 
appear solely as second-order carry-over. so that it is 
reasonable to assume that if there is no evidence of 
difference in first-order carry-over, there is no 
treatment-period interaction at all, and hence no 
difference in second-order carry-over effects. 
Consequently, whatever view of carry-over is taken. it 
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seems reasonable to omit second-order carry-over from the 
model if there is no evidence of first-order carry-over. 
In addi tion, the wi thin subj ect comparison KiJ = yiJ2 -
ylJ3 which was proposed for testing difference in first-
order carry-over effects is also affected by any 
difference in second-order carry-over effects, the 
expected value of the estimator ~(Kl. - K2.) being 
(aA - as) - ~(~A - ~.). Thus if the differences in first 
and second-order carry-over effects have the same sign, 
which will be the case if second-order carry-over is a 
diminished form of first-order carry-over, the presence 
of a non-zero difference in second-order carry-over 
effects reduces the estimate of the first-order carry-
over effect, making it more difficult to detect. 
Nevertheless, the test of first-order carry-over is qUite 
powerful, and an experimenter may feel that, if this test 
is non-significant, there will be no need for second-
order carry-over effects in the model. However, the 
corollary to this is that if the test is significant, an 
experimenter should be reluctant to omit second-order 
carry-over effects from the model. 
Although it has been argued above that significant 
second-order carry-over is unlikely in the absence of 
first-order carry-over, the consequences for the analysis 
of the various combinations of significant and non-
significant carry-over effects should be considered. The 
design is only affected by second order carry-over, 
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because £irst-order carry-over is allowed £or and does 
not affect the estimation or testing. Thus, if there is 
only a difference in the first-order carry-over effects, 
and not in the second-order carry-over effects, all the 
data can be retained, and an efficient estimate of 
treatment difference obtained. If there was a difference 
in the second-order carry-over effects, but no difference 
in first-order carry-over effects, the data from the 
third treatment period would have to be discarded, 
leaving a simple two-period cross-over design. In this 
case, significant first-order carry-over would make it 
necessary to discard the data from the second treatment 
period also, leaving only a parallel design. Hence, an 
experimenter who took the conservative approach, and 
regarded a significant result for the test of first-order 
carry-over as indicative that there is a carry-over 
"problem" in the experiment, and that second-order carry-
over may well be present also, even if the test for it is 
non-significant, would have to discard the data from the 
second and third periods, reducing to a parallel design. 
Although this might be a sound approach, it does seem 
rather drastic, since, with carry-over from 
pharmacological or psychological effects, it is quite 
possible that the carry-over effects would be strong in 
the period immediately following a treatment, but would 
have weakened to become negligible by the second period 
after the treatment, giving presence of first-order 
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carry-over differences but absence of difference in 
second-order carry-over. In these circumstances,the 
design is very efficient, and indeed has been shown to be 
optimal for the estimation of treatment and first-order 
carry-over effects. <Laska et al.[1983]) 
5,2,1 The TWO sequence Desiin with Baselines 
It was noted in section 4.2 that the addition of 
baseline observations to the simple two-period cross-over 
helped to overcome the problems caused by carry-over, and 
it can be shown that baseline observations will alleviate 
the similar problems caused by second-order carry-over in 
the three-period design. Introducing ~o for the period 
effect of a baseline observation as before, the model for 
baseline observations will be exactly as given above for 
the simple two-period cross-over, i.e. 
YII.O = J.1 + '" 1 + WI I. + 'Jto + E 1.0 
y2~0 = J.1 + '" 2 + W2~ + 'Jto + E 2~O 
The addition of the baseline observations allows a 
test of second-order carry-over by a within-subject 
comparison. The combination 4yuo - 2Y..,1 - yl.J2 - y'~3 has 
expected value (4'Jto - 2'Jt1 - 'Jt2 - 'J(3) - ~A for a subject in 
sequence 1 and (4xo - 2Xl - 'Jt2 - '1(3) - ~. for a subject in 
sequence 2. Thus a two-sample test comparing the two sets 
of combinations will test ~A = ~., and the difference in 
the means of the two sets of combinations will give an 
unbiased estimate of ~A - ~. which has a variance of 
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220'Hl/nl + l/n2}. 
The other possibility presented by baseline 
observations is for the combination of estimators of 
treatment difference if carry-over is not present. In 
these circumstances both the estimator from comparison of 
the baseline and first period observations, and the 
cross-over estimator <in this case from the combination 
Ht3 = 2YiJl - yiJ:2 - YiJ3) are valid. It was noted in 
section 4.2 that combining such estimators for the simple 
two-period cross-over did not yield a better estimator, 
because of the positive correlation between the two 
estimators, and this is again the case for this design. 
5.2.2 Baseline and Washout Observations 
The analysis of the design will now be considered if 
there is both a baseline observation before the first 
treatment period , and washout observations between the 
first & second, and second & third treatment periods. 
There are now effectively six periods in the experiment, 
and as before, the period effect for the baseline 
observation will be labelled ~o, with the period effects 
for the washout period between treatment periods 1 & 2, 
and 2 & 3 being labelled 1£t' and ~2' respectively. It will 
be assumed that the six period effects are fixed and sum 
to zero. First-order carry-over effects aA, aa will apply 
to effects of a treatment carrying over to the following 
washout period, while second-order carry-over effects ~A' 
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~8 will apply to treatment effects carrying over from one 
treatment period to the next, through the intervening 
washout period. It would be possible to include. third and 
fourth-order carry-over effects, for effects from the 
first treatment period which affect the second wasout, 
and third treatment periods respectively, but this seems 
unnecessarily complicated. With the other model 
parameters as before, the models for the six observations 
in each sequence are: 
for subject i in sequence 1i 
baseline: yuo = )J. + ~ 1 + Wli + 1£0 + E liO 
period 1: YUl = )J. + ~1 + Wu + 1£1 + 'r,r. + Elil 
washout : yl 11' = )J. + ~ 1 + WI I + 'Jtl' + all + E l' 1 ' 
period 2: YU2 = Jl + ~ 1 + W" + 1£2 + 'T. + 13 .. + E 112 
washout : Y"2' = Jl + ~1 + Wu + 1£2' + a. + EU2' 
period 3: ylt3 = )J. + ~1 + WIt + 1£3 + 'T. + 13. + Ella 
for subject j in sequence 2i 
baseline: y2JO = Jl + ~2 + W:u + 1£0 + E:uo 
period 1: y211 = )J. + ~2 + W2J + 1£1 + 'T. + E2J1 
washout: y2Jl' = Jl + ~2 + W2J + 1£1' + a. + EaJl' 
period 2: YU2 = Jl + ~2 + W2J + 1£2 + 'Til + 13. + E2J2 
washout : Y2J2' = Jl + ~2 + W21 + 'Jt2' + all + EU2' 
period 3: Y2n = Jl + ~2 + W2J + 1£3 + 'Til + 13" + €2n 
. ,5,2,2,1 
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The advantage of inserting washout periods can be 
seen from the fact that first and second-order carry-over 
effects have been separated out, and do not occur 
together in any of the above expressions. This enables 
within-subject comparisons which will test for 
differences in treatment, first and second-order carry-
over effects. The familiar combination of the three 
treatment periods H,,, = 2YUl - Y'J2 - ytJ3, will provide a 
test of differences between the treatments. First-order 
carry-over effects are not involved in this combination, 
and second-order effects are eliminated from its expected 
value by the restriction ~A + ~. = O. Hence, in the 
absence of higher-order carry-over effects, carry-over 
does not affect th~ test or estimation. Similarly, the 
comparison of the two washout observations D'u = 
Y'Jl' - Yuz', gi ves a test of equality of first-order 
carry-over effects without involving second-order 
effectsj and the difference between the observations for 
the second and third treatment periods KtJ = YtJ2 - YU3, 
gives a test of the equality of the second-order carry-
over effects. It is interesting to note that the baseline 
observations are not invoved in any of these comparisons, 
suggesting that the baseline observations are redundant 
and need not be taken. Comparison of the baseline 
observations would be used to test for a systematic 
difference between the two groups of patients (i.e. ~, = 
~2), which might still be regarded as important. but as 
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the ~'s are eliminated from within-subject comparisons 
such as those above for testing for treatment, first-
order, and second-order carry-over effects, any 
difference between the groups would not affect the tests 
for these effects. 
The introduction of washout periods seems from the 
above analysis to have solved all the problems of this 
cross-over design. However, the problems have only 
disappeared because of the parameterisation that has been 
used, and in particular the simplistic view that has been 
taken of carry-over. By not including higher than second-
order carry-over effects we are tending to the 
pharmacological/psychological view of carry-over, and 
assuming that such effects will diminish with time, 
becoming negligible after two periods. This may be 
reasonable if pharmacological/psychological effects 
really are involved, but it should be remembered that 
carry-over is intended to cover any effect that makes a 
treatment be perceived differently in different treatment 
periods. Although pharmacological/psychological carry-
over is the most obvious mechanism for such a treatment-
period interaction, we should not be seduced into 
thinking that carry-over must arise in this way. On the 
other hand, if we insist on introducing parameters into 
the model which allow the treatments to be different in 
the different periods, we inevitably re-introduce the 
familiar problems associated with the two-period cross-
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over. If it is believed that at least some of any 
treatment-period interaction will be due to 
pharmacological/psychological effects, and that these can 
be reduced by extending the design by introducing washout 
periods, it will be worth taking these steps,even though 
other, less-obvious causes of treatment-period 
interaction may remain. 
5.3 Fgur Se~uence Desi&ps 
As an alternative to the three-period design with 
sequences ABB & BAA, Ebbutt[1984J considers the design 
with the four sequences ABB, BAA, ABA & BAB. Kershner & 
Federer[1981] also consider this design and two other 
four sequence three-period designs : AAB, BBA, ABB & BAA; 
and AAB, BBA, ABA & BAB. Kershner & Federer show that the 
last of these designs gives estimates of treatment and 
first-order carry-over effects which have much larger 
variances than those from the other two designs, and this 
design will be ignored. In chapter 3, it was suggested 
that,by analogy with the complete two period design, it 
might be worth considering the design with sequences AAA, 
BBB, ABB & BAA. Hence the three four-sequence designs 
shown in table 3 will be considered in this section. 
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Table 3: Sequences in the three designs. 
Design No. Sequences 
1 ABB BAA ABA BAB 
2 ABB BAA AAB BBA 
3 AAA BBB ABB BAA 
Clearly, apart for the fact that four sequence 
effects ~1 ••• ~. will be reqUired, the parameterisation 
used for the design ABB, BAA in section 5.2 above can be 
used to define expressions for each observation in each 
of the three deSigns. First and second-order carry-over 
effects will be included from the outsetj Kershner & 
Federer have identified the best linear unbiased 
estimators for treatment and first-order carry-over 
differences if second-order carry-over is omitted from 
the model. Initially it will be assumed that an equal 
number of subjects is allocated to each of the four 
sequences in the designs, and the within-subject 
comparisons that give the best unbiased estimators of the 
difference in treatment effects will be identified. 
For design 1, the comparison required for each 
sequence is Lu = yin - YtJ3. This comparison yields the 
following expected values for each of the four sequencesj 
E{L~u} = (1t, 
E {L3~} = (1t, 
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1" 8 ) - ex. - ~A 
1" • ) - CXA - ~. 
.. 5.3.1 
Thus, writing LI. for the average of the L values in 
sequence i, the combination ~d". - Lz. - 13. + LA.> gives 
an unbiased estimate of ~A - ~8, with variance 2~l/n or 
8~~/N, if there are n subjects in each of the four 
sequences, and N = 4n subjects altogether. 
For design two the comparison Hu = 5YtJl - 4YlJ 2 -
YIJ3 is used for sequences 1 & 2 (ABB & BAA), and H'IJ = 
3YIJI - 2YIJ2 - YIJ3 for sequences 3 & 4 (AAB & BBA). These 
give the following expected values; 
E {H, J} = (5n:, 4n:2 ~a) 
Ta) 
2n:2 
Ta) - 3a. - ~ •. 5.3.2 
Assuming there are n = N/4 subjects in each of the four 
-sequences, and writing HI. and H'I. for the averages of 
the H and X' combinations, the estimator ~<H,. - L. - H1 3 . 
+ i'A.) is unbiased for ~A - T., and has variance 1.75~i/n 
or 7~UN. 
For design 3, two different combinations are again 
used, Pu = 2ytJl + ylJ2 - 3YIJ3 for sequences 1 & 2 (AAA & 
BBB) and pi tJ = 8YtJl - 5YiJ2 - 3YtJ3 for sequences 3 & 4 
(ABB & BAA). These result in the expected valuesj 
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E{P'J} = <21(, + 1(2 - 31(3) 20:A 3J3A 
E {P2J } = (21(1 + 1(2 - 31(3) 20:. 3~B 
E{P' 3j} = (81t1 51£2 31t3) + 8 (1'A 1'a) 50:A - 30:. - 3J3A 
E{P' "J} = (81t1 51£2 31t3 ) 8(1'A 1'a) 30:A - 50:8 - 3J3a 
•• 5.3.3 
- -Wri ting Pt .. and P'1. for the averages of the combinations 
as appropriate, and assuming n = N/4 subjects in each 
sequence, the combination (P,. - P2. - P1 3. + P' ... ) /16 is 
an unbiased estimator of-~A - 1'~with variance O.875~~/n 
or 7~U2N. 
It is interesting that the estimator with the 
smallest variance arises from the design which is a 
combination of the cross-over and the parallel designs, 
confirming the apparent usefulness of this strategy, 
which was noted with the two-period designs. Since 
unbiased estimators of the treatment difference have been 
obtained from these designs, no attempt will be made to 
consider the addition of baseline and washout 
observations. The estimators obtained are efficient, in 
the sense that the model used in obtaining them contains 
both first and second-order carry-over effects, these 
being eqUivalent to treatment-period interaction for a 
three period design. 
The variances given for the estimates have assumed 
that n = H/4 subjects were allocated to each of the four 
sequences, but it may be that the variances can be 
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reduced by unequal allocation. It should be noted at the 
outset that observations on all four sequences are 
required for each design. unlike the two-period case 
where the two sequences AA & AB were found to be as 
efficient as the four sequences AA, BB. AB & BA. 
Consideration of design 3 above shows that the variance 
of the estimate of treatment difference can be reduced by 
keeping the same number of subjects in the complementary 
sequences (AAA & BBB. and ABB & BAA) but by having 
unequal numbers in these two sequence types. If m 
subjects are allocated to the ABB & BAA sequences. and 
2n-m subjects to the AAA & BBB sequences. so that a total 
of 4n = N subjects take part in the experiment. the 
variance of the estimator of TA - Te is 
~i{98(2/m) + 14(2/[2n-ml)}/256. which reduces to 
7~~{7/m + 11 (2n-m)}/64. It can be shown that the value of 
m which minimises this variance is (7 - 7-)n/3. making 
the ratio of the number of subjects in sequences 3 (ABB) 
and 4 (BAA) to the number in sequences 1 (AAA) and 2 
(BBB) 7- : 1. With a total of 4n subjects in the four 
sequences. this then makes the variance of the estimator 
equal to {(7~ + 4)7~i}/64n = O.7269~i/n = 2.907~i/N. Of 
course. it is not possible to make the optimum allocation 
of subjects with a ratio of 7~ : 1. but this can be 
approximated to. If the ratio of the number of subjects 
in sequences 3 & 4 to the number in sequences 1 & 2 is 
5 : 2 or 8 : 3. the variance of the estimate of treatment 
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difference is approximately 2.91~~/N. Similar 
improvements could be made for the other two designs, but 
these would not yield an estimator with a lower variance. 
5.4 Reyiew 
In chapter 4 it was found that the addition of 
baseline observations to a two-period cross-over design 
lead to considerable improvement in the estimates that 
are POSSible, but that washout observations between the 
two treatment periods were comparatively unhelpful. In 
the present chapter, the usefulness of baseline 
observations with three-period designs has again been 
apparent, but washout observations have also been found 
to be useful. In a two-period design without washout 
observations, there is no place for second-order carry-
over in the model,so the in~duction of these effects 
with wash-out observations creates a further 
complication. On the other hand, second-order carry-over 
will affect the third treatment period in a three-period 
design, in addition to first-order carry-over. The 
addition of washout observations in this case separates 
first and second-order carry-over leading to a 
simplification of the analysis. 
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Chapter 6; The two period Cross oyer with Binary Data 
6.1 Introdyction 
In clinical trials, it is not uncommon for the 
outcome to be a dichotomy, for example improved/not 
improved or relief/no relief. In general, the two 
mutually exclusive and exhaustive outcome classifications 
can be thought of as success and failure for the 
treatment. Such results are usually recorded as 0 for 
failure and 1 for success, giving rise to what is termed 
binary data. Many authors have considered the analysis of 
such binary data for the Simple two-period cross-over, 
although many of the tests given have been based on 
intuition and common sense, rather than any formal 
mathematical modelling of the data. Kenward & 
Jones[1987a] have attempted to put these tests on a 
formal basis by relating them to a general model for 
binary data, but have also generated some controversy as 
to the most appropriate way of modelling such data. This 
chapter reviews the various tests proposed and discusses 
the modelling strategies, in preparation for 
consideration of the analysis of more complex cross-over 
designs in chapter 7. 
6.2 Models for Binary Data 
In considering models for binary data, the notation 
Yijk = response for subject j in sequence i for period k 
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will be retained. However, this response is now binary, 
typically 0 (failure) or 1 <success>. Interest will now 
be in the probability of a particular treatment giving a 
successful outcome, but this is, of course, not directly 
observable. The probability that a particular observation 
is "success" i.e. P(YI~" = 1), will depend not only on the 
treatment that was applied, but also on the subject and 
other circumstances such as the period. Following the 
usual practice with continuous observations, it would be 
natural to use a linear model containing parameters for 
these various effects to model P<yt.tk = 1). Such an 
approach has been used for the two-period cross-over by 
Zimmerman & Rahlfs[19781, and will b8 considered in more 
detail later. 
The problem with modelling the probability directly 
is that the linear model must then yield a value between 
o and 1, which is difficult to ensure. To avoid this 
difficulty, it is common practice to transform the 
probability into a variable which can take any value 
between -~ and ~, before employing a linear model. The 
functions most commonly used for this purpose are the 
probit and logit transformations, both of which are 
discussed in Cox(1970). Host of the tests proposed for 
the simple two-period cross-over relate to the logit 
transformation, while Cox & Plackett[1980) have proposed 
a test based on the probit transformation. Since the two 
transformations have similar characteristics, there seems 
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to be little to choose between them, although logit 
models may be slightly more convenient to use. 
If a linear model for the logit, or probit, of the 
probability of success is to be used, it would seem 
reasonable to make it identical in form with that which 
was used for continuous responses. Thus, writing 
logit{p<Yuk = 1)} = AUk, we have, for instance: 
A 1 J2 = }J. + 'V 1 + <.) 1 J + '£2 + 'T • + a" .. 6.2.1 
where 'V is the group or sequence effect, ~ is the subject 
effect, x is the period effect, 'T is the treatment 
effect, and a is the carry-over effect from the previous 
treatment. 
There are several problems with the use of such a 
model for the binary data from a cross-over trial. For 
the simple two-period cross-over it will be found that 
the sequence and carry-over effects are aliased, as in 
the case of continuous responses. In fact the estimation 
and testing problems that have been discussed for the 
case of continuous responses will continue to complicate 
the analysis for binary data. With binary observations, 
there is perhaps more justification for simplifying the 
model than with continuous observations. The multiplicity 
of parameters can help to explain slight differences in 
observations with continuous responses, but slight 
differences in the logit or probit, and hence 
probability, will be hidden by the binary nature of the 
observed response. The subject parameters are a 
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particular problem, as very little information can be 
gained about them. However, it is intuitively reasonable 
to believe that subjects will react differently in 
similar circumstances. In terms of the observed binary 
response, this will mean that some subjects are more 
likely than others to give a "success ", which will in 
turn imply a correlation between the observations on the 
same subject at different times. 
Because of the correlation between the two responses 
on each subject in the simple two-period cross-over, some 
authors have considered the two responses for a subject 
as the basic observation. There are then four different 
possible patterns of response that can be observed: 00, 
01, 10 and 11,and the number of times each pattern is 
observed for subjects receiving a particular treatment 
sequence can be thought of as having a multinomial 
distribution. Taking this view, it is then possible to 
construct a linear model for the four probabilities 
associated with the four different patterns, rather than 
for the probability of success for an individual 
response. If the four possible responses for a single 
subject are considered as forming a 2x2 table, the 
probabilities a~ociated with the marginal events are 
those considered originally, i.e. P<YUk = 0) or 
P<YUk = 1), 
'7'7 
period 2 outcome 
period failure (0) success (1) 
1 failure (0) 00 01 P<YlJ 1 = 0) 
outcome success (1) 10 11 P <YiJ 1 = 1) 
P <YiJ2 = 0) P<YiJ2 = 1) 
The advantage of modelling these marginal 
probabilities, or a function of them, is the ease of 
interpretation of the period, treatment, and other 
parameters, but the disadvantage is that, if subject 
effects are used these are nuisance parameters. The 
advantage of modelling the jOint probabilities is that, 
by considering them as the multinomial probabilities, 
they could be assumed to be averaged over subjects, 
making individual subject effects irrelevant. The 
disadvantage is that parameters in a linear model do not 
have a simple interpretation, or relate in a simple way 
to the period, treatment, and other effects associated 
with the marginal or individual probabilities. 
The problem of modelling binary data for cross-overs 
thus revolves around the choice of whether to model the 
joint or marginal probabilities, and how to model the 
dependence structure between the observations on the same 
subject. The most natural choice seems to be to model the 
marginal probabilities and include subject parameters, as 
for the case of continuous responses, but this proves to 
be rather intractable. Kenward & Jones[1987a] have also 
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modelled the marginal probabilities, but have suggested 
that the dependence structure should be treated 
separately, and modelled by adding appropriate parameters 
to a linear model from which subject effects have been 
omitted. Although this much simplifies the modelling, the 
resulting dependence parameters are not related in any 
obvious way to the subject parameters they replace, and 
seem rather arbitrary. Fidler[1984,19861 favours 
modelling the joint probabilities, but this leads to a 
more complex interpretation of the parameters involved. 
The various tests for the two-period cross-over, and the 
models on which they are based will now be briefly 
considered. 
6,3 The Mainland-Gart Test 
Historically, the first test to be proposed was the 
Kainland-Gart test, suggested by Kainland[1963J on 
common-sense grounds, and given a rigorous foundation by 
Gart[19691. Gart used a logistic or log-linear model, in 
which the log of the odds ratio, or logit, of the 
probability of success for a particular observation is 
expressed as a linear model. i.e. for an observation y, 
logit{p<y = l)} = In<p(y = l)/p<y = a)} = L, where L 1s 
the linear model. Thus 
p(y = 1) = e~/{l + e L } 
p<y = 0) = l/{l + e L } 
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Gart's linear model contained terms for subject, period 
and treatment effects, but contained no term for carry-
over. An overall mean term was also omitted from the 
model, being effectively included in the subject effects. 
Using the notation of the previous chapters, the model 
is; 
for subject i in sequence 1: 
log i t {p (y Ii 1 = 1)} = e xp < W Ii + 1t 1 + 'f A ) 
logit{p<Yli2 = 1)} = exp(wll + 1t2 + 'fa> 
for subject j in sequence 2: 
1 ogi t {p (Y2J 1 = 1)} = exp (w:ZJ + 1tl + 'f a) 
logit{p(Y2J2 = i)} = exp(w2J + 1t:z + 'fA) .. 6.3.1 
Gart is thus adapting the usual method for continuous 
responses to binary data, using subject effects to 
account for the dependence between the two observations 
on the same subject. Given the subject effect, the joint 
probability of a particular pattern of two responses can 
be obtained from the product of the two individual 
probabilities. With the usual restrictions 1tl + 1t2 = 
'fA + 'fa = 0, this gives the following probabilities of 
the four different patterns of responses, <00, 01, 10 & 
11). 
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for subject i in sequence 1 : 
p(OO) = liT, 
p(Ol) = exp(c...h' + 1t:z + 'Ta)/T, 
p(10) = exp<wl' + 1(1 + 'TA) IT, 
p(11) = exp (2(,,)1 i) IT i 
for subject j in sequence 2: 
p<OO) = liT' J 
p(Ol) = exp <W2J + 1(2 + 'TA)/T'J 
p<10) = exp<w2~ + 1(1 + 'Ta) IT' J 
p(11) = eXp(2w2J) IT' J .. 6.3.2 
where T, = {1 + exp<wl1 + 1(1 + 'TA)} {1 + exp(wli + 1(2 + ,..)} 
and T'J = {l + exp<w2~ + 1(1 + 'T.)}{1 + exp<w2J + 1(2 + .,°A)}. 
It can be seen from these expressions that only the 
probabilities for the patterns 01 and 10 contain the 
parameters of interest (1( & 'T) in the numeratori that is, 
apart from the normalising constants T, and T'J' This re-
inforces the common-sense idea that information about the 
relative merits of the two treatments can only be 
obtained from subjects who react differently to them. 
Hence it seems sensible to find the conditional 
probabilities of success for treatment Alar success in 
period 1 given that the two responses are different. BoL~ 
that this is conditioning on the sufficient statistic for 
the subject effect, which is the number of successeSi 
rather than the more usual practice of conditioning on an 
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ancillary statistic. It is only when there is one success 
that there is any choice in the pattern of response, and 
thus any information about parameters other than the 
subject effects we are conditioning on. The expressions 
for the conditional probabilities are: 
for subject i in sequence 1: 
p<success for treatment A I only 1 success) = 
p<success in period 1 I only 1 success) = 
{exp<~l + TA)}/{exp<~l + TA) + exp<~2 + Ta» 
for subject j in sequence 2: 
p<success for treatment A I only 1 success) = 
{exp(~2 + TA)}/{exp(~l + T.) + exp(~2 + TA» 
p<success in period 1 I only 1 success) = 
{exp(~l + Ta)}/<exp(~l + Ta> + exp<~2 + TA)} .. 6.3.3 
These expressions no longer contain the subject effects, 
and it can be seen that p(success in period 1 only 1 
success> is the same for both sequences if TA = T., 
giving a test of equality of treatment effectsj while 
p(success for treatment A only 1 success) is the same 
for the two sequences if ~1 =.~2, giving a test of the 
equality of the period effects. These tests are made by 
testing for the equality of these conditional 
probabilities using the estimates given by the 
observations. If N subjects receive treatment sequence AB 
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of which noo, nOI, n,o and nil give responses 00, 01, 10 & 
11 respectively, and N' subjects receive treatment 
sequence BA with n'oo, n'OI' n',O and n'" giving responses 
00,01,10 & 11, the estimates of p<success in period 1 
only 1 success) are n,ol (nol + n,o) for sequence 1, and 
n' 101 <n t 01 + n' 10) for sequence 2. If the treatment effects 
are equal, the expected values of these estimates are 
equal, so that the hypothesis of equal treatment effects 











Similarly, the estimates of the conditional probabilities 
p<success for treatment A I only 1 success) are 
n,ol <nol + n,o) for sequence 1 and n '0'/ <n '01 + n' 10) for 
sequence 2. The hypothesis of equal period effects 
implies that the expected values of these estimates are 
equal, so that the hypothesis can be tested by the usual 









It should be noted that in testing for a difference 
between treatments, the entries in each row refer to the 
same period, while in testing for a difference between 
periods each row refers to a treatment, so that the 
periods are reversed for sequence 2. It will be found 
that it is generally true that a test for periods will 
result when the order of the observations relating to 
sequence 2 are reversed in a test for treatments. 
6.4 Zimmerman & Rahlfs Model 
Zimmerman & Rahlfs(1978) model the marginal 
probabilities directly, without making a logit or prob1t 
transformation. Using the usual notation yUk = response 
for subject j in sequence i for period k, the model is: 
P<Yl.tl = 1) = Pl. = J.1 + Xl + '1'" 
P <Yl J2 = 1) = P·l = J.1 + X2 + '1'. + a" 
p <Y2.t 1 = 1) = ql. = J.1 + Xl + '1'. 
P <Y2J2 = 1) = q.l = J.1 + X2 + '1'A + a. .. 6.4.1 
where, as usual, J.1 is an overall mean, ltl, lt2 are 
period effects, '1'''' T. are treatment effects, and aA, a. 
carry-over effects. 
It will be noticed that no subject effects are 
included in the model, so that the probabilities must be 
regarded as the average over a large number of subjects, 
and the correlation between observations on the same 
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subject is not modelled. Since the model is identical in 
form to the model for continuous responses, the 
combinations used for estimation in that case can be 
applied here. Hence, if carry-over effects are not 
present, i. e. all = a. = 0, we expect Pl. + P.I to be equal 
to ql. + q.I, and PI. + P.I - ql. - q.1 is an estimator of CXA 
- aB. Tests can be performed using the methodology 
proposed by Grizzle, Starmer & Koch[1969l, based on the 
minimum logit X2, and Zimmermann & Rahlfs give explicit 
formulae leading to equivalent X2 tests. As with the 
continuous case, if the test indicates that there is no 
carry-over, the hypothesis of equal treatment effects 
leads us to expect that Pl. - P.I = ql. - q.I, and the 
hypothesis of equal period effects implies that Pl. - P.I 
= q.l - ql.. If there is carry-over present, the test for 
treatment effects will be based on the responses for the 
first period in the two different sequences. 
6.5 Cox & Plackett's MOdels 
Cox & Plackett[1980l propose two models for the 
transformed marginal probabilities, one of which uses the 
logit transformation, and the other the probit 
transformation. Apart from using different 
transformations, the two models also differ in form, 
subject effects being present in the probit model, but 
not in the logi t model. Writing >'Uk = logi t <YUk), the 
logi t model is: 
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).., J 1 = }l 
)..1J2 = }l + 1C + 'T + ex 
)..2J 1 = }l + 'T 
)..2J2 = }l + 1t' .. 6.5.1 
where }l is a location constant, 1C relates to period 
differences, 'T relates to treatment differences, and ex 
relates to treatment x period interaction. It should be 
noted that this is effectively the same model as used 
before, but with different constraints on the parameters, 
i.e. 1Cl = 'TA = 0, instead of 1Cl + 1C2 = TA + T. = 0. 
This model assumes that the equality of the cross-
product ratio pllpoo/plOPOl = qllqoo/qloqOl applies, and this 
is tested using the test of zero interactions for a 2x2x2 
table given by Plackett[1974J. If this test is non-
significant, the logits and their variances and 
covariances are estimated from the observed frequencies, 
to give tests of the individual parameters. 
The probit model is: 
P<Y1Jl = 1) = ;<jJ + W1J) 
P<Y1J2 = 1) = ;<jJ + 1[ +,. + ex + Wlj) 
P<Y2Jl = 1) = _<jJ +,. + W2J) 
P<Y2J2 = 1) = ; <jJ + 1[ + WaJ) .• 6.5.2 
where ;(x) is the cumulative normal probability, and 
}J,1[,T and ex are as for the previous model. 
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Testing for this model invoves using numerical 
methods to maximise the log likelihood, in order to 
obtain a deviance. 
6.6 Fidler's Hodel 
Fidler[19841 models the joint probabilities rather 
than the marginal probabilities. Thus, in his notation 
the probability models are: 
Outcome Seq 1 (AB) Seq 2 (BA) 
00 C, C2 
01 C,exp {a,l 
- l' - 1t} C2exp {a 12 + l' - 1t} 
10 C,exp {a,l + l' + 1t} C2exp{a,2 - l' + 1t} 
11 C,exp {a21} C2exp{a22} .. 6.6.1 
C, a.nd C2 a.re normal ising constants, and 1', 7t, a", 
a 12 I a21 and a22 are the mode 1 parameters. For each 
sequence, the probability of the four possible outcomes 
forms a quadrinom1al distribution, so these six model 
parameters are equivalent to the two sets of three 
unknown probabilities, and constitute a fully saturated 
model. T and 7t correspond to the main effects of 
treatments and periods, with T having a positive 
coefficient when the success is for treatment A, and 7t 
having a positive coefficient when the success is in 
period one. When there is a success on both treatments, 
and in both periods, the restriction that the sums of the 
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treatment effects and of the period effects are zero 
means that neither ~ nor ~ are required in the model. The 
parameters all, a12, a21, a22 must control the group and 
carry-over effects. If there is neither a group nor a 
treatment effect, the probability of success in period 
one would be the same for each sequence, however, this 
marginal probability contains both all and a21 in sequence 
1 and al2 and a22 in sequence 2. Similarly, if there is 
neither a treatment nor a group effect, the absence of a 
carry-over effect would imply that the probability of 
success in the second period was the same for each 
sequence. Again the marginal probability of success in 
period 2 will contain all and a21 in sequence 1 and a21 and 
a22 in sequence 2. The parameters can thus not be 
separated out in any simple way to give each a simple 
interpretation, but if all = a12 = aI, and a21 = 8.22 = a2, 
both group and carry-over effects are absent. By 
considering the fully saturated model, and models 
omitting group, group and carry-over, and period effects, 
Fidler obtains tests for treatments. Using the fully 
saturated model, the test for treatments obtained is just 
the Mainland-Gart test, while omitting group and carry-
over effects leads to the test first proposed by 
Prescott[19811, which is discussed in 6.8 below. Tests 
for carry-over are also obtained by considering 
departures from the model with no group or carry-over 
effects of the form a21 - a22 ;It O. Two tests are possible I 
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depending on whether all - a12 is considered to be zero. 
The simpler of these was proposed by Armitage & 
Hills[1982] and is also discussed in 6.8 below. 
Although Fidler's model seems more complicated to 
interpret than models for the marginal probabilities, he 
has pointed out in a letter (Fidler[1988]) that 
parameters in models for marginal probabilities often 
need to be interpret ed with more care than might at 
first seem necessary. especially if there are no subject 
parameters to take care of the dependence structure in 
the data. 
6.7 Kenward and Jones' Model 
Kenward and Jones[1987a] model the marginal 
probabilities with a logit model with treatment, period 
and carry-over effects, a parameter representing the 
overall tendency to give a positive response and 
normalising constants for the two sequences, which are 
eqUivalent to the overall mean and group effects. 
Ignoring the normalising constants, four parameters are 
therefore included to take care of the effects of 
interest, which, by analogy with the six parameters 
available for two quadrinomial distributions, implies 
that two more parameters are available for a saturated 
model. These two parameters are used to take care of the 
dependence structure in the data, one, ~, being described 
as the "average" within-subject dependence, and the 
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second, ~, as the difference in dependence between the 
two groups, or the group-by-dependence interaction. With 
C, and C2 as normalising constants, M as the overall 
tendency of subjects to give a success, and x, T, and a 
as the period, treatment and carry-over effects 
respectively, the model for the possible outcomes in 
sequence 1 are: 
00 C,exp{~ + _} 
01 C,exp{M + x + 7 - a - ~ - _} 
10 C,exp<p - x - 7 - ~ - _} 
11 C,exp{2M - a + ~ + ~} 
while for sequence 2 they are: 




Czexp{M + x - 7 + a - ~ + e} 
C2exp<M - x + 7 - ~ + ~} 
Czexp{2M + a + ~ - ~} .. 6.7.1 
The inclusion of the parameters ~ and ~ is meant to 
mimic the situation that would result if the subject 
parameters were integrated out. However, the authors 
themselves admit that it is difficult to envisage how 
such a process could result in such a convenient 
parameterisation. If subject parameters were integrated 
out, the marginal probabilities would be independent, so 
the model is an attempt to get the benefit of having 
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independent marginal probabilities, while avoiding the 
nuisance of the subject parameters themselves. If the 
subject parameters are considered to be random effects 
with normal distributions, as in the continuous case, 
integrating them out proves very difficult, and requires 
numerical integration methods. 
Kenward & Jones use their model to evaluate the 
various tests that have been proposed by identifying the 
parameters in their model which are involved in each 
test. In doing so, they are concerned if a test 
apparently breaches the marginality rules by fitting 
carry-over <or treatment-period interaction> when testing 
for treatments or periods <i.e. with one of the main 
effects for the interaction potentially omitted>. The 
introduction of the idea of treatment-period interaction 
in place of carry-over was noted earlier as a way of 
avoiding the simplistic view of carry-over as a mere 
pharmacological effect, but this concern over marginality 
seems to be an almost equally mis-placed view of carry-
over,as it can reasonably be regarded as a genuine effect 
of a treatment. In any case, the marginality rules do not 
seem to be universally agreed upon, as can be seen from 
the literature associated with the fitting of linear 
models with the SAS package <see e.g. Pendleton et 
a1(1986]> 
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6.8 Other Tests 
6.8.1 Prescott's Test 
Although it seems intuitively reasonable that 00 and 
11 responses give no information about the relative 
merits of the two treatments, it is nevertheless 
uncomfortable to discard this data, and it may sometimes 
mean that the remaining 2x2 table for Gart's test is 
sparse. Prescott[19811 reasoned that there are three 
types of responses: 10, 00 & 11, and 01, that are 
progre~vely less favourable to the first treatment, and 
more favourable to the second. Since the first treatment 
is different in the two sequences, there will be no 
difference in the relative frequencies of these responses 
in the two sequences, provided there is no difference in 
the treatments, and no carry-over. Alternatively, if 
there is a difference in the treatments, a trend in the 
three types of response can be expected, being in 
opposite directions for the two sequences. Thus a test 








00 or 11 01 
noo + n" 
n '00 + n I 11 n '01 
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The proposed test can be thought of as arising from 
the regression of dummy variable X, characterising the 
~ponse type, and dummy variable Y, characterising the 
sequence (Cox[1970J,p61-64). Variable X may conveniently 
be defined as taking the value 1 if the response is 10, 
zero if the response is 00 or 11, and -1 if the response 
is 01i while variable Y takes the value 1 for sequence 1 
and 0 for sequence 2. This means that Ixy = n,o - nO!. 
Given fixed margins in the 2x3 table, the evidence of a 
relationship between X and Y increases with the magnitude 
of Ixy. The probability of obtaining a value of Ixy that 
is as extreme or more extreme than the observed value is 
calculated using a randomisation test which assumes that 
the subjects in each of the three response catagories are 
allocated to the two sequences at random. 
6.8.2 Tests of Carry-oyer 
Clearly, as Gart's logistic model contains no term 
for carry-over, it is not possible to perform a test for 
carry-over effects under his scheme. However Hills & 
Armitage[1979, 1982] have proposed two tests of carry-
over, both on common-sense grounds. The first of these 
<Hills & Armitage[1979]) arises by analogy with the 
situation with continuous response variables. 
It will be recalled that testing for carry-over with 
continuous responses involves comparing the sum of th~ 
two observations for subjects in the two sequences. If 
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there is no carry-over the sums are expected to have the 
same mean in the two sequences, i.e. the average level of 
response will be the same. For binary responses, the 
equivalent consequence is that approximately equal 
proportions of 0 and 1 responses will be expected in each 
sequence. Since the number of 0 & 1 responses are most 
affected by variation in the number of 00 and 11 
patterns, this can be tested by comparing the relative 
frequencies of these in the two sequencesj i.e. the 







n I 11 
The second test (Armitage & Hills[19821) carries 
this idea a stage further by including the 01 and 10 








01 or 10 11 
n'Ol + n'lO n'" 
The test used was proposed by Armitage[19551, and is 
analagous to the -due to linear regression" term in the 
analysis of variance for a regression. In this case, the 
"regression" is at the proportion in sequence 1 of the 
three types of response on a dummy variable taking values 
-1, 0, and 1 which characterises the three types of 
response. Because these variables will not be normally 
distributed, a X2 statistic is defined, rather than using 
the normal F-test. The basis of this test is very similar 
to that used by Prescott, but instead of using a 
randomisation test, a XZ equivalent to the usual F-test 
is used. 
6.9 Discussion 
Models for cross-over designs with binary data have 
been considered in detail in this chapter. Most of the 
models considered have used the logit transformation, 
with a linear model for the logit of the probability of a 
positive response for each treatment-period combination. 
The obvious choice of making this linear model an exact 
analogue of the model used for continuous responses 
proves to be inconvenient, with the subject effects being 
nUisance parameters. However, if subject parameters are 
omitted from the model, the problem of the dependence 
between the two observations on the same subjects arises. 
In some models, this problem has simply been ignored, and 
no attempt has been made to allow for the dependence. 
This is clearly not very satisfactory, but the solution 
adopted by Kenward & Jones is also open to criticism, on 
the grounds that it is arbitrary. 
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Chapter 7; Higher order Cross ayers with Binary Data 
7.1 Introduction 
In chapter 6, possible models for the analysis of 
the simple two-period cross-over with binary data were 
reviewed. In most cases, these models can be generalised 
and applied to more complex cross-over designs with 
little difficulty. In this chapter, such generalisations 
will be considered for the cross-over designs considered 
in chapters 4 & 5, i.e. the "complete" two-period cross-
over, with sequences AA, BB, AB & BAi and the three-
period designs with sequences ABB & BAA, and with 
sequences AAA, BBB, ABB & BAA. Baseline observations with 
binary data are not always sensible, particularly when 
the binary clasifications are changes in the condition of 
the patient for example "improved" and "not improved", 
and will not be considered in detail. 
7.2 The Complete Two-period Cross-over 
In chapter 4, it was found that, with continuous 
response variables, the "complete" two-period cross-over, 
with sequences AA, BB, AB & BA, allowed unbiased 
estimates of both the treatment and first-order carry-
over effects to be made. In addition, use of the two 
sequences AA & AB only, allowed an unbiased estimate of 
the treatment effect to be made, even if carry-over was 
present. It will be shown that these properties also 
Q6 
apply when the observations are binary. Using a model 
similar to that employed by Gart[19691 for the simple 
two-period design, the logit of the probability of 
success for the observation in each period is expressed 
as a linear function of the overall mean, subject, 
period, treatment and carry-over effects, in a manner 
exactly analagous to the model for continuous responses. 
Because of the inclusion of subject parameters, the 
probabilities for the two observations for a single 
subject can be multiplied to give the joint probability 
of a particular pattern of responses. This gives the 
following probabilities for subject j in each of the four 
sequences: 
sequence AA klJ p(OO) = 1 
kIJ P (10) = exp{Jl + WIJ + XI + l' ",} 
kIJ p(Ol) = exp{Jl + W1J + X2 + 1'A + (XA} 
klJ p(11) = exp{2Jl + 2wIJ + 21'A + cx"'} 
where k, J = (1 + exp{Jl + WIJ + 1[1 + 1'A})(l + exp{Jl + W'J 
+ X2 + 1'", + Q",}) .. 7.2.1 
sequence BB kaJ p(OO) = 1 
kaJ p(lO) = exp{Jl + W2J + x, + 1'.} 
kaJ p(Ol) = exp{Jl + WaJ + Xa + 1'. + Q&} 
kaJ p(ll) = exp{2Jl + 2W2J + 21'1\ + exe} 
where k2J = (1 + exp{Jl + W2J + 1[1 + 1'.})(1 + exp{Jl + W2J 
+ Xa + 1'. + a.}) 
.. 7.2.2 
97 
sequence AB k3J p<OO) = 1 
k3J p(lO) = exp{jJ. + W3J + 11:1 + l' A} 
k3J p<Ol) = exp{jJ. + W3J + 11:2 + 1'8 + aA} 
k3J p(ll) = exp{2jJ. + 2W2J + aA} 
where k3J = (1 + exp{jJ. + W3J + 11:1 + 1'A})(l + exp{jJ. + W:u 
+ 11:2 + 1'8 + aA} ) .. 7.2.3 
sequence BA k4J p(OO) = 1 
k4J p(lO) = exp{jJ. + W4J + 11:1 + l' .} 
k4J p(Ol) = exp{jJ. + W4J + 1[2 + 1'1' + a.} 
k4J p<ll) = exp{2p. + 2W4J + a.} 
where k4J = <1 + exp{}l + W4J + 'h + 1'a}) (1 + exp{J.1 + W4J 
+ 1£2 + 1'1' + a.} ) .. 7.2.4 
It can be seen that, apart from the normalising 
constants klj ... k4J, the treatment and carry-over effects 
only appear in the expressions for the 10 and 01 
patterns. Following the procedure adopted by Gart(1969J, 
the subject effects can be eliminated by conditioning on 
their sufficient statistic, which is the number of 
successes. The expressions for the probability of success 
in period one, given there is only one success in the two 
periods, is as follows for the four sequences: 
seq. AA exp{ltl}/(exp{ltl} + exp<lt2 + QA}) 
seq. BB exp{ltl}/(exp{ltl} + exp{lt2 + ae}) 
seq. AB exp{ltl + 1'A}/(exp{ltl + 'TA} + exp<lt2 + T. + QA}) 
Q8 
seq. BA exp{nl + ~B}/(exp{nl + ~.} + exp{K2 + ~A + as}) 
... 7.2.5 
Clearly, the subject effects have been eliminated, 
and these conditional probabilities can form the basis of 
hypothesis tests and estimates. It can be seen that the 
expressions for sequences AA and BB will be identical if 
aA = aBo Thus a test of the equality of these two 
conditional probabilities is a test of whether carry-over 
effects can be omitted from the model. The test can be 
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where m'0, mo, are the observed number of subj ects in 
sequence AA giving the response patterns 10 & 01 
respectively, and m',0, m' 01 are the corresponding 
observed frequencies in sequence BB. 
If ~A = ~., the conditional probabilities for 
sequences AA & AB, and for sequences BB & BA, will be 
identical, whether or not carry-over is in the model. 
Testing the hypothesis of no difference in treatment 
effects can thus be achieved by conSidering the 2x2x2 
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table with classifications Q ; sequence pair <AA, AB or 
BB, BA), S = sequence within pair <parallel or cross-
over) and P = period with the success. If there is no 
treatment effect, there will be no S x P interaction. 
This can be tested using a log-linear model fitted using 
a package such as GLIK. 
It should be noted that, if only one sequence pair 
is used, for example AA & AB, a test of the treatment 
effects is possible via a 2x2 table with the 
classifications S & P. This test is valid whether or not 
there is significant carry-over, but a separate test of 
carry-over is not possible. If there are neither 
treatment nor carry-over effects, the conditional 
probabilities for sequences AB & BA will be the same. 
Hence for the 2x2x2 table described above, there will be 
no Q x S or Q x P interaction. There should in no 
circumstances be a three-factor interaction in this 2x2x2 
table, and the existance of such an interaction would 
cast doubt on the form of the model. 
By equating the observed relative frequency of 
success in period 1 given only one success with the 
theoretical model for this conditional probability, it is 
possible to obtain estimates of the effects in the model. 
Writing mlO, mol for the observed frequencies of the 10 
and 01 patterns in the AA sequence, with milO, m'oli nlO. 
nOli and n'IO, n'OI for the corresponding observed 
frequencies in the BB, AB and BA sequences respectively, 
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it can be seen that m'0/ (m,0 + Dlol) estimates 
exp{n,}/(exp{n,} + exp{n2 + aA}) 
By writing n = n, = -n2, and a = ~ = -a., the expression 
being estimated can be simplified to 1/(1 + exp{-2n + a}) 
so that mo, /m'0 must be an estimate of exp {-2n + a}. 
Similarly, m' odm' 10 is an estimate of exp{-2n - a}, so 
that In{mo,m' 10/m'0m' 10} is an estimate of 2a, or a" - a •. 
Similarly, by writing T = T" = -Ta, it can be shown that 
nolln'0 estimates exp {-2n - 2T + a}, and n' 01 /n' 10 
estimates exp{-2n + 2T - a}. Thus. In{lDo,n,O/m,0nO,} and 
In {m' lon' odm' 01n' 10} both estimate 2T, or TA - Ta. If only 
sequences AA and AB are used, the first of these two 
estimators can be used to estimate the treatment 
difference, but if all four sequences are used, the two 
estimators can be combined to give 
~ln{lDolm' lOn,0n' O'/m,0m' 01nOln' 10} as the estimator of 2,.. 
The disadvantage of including subject effects in the 
model is that, by conditioning on the sufficient 
statistic to eliminate these nuisance parameters, one 
neccessarily eliminates the patterns consisting of two 
successes, or two failures. As with the simple two-period 
cross-over, this means discounting half of the possible 
patterns, which will probably lead to a drastic reduction 
in the number of observations included in the analysis. 
To avoid this, it would be possible to adapt Prescott's 
test to the present design. The reasoning behind 
Prescott's test was that the response patterns 10, 00 or 
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11, and 01 are progressively less favourable to treatment 
A, and more favourable to treatment B in the AB sequence, 
and have the opposite interpretation for the BA sequence. 
As far as the AA and BB sequences go, ~ trend in the 
number of responses to this set of patterns would suggest 
the operation of carry-over, with any trend being 
expected to be in the opposite direction for the two 
sequences. Thus a test of trend for these two sequnces, 
either using the randomisation test used by Prescott, or 
the X2 test used by Armitage, will give a test of carry-
over. 
It would also be possible to generalise Kenward & 
Jones' model to this design. The model for the logit of 
the probability of success for each period would be 
similar to that used above, except that subject 
parameters would not be used. When these are combined to 
give an expression for the log of the probability of a 
particular pattern of responses <e.g. 00, 01 etc.} a 
parameter for the overall tendency for a success to occur 
is introduced which is modified by dependency parameters. 
Since the probabilities for the four possible patterns 
within each sequence may be considered as forming a 
multinomial distribution, only two dependency parameters 
can be allowed, in addition to parameters for period, 
treatment, carry-over and tendency of success, in order 
to avoid over-parameterisation. The two dependency 
parameters could be defined in several different ways, 
102 
but there seems no reason to change from Kenward & Jones' 
original parameterisation of having one parameter (~) 
which is positive if the responses for the two periods 
agree, and the other <;) which represents a difference in 
dependency between the two sequences in a complementary 
set (AA & BB, and AB & BA). With this parameterisation, 
the expressions for the log of the probability of the 
occurence of each pattern within each sequence are: 
seq 1 (AA) 
00 }l1 + 0- + P 
01 }l1 + 'I + 1h + 1'1' + a" - ~ - pi 
10 }l1 + 'I + 111 + 1'41' - ~ - pi 
11 }l1 + 2'1 +CXA+~ 
+ -
.. 7.2.6 
seq 2 (BB) 
00 }l2 + 0- - pi 
01 }l2 + 'I + 112 + 'fa + a. - 0- + ; 
10 }l2 + 'I + 111 + 1'a - 0- + ; 
11 }l2 + 2'1 + a. + 0- -
-
.. 7.2.7 
seq 3 <AB) 
00 }l3 + 0- + tJ 
01 }l3 + 'I + 112 + 'f. + a" - 0- - ; 
10 }l3 + 'I + 1tl + 1'" - 0- - P 
11 }l3 + 2'1 + CXA +0- + ; .. 7. 2.8 
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seq 4 (BA) 
00 ~A + ~ - ~ 
01 ~A + Y + n~ + TA + o. - ~ + 
-10 ~A + Y + n, + T. - ~ + , 
11 ~A + 2y + Oa + ~ - ; .. 7.2.9 
~1 ••• ~A are normalising constants. 
A log-linear modeUing package can then be used to 
fit a hierarchy of models containing all or some of these 
parameters to give tests of the various effects 
7.3 Three-period Pesi&ns 
It has been seen that the main disadvantage of the 
Gart methodology, of including subject parameters in the 
model and conditioning on the sufficient statistic to 
eliminate them, is that the patterns consisting of all 
successes or all failures cannot be used to obtain 
information about treatment or carry-over effects. For 
two period deSigns, this means that only half the 
possible patterns are used, but for three-period deSigns 
the effect is less severe, as the 000 and 111 patterns 
which cannot be used only account for a quarter of the 
possible patterns. Designs with more treatment periods 
would be even less badly affected, but this advantage 
might well be negated by the extra expense and the 
increased probability of drop-outs with a long trial. 
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7.3.1 The Two-sequence Desiin 
It is a simple matter to write down a Gart-type 
model for the three period design with sequences ABB and 
BAA, as the model for the logit of the probability of 
success is again an exact analogue of the model for 
continuous responses given in 5.2.1. If we condition on 
the number of successes, the sufficient statistic for the 
subject parameters, there are three patterns giving only 
one success, and three giving two successes with one 
giving no successes and one giving three successes. In 
the patterns with only one success, or only one failure, 
it is natural to characterise the response according to 
which treatment gives the untypical response, although 
for the same pattern this is different in the two 
sequences. An equivalent alternative is to assign a score 
to each pattern, which characterises the degree to which 
the pattern supports the hypothesis that treatment A is 
more effective than treatment B. From the analysis of the 
continuous case, it would seem that a score formed by 
taking 2*(response for period 1) - <response for period 
2) - <response for period 3) might be useful, where the 
response is 1 for "success" and 0 for "failure". This 
gives the ordering given in table 4, which seems logical. 
It is clear that patterns 100 and 011 are the most 
extreme, with one treatment giving success, and the other 
failure. It is also clear that patterns 010 and 001 must 
favour the treatment given in the second and third 
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periods, although not as strongly as the 011 pattern . 
.I 
Kore contentious perhaps, are the 110 and 101 patterns, 
where each treatment scores one success. In these cases 
there is some evidence of inef~ctiveness in the second 
treatment, but not for the first, so that it is 
reasonable to regard the patterns as slightly favouring 
the first treatment. 
Table 4 Implication of patterns in the three-period 
design 
implication in sequence 
score patterns ABB BAA 
2 100 most favours A most favours B 
1 110 101 favours A favours B 
0 000 111 neutral 
-1 010 001 favours B favours A 
-2 011 most favours B most favours A 
It is clear that the patterns 110 & 101 give the 
same evidence for the comparative efficacy of the two 
treatments, as do the patterns 010 & 001, so that the 
occurence of one of the patterns rather than the other 
might be due to carry-over effects. In order to 
investigate this, conditioning on the score (+1 Or -1) 
will be necessary rather than on the number of successes. 
Defining a type R pattern as one in which their is a 
success in the second period (i.e. 110 or 010), and type 
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S as one in which their is a success in the third period 
(i.e. 101 or 001), and using l' = 1'" = -1'.; a = a" = -a., 
the relevant conditional probabilities are: 
probability of type R given score =1 
for seq 1 (ABB): exp{xz + a}/(exp{xz + a} + exp<x3 - a}) 
for seq 2 (BAA): exp{xz - a}/(exp{x2 - a} + exp<x3 + a}) 
probability of type R given score = -1 
for seq 1 
for seq 2 
exp{X2 + a}/(exp{x2 + a} + exp<x3 - a}) 
exp<x2 - a}/(exp{x2 - a} + exp<x3 + a}) 
The two sets of conditional probabilities are 
identical, a fact that can be used to give a test of the 
assumptions underlying the DXJdel. Defining nOlO, nOOl etc. 
as the observed number of subjects giving patterns 010 , 
001 etc. in sequence 1 and n' 010, n' 001 as the 
corresponding observed frequencies for sequence 2, the 
test relates to the 2x2x2 contingency table: 





nOlO n' 010 
nOOl n' 001 
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n'0' n' 101 
The test of the model is a test of no three-factor 
or pattern x score interaction, which may be carried out 
using a log-linear modelling package such as GLIX. 
It is clear that all four of the conditional 
probabilities above will be equal if there is no carry-
over effect. This would imply that there is no 
interaction between patterns and sequences in the 
contingency table, giving a test for the absence of 
carry-over. It is also possible to obtain an estimate of 
the carry-over effect a by equating the observed relative 
frequencies with the expressions for the conditional 
probabilities derived from the model. The two relative 
frequencies relating to sequence 1 both estimate 
L = exp{n2 + a}/(exp{n2 + a} + exp{n3 - a}), while the two 
conditional probabilities relating to sequence 2 both 
estimate K = exp{n2 - a}/(exp{n2 - a} + exp{n3 + a}). It 
is natural to combine the two estimators of each of the 
above expressions in some way. One way would be to weight 
the two estimators according to the size of their 
variances, but as the variances contain the parameter we 
wish to estimate, this is not possible, and a more ad hoc 
approach must be used. The most reasonable approach is to 
add the numerators and denominators of the estimators. 
This gives 
(nOlO + n110) / (nOlO + nOOI + nno + n,Ol) as the estimator of 
L, and (n'OlO + n',lO)/(n'OIO + n'OOI + n',IO + n',OI) as the 
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estimator of M. Since In{L/(l - L)}ln{X(l - M)} = 40 the 
estimator of 0 is 
'd = 1.. In S (nolo + n1Jo) (n l 001 + nl lad ~ 
4 ~ (nOOl + nlOl) (n l 010 + n' 110) 5 ... 7.3.2 
In order to provide a test of the treatment effect, 
it is necessary to condition on the number of successes, 
rather than the score. This gives the following 
conditional probabilities: 
probability that success is in period 1 given 1 success 
seq 1 : 
exp{ltl + 1'} + exp{lt2 - l' + o} + exp{lt3 - l' - a} 
seq 2: < <} exp It, - 1'} + exp(lt2 + T - o} + exp lt3 + l' + a exp {ltl - 1'} 
probability that failure is in period 1 given 1 failure 
seq 1 : 
exp{lh + lb - 2r} 
exp{lt2 + lt3 - 2r} + exp{ltl + 1[3 - a} + exp{1tl + lt2 + a} 
seq 2 : 
exp{lt2 + lt3 + 21'} + exp{lt, + lt3 + a} + exp{1[l + lt2 - a} 
Equating the observed relative frequencies which 
estimate these conditional probabilities with the above 
expressions allows algebraic simplification, yielding the 
following four equations: 
n'QO 
= nOlO + nOOl 
n' lOa 
= n I 010 + n' 00 I 
exp {-It I + t} 
exp{ltz - l' + a} + exp(lt3 - T - a} 





exp{na + n3 - 2T} 
.. 7.3.5 npl1 
nlOI + n))O 
n' 011 
= n'lOl+n'IIO exp{n1 + n3 + o(} + exp{nl + n2 - a} .. 7.3.6 
Dividing equation 7.3.3 by equation 7.3.4 and 
removing common factors of exp{T} and exp{-T} from the 
top and the bottom of the quotient on the R.H.S. of the 
resulting equation gives: 
nl00(n'plp + n'Op1) 
n' 100 (nOlO + n001) 
= exp{47} (exp{X2 - q} + exp<Xa + a}) 
(exp{n2 + a} + exp{1h - a}) 
.. 7.3.7 
Similarly, dividing equation 7.3.5 by equation 
7.3.6, removing common factors of exp<-27} and exp{27}, 
and cancelling common factors of exp{n1} from the top and 
bottom of the quotient on the R.H.S. of the resulting 
equation gi ves: 
nO 1 1 (n ' ] P 1 + n' 1 ] P ) 
n'011(n,0, + n,,0) 
= exp{-4T} (exp<Xa + a} t exp{n2 - q}) 
(exp{n3 - a} + exp{n2 + a}) 
.. 7.3.8 
Apart from the initial multipliers of exp{47} and 
exp{-47} the right-hand sides of the above two equations 
are identical, so that, if T = 0, the left-hand sides of 
the two equations should be equal. Testing the equality 
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of these expressions 1s thus a test of the treatment 
effect. The test can be carried out by testing for three-
way interaction in the 2x2x2 table 
1 success seq 1 seq 2 
in first no nOlO + nOOl n ' Ol0 + n ' OOl 
period? yes n'00 n"00 
1 failure seq 1 seq 2 
in first no n'0' + n"0 n I 101 + n'110 
period? yes nOll n 1011 
It should be noted that, if there is no carry-over, 
so that a = 0, the test of period by sequence interaction 
in the above table is also a test of ~ = O. 
An estimate of ~ may be obtained by dividing 7.3.7 
by 7.3.8, as the R.H.S. of the resulting quotient is 
exp{8~}. Hence the resulting estimate of ~ is: 
~ = 1.. In n,00( n' OIO + nloo,)n'oJJ(nJoJ + nIJO) 
8 n',OO(nOlO + n001)nOll (n ' ,0, + n'll0) .. 7.3.9 
Tests and estimates of treatment and first-order 
carry-over effects are thus possible for this design 
using a Gart-type model containing individual subject 
effects. The tests are based on contingency tables and 
may be conveniently carried out using a log-linear 
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modelling package such as GLIX. Further details and a 
worked example are given in KorreyC19891. 
Jones & Kenward[19871 have extended their model to 
the three-period design containing six sequences 
consisting of all possible orders of three treatments. 
The model consists of a conventional logit model with 
parameters for period treatment and first-order carry-
over effects, plus a parameter for the overall tendency 
for the result to be a success, and three dependency 
parameters. The dependency parameters are labelled ~12, 
~13, and ~23, and each is positive in the model if the 
response for the two periods denoted by the subscipts is 
the same (i.e. both a or both 1). It would be a simple 
matter to apply such a model to the design under 
conSideration, by removing the subject parameters from 
the previous model, and introducing the parameter 
repre~ting the overall tendency of success, and the 
three dependency parameters. Analysis is by fitting the 
model via a log-linear modelling package, as before. The 
advantage of the model over the Gart-type approach is 
that the responses for the 000 and 111 patterns are still 
used in the analysis, but the disadvantage of the 
artificiality of the dependency parameters remains. In 
both approaches, the introduction of second-order carry-
over would cause problems, as with the case of continuous 
observations. 
112 
7.3.2 The Four-sequence Desiin 
In a similar way to the above, logit models for the 
design with four sequences AAA, BBB, ABB and BAA can be 
constructed. Once again, the logit of the probability of 
success £or a particular subject in a particular period 
will be an exact analogue of the linear model used when 
the design was considered with continuous response 
variables. However, the score defined with the two-
sequence design does not give a sensible ordering of the 
possible response patterns for the AAA and BBB sequences. 
For these, three successes is the response pattern most 
favourable to the treatment being applied, while no 
successes is the least favourable response. If we 
condition on the number of successes as before, in order 
to remove the nuisance parameters representing subject 
effects, we will effectively prevent any information 
about the treatment effect being recovered. The relative 
frequencies of the different patterns giving one, or two, 
successes tell us nothing about the effectiveness of the 
treatment in an AAA or BBB sequence, but they may give 
information about carry-over. The same phenomenon occurs 
with continuous responses, where, by taking a within 
subject comparison to remove the subject effect, we 
necessarily also remove the treatment effect. 
If the conditional probabilities "for success in 
period 1 given only one success", and "failure in period 
1 given only one failure" are considered, and the 
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estimates of these conditional probabilities from the 
observed frequencies are equated with the expressions for 
the conditional probabilities derived from the model as 
before, estimators of the carry-over effect can be 
obtained. Writing miJk, and m'iJk for the number of subject 
showing response i in period 1, response j in period 2 
and response k in period 3 (i,j,k = 0 or 1), for sequence 
AAA and sequence BBB repectively, we obtain: 
for sequence AAA 
m100 
= 
lDol0 + IDoOl 
__ lPp-.o-) 1,--_ = 
mll0 + ml0l 
exp (0) exp (Xa+Xa) 
for sequence BBB 
m' 100 
---""_ ...... _-- = exp (g) exp (Xl) 






m'110 + m' 101 
exp (][2+1t=,) 
.7.3.2.4 
exp<aHexp(1tdlt2) + exp(1tl+1t3)] 
Clearly, dividing 7.3.2.3 by 7.3.2.1 gives an 
estimator of exp(2a), while another estimator of exp(2a) 
is provided by dividing 7.3.2.2 by 7.3.2.4. These 
estimators CQuld be combined by adding their numerators 
and denominators as before, but it is less clear how they 
may be combined with the estimator of exp(4a) derived 
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from the sequences ABB and BAA, which yielded the 
estimate of a given in 7.3.2. One option would be to 
multiply the two new estimators to obtain an expression 
whose expectation will be exp<4a), and then combine this 
with the previous estimator of exp<4a) by adding the 
numerators and denominators. This gives the rather 
unwieldly estimator given below: 
A 
.l. a + b a = In 4 c + d 
where a = <nOlO + nll0) (n' 001 + n' 101) 
b = lIIoll <lIIol0 + lIIoOl) (m' 110 + m' 101) m' 100 
c = (nOOI + nl0l) (n' 010 + n'110) 
d = m' Oil (m' 010 + m' 001 ) (milO + m,Ol) ml00 .. 7.3.2.5 
Although the practice of conditioning on the number 
of successes has allowed us to obtain an improved 
estimator of carry-over, no information about the 
treatment effect can be obtained. The benefit of this is 
somewhat dubious, and it may not be worthwhile running 
sequences AAA and BBB merely to improve the estimate of 
carry-over. Alternatively, conditioning on the number of 
successes could be abandoned for these sequences and the 
number of successes used to provide information about the 
relative efficacy of the two treatments. Intuitively, the 
number of subjects having 3,2,1 or 0 successes in the two 
sequences should show trends with opposite slopes if the 
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treatment effect is non-zero. This could be tested using 
a test for trend in the appropriate 2 x 4 contingency 
table. 
7.4 Discyssion 
It has been seen that Gart's basic method of 
conditioning on the number of successes to remove subject 
effects can be applied to higher-order cross-over designs 
with success, allowing tests and estimators to be 
derived. The method does have a distinct drawback when 
sequences of a single treatment (ie AA or AAA) are used, 
because it does not allow any information about the 
treatment effect to be obtained from these sequences. It 
is doubtful whether such sequences are useful when the 
response is binary. 
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Chapter 8; Power of Tests 
8.1 Introduction 
An important characteristic of any significance test 
is its power, which is defined as the probability that 
the test rejects the null hypothesis. This probability 
will be a function of the parameters which are the 
subject of the test, usually increasing as their value 
diverges from that specified in the null hypothesis. 
Thus, in a test of equality of the treatment effects TA 
and Ta, the null hypothesiS will be that TA - T. = 0, and 
an unbiased estimator of TA - TB will be used as the 
basis of a test of this hypothesis. If it is assumed that 
the true difference TA - Ta = ~~, and the unbiased 
estimator of this is~, with variance ~i, and the data is 
normally distributed, then ~ will also have a normal 
distribution, provided the estimator is a linear function 
of the observations. Thus, if z. is the value of the 
standard normal variate Z such that p<- z. < Z < z.> = 1 
- a, the test will be such that the null hypothesis will 
not be rejected in a test at the a% level if: 
- z .. < z. 
and hence if: 
- z. - ~< i.. _ -'k- < -'k-z. - 8.1.1 0'6 ~a ~6 O'a 
Since (~ - ~ ... )/~6 has a standard normal distribution, the 
probabiU,ty that the null hypothesiS is rejected will be: 
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.. 8.1.2 
where G(z) is the probability that a standard normal 
variate takes a value less than z. 
The above applies if there is a single test 
involved, but in previous chapters it has been shown that 
testing for a treatment difference with a cross-over 
design often involves a pre-test to determine whether 
there is significant carry-over. The exact form of the 
test for treatment difference depends on the result of 
the pre-test for carry-over. In general, the situation 
can be summarised as follows: 
Stage 1 
Stage 2 
perform pre-test <test P> 
perform main test 
If test P is significant use test S 
If test P is non-significant use test R 
Thus the probability that the test procedure 
indicates a significant treatment difference is: 
p[ <test P sig & test S sig> or (test P non-sig & test R 
sig)]. Since test P being significant and test P being 
non-significant are mutually exclusive events, this may 
be written: 
p[test P sig] * p[test S sig I test P sig] + 
p[test P non-sig] * p[test R sig I test P non-sig] 
... 8.1. 3 
118 
It will be assumed that the estimators used as the 
basis for tests P, R, & S are all normally distributed. 
In order to calculate the power for a given treatment 
difference ~T' it will be necessary to determine whether 
the tests P, R, & S are independent. If a main test is 
not independent of the pre-test, the joint probability 
distribution of the two estimators for the tests will 
have to be considered, and this will have a bivariate 
normal distribution. The power of the test procedure will 
depend on: 
(1) the true size of the parameters which are the 
subject of the pre-test 
(2) the significance levels of the pre-test and the main 
tests 
(3) the number of subjects in the experiment 
(4) the true size of the difference in treatment effects 
It is possible for the situation to become still 
more complex, if two pre-tests may be required, for 
example for significant first- and second-order carry-
over. This could lead to a sequence of three tests (two 
pre-tests and the main test), and, if all three tests 
were related, their joint distribution would form a tri-
variate normal distribution. 
This chapter will consider the power calculations 
for the four cross-over designs considered previously, 
and, for comparison, the parallel and simple two-period 
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cross-over designs. It will be assumed through-out that 
the data are normally distributed. 
8.2 Calcylation of Multiyariate Normal Probabilities 
As has been pOinted out above, if the estimators 
involved in the pre-test and main test are correlated, it 
will be necessary to calculate bivariate normal 
probabilities in order to calculate the power. Further, 
if there are two pre-tests before the main test, and all 
three estimators are related, calculation of trivariate 
normal probabilities will be involved. In this study, a 
NAG routine was used to calculate univariate normal 
probabilities, with the t-function described by 
Owen[19561 being used to facilitate calculation of 
bivariate normal probabilities, while the S-function 
described by Steck(19581 was used for calculation of tri-
variate normal probabilities. Further details of these 
functions are given in appendix A, and listings of the 
computer programmes used for power calculations are 
contained in appendices B & C. 
8.3 The Parallel Desi~n 
For the purpose of comparison, it is useful to 
consider the power of the parallel design, in which N 
subjects are randomly allocated to receive either 
treatment A or treatment B. For convenience, it will be 
assumed that N/2 subjects are allocated to each 
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treatment. In these circumstances, the unbiased estimator 
of the treatment difference A~ will be the difference in 
the mean response of the two groups, 1. e. ~ = Yl. - Y2. 
which has variance ~t = 4<~a + ~i)/N. Thus the expression 
for the power given in 8.1.2 contains both the within-
subject and between-subject variability. As the between-
subject variability is eliminated from many of the tests 
in cross-over designs, the power for this test cannot be 
compared with those for cross-over designs unless some 
assumption is made about the relative sizes of the 
between-subject and within-subject variation. To avoid 
making some arbitrary assumption about the relative sizes 
of these variances, the parallel design with baselines 
will be considered, allowing the between subject 
variation to be eliminated. In such a design, the 
unbiased estimator of the treatment difference is 
obtained from the contrast between the baseline and first 
period observations, 1. e. ~ = <Yll. - Yl0.) - <y:.t1. - Y:zo.). 
This has variance ~i = 8~f/N. Thus for a test at the 5% 
level, 8.1.2 gives the following expression for the 
power: 
1 - {O <1. 96 4T/« > 
0' ",,/8 G ( -1. 96 - ) } 
This clearly depends on the sizes of A~, ~., and N, of 
which only N can be controlled by the experimenter. In 
order to consider the behaviour of the power function for 
this and other deSigns, it will be necessary to give a 
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value for the unknowns 6~ and ~., and the simplest option 
is to assign specific values to the ratio 6T/~. and 
observe the behaviour of the power function. A plot of 
the power against values of the ratio 6T/~' between -4 & 
4, for N = 20, 40 & 60 is given in figure 1 
8.4. The simple two-period cross-oyer 
In order to facilitate comparisons, it is necessary 
to consider the two-period cross-over with baselines, 
since, if the presence of carry-over necessitates the 
deletion of the data from the second period, the test 
procedure reduces to the parallel with baselines 
considered above. It will be assumed that N/2 subjects 
are allocated to each of the two treatment sequences. The 
required pre-test in this case is for the presence of a 
significant difference in first-order carry-over, so that 
the null hypothesis for this pre-test is 6 ... = IXA - lXa = O . 
.A 
The unbiased estimate of this difference is given by 6 ... = 
variance of 24~~/N. If this test is significant, the test 
for treatment effect would be the one for the parallel 
design given above, while if the pre-test is non-
significant, the test for treatment would use the 
contrast between the first and second period observations 
i.e. the estimator of treatment difference 
"... - - ... -t:. = lA!{(Yll. - Y12.> - <Y21. - Y22.)}. It should be noted that 
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Fig 1 : Power of the test for treatment difference for 
the parallel design with baseli n e observati o ns 
POWE"a. 
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KEY 
N = 60 
N = 40 
N = 20 
3 4 
the estimator has expected value (~A - ~B> - ~(aA - as> = 
6 T - ~6a, so that the estimator is only unbiased for the 
treatment difference if there is no difference in carry-
over. 
In order to calculate the power for this suite of 
tests, it is necessary to determine whether the main 
tests are independent of the pre-test. If the estimators 
associated with the three tests are considered as 
contrasts between the baseline and first and second 
period observations, the co-efficients for the contrasts 













seq 2, period 
o 1 2 
2 -1 -1 
1 -1 0 
o -~ ~ 
From this, it is clear that the pre-test and the 
test used if the pre-test is non-significant (test R) are 
based on orthogonal contrasts, and so are independent, 
but that the contrasts for the pre-test and test S are 
not orthogonal, so that the tests are not independent. It 
is simple to show that the covariance of the estimators 
for tests P and S is 12~j/N, giving a correlation between 
the estimators of J3/2, or 0.866. 
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Because of the correlation between these two tests, 
it is necessary to calculate bivariate normal 
probabilities to evaluate the power function, which will 
be a function of the true difference in carry-over 
effects, ~Q, the true difference in treatment effects, 
~~, and the number of subjects, Ni as well as the 
significance levels of the tests. It is common practice 
to perform the pre-test at a lower significance level 
than the main test, Grizzle[1965] having recommended the 
use of a 10% significance level for the pre-test, and a 
5% level for the main test. Using these significance 
levels for the tests, the power for ~~/~. = i. and for 
~g/~. between -4 and 4 has been calculated for N = 20, 40 
& 60. Tables 5.6 & 7 give the power of the test procedure 
( i.e. the probability of rejecting the hypothesis that 
~~ = 0 ). the probability that the pre-test for A« is not 
significant, and the expected value of the estimate of 
A~. The results are plotted in figures 2.3 & 4. These 
results agree with those given by Freeman[1989l, although 
they are presented in a different form. 
Table 5 : N = 20 (nl = n2 = 10) 















-3.4 0.0723 1.1229 0.3535 
-3.2 O. 1009 1.1615 0.3551 
-3.0 0.1370 1. 2055 0.3588 
-2.8 0.1811 1.2535 0.3660 
-2.6 0.2331 1.3030 0.3793 
-2.4 0.2924 1.3509 0.4011 
-2.2 0.3580 1. 3940 0.4331 
-2.0 0.4279 1.4279 0.4'761 
-1. 8 0.5001 1.4501 0.5287 
-1. 6 0.5721 1.4577 0.5880 
-1. 4 0.6414 1.4490 0.6502 
-1. 2 0.7055 1.4233 0.7112 
-1. 0 0.7626 1.3813 0.7672 
-0.8 0.8110 1.3244 0.8149 
-0.6 0.8495 1.2549 0.8506 
-0.4 0.8'774 1. 1'755 0.8706 
-0.2 0.8943 1.0894 0.8706 
0.0 0.9000 1.0000 0.8467 
0.2 0.8943 0.9106 0.'7975 
0.4 0.87'74 0.8245 0.7260 
0.6 0.8495 0.7451 0.6403 
0.8 0.8110 0.6'756 0.5525 
1.0 0.7626 0.6187 0.4748 
1.2 0.7055 0.5'76'7 0.4158 
1.4 0.6414 0.5510 0.3783 
1.6 0.5721 0.5423 0.3599 
1.8 0.5001 0.5498 0.3551 
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2.0 0.4279 0.5721 0.3589 
2.2 0.3580 0.6062 0.3672 
2.4 0.2924 0.6491 0.3777 
2.6 0.2331 0.6970 0.3880 
2.8 0.1811 0.7465 0.3962 
3.0 0.1370 0.7945 0.4006 
3.2 0.1009 0.8385 0.4003 
3.4 0.0723 0.8771 0.3957 
3.6 0.0503 0.9094 0.3884 
3.8 0.0341 0.9353 0.3801 
4.0 0.0224 0.9552 0.3722 
Tab 1 e 6 : N = 40 < n 1 = n2 = 20) 
6 a ::: 0", - Oa p <Test P not s1g) Est of 6~ Power 
-----------------------------------------------------
-4.0 0.0002 1.0004 0.6088 
-3.8 0.0006 1.0011 0.6088 
-3.6 0.0013 1. 0024 0.6088 
-3.4 0.0030 1.0051 0.6088 
-3.2 0.0065 1. 0103 0.6088 
-3.0 0.0129 1. 0194 0.6088 
-2.8 0.0244 1.0342 0.6088 
-2.6 0.0435 1.0565 0.6088 
-2.4 0.0730 1.0876 0.6088 
-2.2 0.1160 1.1276 0.6089 
-2.0 0.1743 1. 1743 0.6094 
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. 
-1. 8 0.2485 1.2237 0.6114 
-1.6 0.3369 1.2695 0.6175 
-1. 4 0.4351 1. 3046 0.6320 
-1. 2 0.5374 1.3224 0.6600 
-1. 0 0.6366 1.3183 0.7036 
-0.8 0.7260 1.2904 0.7593 
-0.6 0.8001 1.2400 0.8190 
-0.4 0.8551 1. 1710 0.8736 
-0.2 0.8887 1.0889 0.9167 
0.0 0.9000 1.0000 0.9448 
0.2 0.8887 0.9111 0.9542 
0.4 0.8551 0.8290 0.9393 
0.6 0.8001 0.7600 0.8946 
0.8 0.7260 0.7096 0.8222 
1.0 0.6366 0.6817 0.7378 
1.2 0.5374 0.6776 0.6651 
1.4 0.4351 0.6954 0.6204 
1.6 0.3369 0.7305 0.6037 
1.8 0.2485 0.7763 0.6036 
2.0 0.1743 0.8257 0.6091 
2.2 0.1160 0.8724 0.6148 
2.4 0.0730 0.9124 0.6188 
2.6 0.0435 0.9435 0.6203 
2.8 0.0244 0.9658 0.6193 
3.0 0.1293 0.9806 0.6166 
3.2 0.0065 0.9897 0.6137 











Table 7 : If == 60 (nl = n2 = 30) 


















































































-0.2 0.8831 1.0883 0.9167 
0.0 0.9000 1.0000 0.9517 
0.2 0.8831 0.9117 0.9740 
0.4 0.8329 0.8334 0.9822 
0.6 0.7521 0.7744 0.9722 
0.8 0.6462 0.7415 0.9376 
1.0 0.5248 0.7376 0.8806 
1.2 0.4001 0.7599 0.8214 
1.4 0.2847 0.8007 0.7843 
1.6 0.1881 0.8496 0.7738 
1.8 0.1148 0.8967 0.7769 
2.0 0.0646 0.9354 0.7815 
2.2 0.0333 0.9633 0.7841 
2.4 0.0158 0.9811 0.7849 
2.6 0.0068 0.9911 0.7845 
2.8 0.0027 0.9962 0.7835 
3.0 0.0010 0.9985 0.7827 
3.2 0.0003 0.9995 0.7822 
3.4 0.0001 0.9998 0.7820 
3.6 0.0000 1.0000 0.7819 
3.8 0.0000 1.0000 0.7819 
4.0 0.0000 1. 0000 0.7819 
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Fig 2 : Performance of the test procedu re for the two-
period cross-o ver. N = 20 (n l = n2 = 10) 
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Fig 3 : Performan ce of the test procedure f or the two-
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Fig 4 : Performance of the test pro cedu re for the t wo -
period cross-over. N = 60 (n l = n 2 = 30) 
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It can be seen that, for large values of A./~., the 
power is very similar to that of the parallel design, for 
which the power to detect a difference of A~ = 1 is 
0.3526 when N = 20, 0.6088 when N = 40 and 0.7819 when N 
= 60. This is because the pre-test is almost certain to 
be significant, so that there is a very high chance that 
the main test will be the one used in the parallel 
design. Similarly, if A./~. is close to zero, there is a 
high chance that the pre-test will be non-Significant, 
and that the more powerful cross-over test will be used, 
giving a larger value for the power than the parallel 
design. For moderate values of Aa/~., the pre-test mayor 
may not be Significant, so that either of the main tests 
might be used. The advantage of using the cross-over test 
is less clear-cut because the estimator on which it is 
based is biased. As Freeman[1989] painted out, there is a 
sense in which increasing the sample size does not help, 
because the size of the carry-over difference A. which 
causes problems merely decreases, rather than the problem 
disappearing. It can be seen from tables 5 .. 6 that the 
largest bias in the estimate of A~ occurs at 
approximately the value of Aa which gives an equal chance 
of the pre-test being significant. As the sample sizes 
are increased, this value also decreases. 
Lehmacher[19911 has painted out that the signs of 
the treatment and carry-over differences are important. 
Since the expectation of the estimator of the treatment 
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difference for the cross-over test (test R) is AT - ~A«, 
the estimate of the treatment difference is larger than 
the actual treatment difference if AT and A« have 
opposite signs, or if 6« is more than four times as large 
as AT, if they have the same sign. As far as the power is 
concerned, this will be beneficial, since the increase in 
the estimate of the treatment difference makes it more 
likely that the treatment difference will be detected. On 
the other hand, if 6 T and Aa have the same sign, and Aa is 
less than four times the size of AT, the estimate of the 
treatment difference will be smaller than the actual 
treatment difference, shrinking to zero if ~ = 26T' This 
will reduce the power by making the treatment difference 
less easy to detect. 
It should be noted that this bias only applies to 
the estimate of the treatment difference used in the 
cross-over test. If the carry-over difference is large 
<i.e. four times the size of the treatment difference) 
the pre-test is likely to be significant, so that the 
cross-over test is unlikely to be used. However, if the 
carry-over difference is small, the pre-test is likely to 
be non-significant, so that the biased estimator of the 
treatment difference is used. If carry-over was 
pharmacological in nature, then the sign of the carry-
over difference would probably be the same as treatment 
difference, with the more effective treatment retaining 
more of its effectiveness in the next period, but in 
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these circumstances, it is difficult to believe that the 
size of the carry-over difference could be much larger 
than the size of the treatment difference. If, on the 
other hand, carry-over was psychological in nature, then 
the sign of the carry-over difference could be expected 
to be different from the sign of the treatment difference 
because a good treatment might make a rather worse 
treatment that followed it seem even more inferior, and 
vice versa. Once again, it is difficult to imagine a case 
where the carry-over difference would be large compared 
to the treatment difference. Because pharmacalogical 
carry-over is relatively easy to avoid, carry-over is 
more likely to have a psychological origin, or to be some 
non-specific treatment-period interaction. The previous 
argument suggests that the carry-over difference is 
unlikely to be four times as large as the treatment 
difference, and is more likely to have the opposite sign, 
so that the bias in the estimate of the treatment effect 
will probably lead to an over-estimation, but this is 
unlikely to have much of a beneficial effect on the power 
to detect a treatment difference. 
8,5 The "Complete" Two-period Cross-over 
In section 4.3, it was shown that the "complete" 
two-period cross-over, with four sequences AA, BB, AB, & 
BA, could give an unbiased estimator of the treatment 
difference even if the carry-over difference was non-
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zero. Thus, if this design is employed, there is no need 
to perform a pre-test for carry-over before the main test 
for difference in the treatments, and the power of the 
test for treatment difference can be calculated very 
simply, using the formula given in 8.1.1. Following the 
notation in section 4.3, AA will be denoted sequence 1, 
-BB sequence 2, AB sequence 3 and BA sequence 4; with Dl . 
denoting the average difference between the first and 
second period observations for the subjects in sequence 
i. If the N subjects are allocated equally to the four 
sequences, giving N/4 in each sequence, the unbiased 
estimator of the treatment difference is ~ = ~{D3. - D,. + 
D2. - D~.}, which has variance O'i = 80'UN. Since this 
variance is identical to that for the parallel design 
with baselines, the power function for this design will 
be identical to the function graphed in figure 1. 
In section 4.3.1 it was noted that the addition of 
baseline observations to this design could give an 
unbiased estimator of the treatment difference with a 
smaller variance. Defining G,. to be the average value of 
the combination yiJO + yiP - 2YlJ2 for the subjects in 
"'" - -sequence i, the unbiased estimator is A = ~{G~. - G,. + Gz . 
- G~.} and has variance O'i = 60'i/N. Thus, for a test at 
the 5% significance level, the power will be given by: 
1 - {G < 1. 96 - AT iN) - G < -1. 9 6 
0'.J6 
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This power function is plotted for values of 6T/~. 
between -4 and 4 and for N = 20, 40 & 60 in figure 5. 
8.6 The Three-period Designs 
Two three-period designs have been considered 
previously, one having the two sequences ABB and BAA, and 
the other having four sequences AAA, BBB, ABB and BAA. 
With both of these designs, the possibility of second-
order carry-over effects must be considered. If the form 
of the test for treatment difference depends on whether 
or not there is any difference in the second-order carry-
over effects, a pre-test for this will be necessary. 
Another pre-test for first-order carry-over may also be 
necessary so that it is possible that the test procedure 
would consist of a set of three tests: two pre-tests and 
the main test for treatment difference. If all three 
tests are correlated it is necessary to evaluate a tri-
variate normal probability to calculate the chance of a 
particular sequence of results for these three tests. 
Hence, when the sequence of three tests lead to a 
decision that there is a significant difference between 
the treatments, a tri-variate normal probability is 
required to calulate the contribution to the overall 
power. 
In view of the problems found with the simpler 
sequence of tests for the two-period cross-over, it is 
interesting to examine how this more complex suite of 
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Fig 5 : Power of the test for treatment difference for 
the "complete" two-period c ross-over 
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tests performs. The situation was not studied by 
Freeman[1989J and results for power calculations for this 
suite of tests have not been published elsewhere. 
8.6.1 The Two-sequence Desiin 
The analysis of the two-sequence design was 
considered in chapter 5, where it was shown that the 
estimator of the treatment difference is only unbiased if 
there is no difference in the second-order carry-over 
effects. If there are no baseline observations, it is not 
possible to find a within-subject comparison which will 
test for second-order carry-over, and, if a between-
subject comparison is made, the variance of the estimator 
would contain the between-subject variance, ~3. As 
before, in order to avoid the necessity of some 
assumption about the relative sizes of the between and 
withing subject variability, the design with baselines 
will be considered. It should also be noted that, if 
there is significant difference in second-order carry-
over effects, the results from the third treatment period 
cannot be used, effectively reducing the design to the 
two-period cross-over, which has already been considered 
with baseli nes. 
From section 5.2.1 it Can be seen that even with 
baseline observations the estimator of tr~ment 
difference with the smallest variance is based on the 
contrast between the three treatment periods HiJ = 2YlJl -
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-Ylj2 - Yij3. Writing Hi. for the average of the HiJ values 
in sequence i, the estimator o~ the treatment difference 
'" -is 6. = 14(Hl. - H2.>. However, this has expected value 'fA -
1'8 - 14<1311 - 138), or~ ... - 14~., where ~.1s the true 
difference in second-order carry-over effects. If a test 
for the equality of second-order carry-over effects is 
non-significant, the above estimator of the treatment 
difference is valid, but otherwise, the results for the 
third treatment period must be discarded, leaving results 
from a two-period cross-over with baselines. Hence, if 
the pre-test for second-order carry-over is significant, 
the situation reverts to that given above for the two-
period cross-over, where a pre-test for first-order 
carry-over is necessary in order to determine the 
appropriate test for treatment difference. The procedure 
if summarised in figure 6. The contrasts used in the five 
tests involved in the test procedure are defined below, 
together with the corresponding estimator and it's 
expectation. The leading co-efficient of the variance of 
the estimator are also given. In order to determine 
whether the estimators on which the tests are based are 
independent, they may each be regarded as contrasts 
between the baseline and three treatment period 
observations of the two groups. The co-efficients for 
these contrasts are also tabulated. 
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Sequence of tests for the three-period 
two-sequence design 
1st pre-test: (test Q) 
Yes No 
Use main test T Discard results from period 3 
to test 6 .. = 0 2nd pre-test <test P) 
No 
Use main test R Use main test S 
CONTRASTS 
Test Q QtJ = 4YtJO - 2Y1Jl - Ylu - yIJ3 
Test P EtJ = 2YIJO ytJ I - ytJ2 
Test T HIJ = 2Y'JI - ylJ':l. - yIJ3 
Test R DtJ = YIJ I - ylJ2 
Test S F IJ = YtJO - ytJ I 
ESTIMATORS 
Estimator Expectation Variance Co-eff 
Test -Q Q2, Ql, 6. 88 
Test -P E2, - El, 6. 24 









Y.!<i)l, - D2,) 
F 2 , - Fl, 
CONTRAST 
seq 1, period 
0 1 2 3 
-4 2 1 1 
-2 1 1 0 
0 ~ -~ -~ 
0 ~ -~ 0 
-1 1 0 0 
CO-EFFICIENTS 
seq 2, period 
0 1 2 3 
4 -2 -1 -1 
2 -1 -1 0 
0 -~ ~ ~ 
0 -Ik ~ 0 
1 -1 0 0 
2 
8 
It is clear that only the contrasts for tests P and 
R are orthogonal, so that all other pairs of estimators 
are correlated. However, for any given experiment, a 
maximum of three tests will be used <Q, P & Ri or Q, P & 
S>, so that only tri-variate normal probabilities will be 
needed. The probability that the complete test procedure 
leads to a decision that the treatments are significantly 
different is: 
p{[test Q sig & {(test P sig & test S sig> or (test P 
non-sig & test R sig)}] or [test Q non-sig & test T sig]} 
Taking into account the mutually exclusive events, 
this may be written: 
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p[test Q sig] * {p[test P sig I test Q sig] * p[test S 
sig I Tests Q & P sig] + p[test P non-sig I test Q sig] • 
p[test R sig I test Q sig & test P non-sig]} + p(test Q 
non-sig] * p[test T sig I test Q non-sig] 
A FORTRAN program was written to calculate this 
probability, given values of n,. n2, A~, A«, A_, and the 
significance level of the five tests. A listing of the 
program is given in appendix C. As with the two-period 
design, calculations were made using a lOr. significance 
level for the pre-tests of first or second order carry-
over (tests Q & P>, and a 5r. significance level for tests 
of the treatment effect (tests T, R & S>. 
The situation is similar to that for the two-period 
design in as much as the test for a treatment difference 
is based on a biased estimator if the pre-test fails to 
detect a non-zero carry-over effect. It is also the case 
that the expected value of the estimator of the treatment 
effect is less than the true value if treatment and 
carry-over effects have the same sign, unless the carry-
over effect is considerably larger than the treatment 
effect. 
In order to avoid a sequence of plots for different 
values of H, it was decided to consider values of 6 n/~., 
where n = n, = n2 = H12. Following FreemanC19891 values 
of ~ n/~. between -6 and 6 were used,with A. n/~. and 
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6. n/~. taking either the value zero or 5 n/~ •. Figure 7 
shows the power of the test proceedure for ~~ n/~. 
between -6 and 6 with 6 .. n/O'. = 6. n/~. = OJ ~~ n/~. = 5 
and 6. n/~. = OJ and ~ n/O'. = ~IJ n/~. = 5. 
As might be expected, the presence of first-order 
carry-over has little effect in the absence of second-
order carry-over, the design being efficient in dealing 
with first-order carry-over. The effect of second-order 
carry-over on the power curves is similar to the effect 
of first-order carry-over on the simple two-period 
design, with a marked assymetry in the power function, 
with a "plateau" in the curve for small negative values 
of the treatment effect ~~ n/~ •. 
8,6.2 The Four Seqyence Desiin 
In section 5.3, it was seen that the design with 
four sequences AAA, BBB, ABB & BAA could give an unbiased 
estimator for ~~ even if ~. and A. were not zero. Thus 
there is no need to perform pre-tests for this design and 
the power of the test for treatment difference has the 
simple form for a single test. Because the estimator on 
which the test has a relatively small variance, equal to 
70'~/2N if the four groups are each allocated N/4 
subjects, or apprOXimately 2.910'~/N if the ratio of 
subjects in the ABB and BBA sequences to subjects in the 
AAA and BBB sequences is 5 : 2 or 8 : 3, the test will be 
correspondingly more powerful than the tests from the 
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Fjg 7 : Performance of the test procedure f or the three-
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parallel design amd the complete two-period cross-over 
for the same significance level and value of N. A plot of 
the power function for values of ~T/~. between -4 and 4, 
and N = 20, 30 & 40, assuming equal numbers in the four 
sequences, is given in fig 8. 
Discussion 
The situation where a sequence of tests is 
performed, or a pre-test determines the exact form of the 
main test, is complicated, and the implications for the 
power of the test proceedure are not intuitively obvious. 
Indeed, some of the results obtained by Freeman[1989J, 
and confirmed here but presented in a different form, are 
counter-intuitive. It was often thought that, if the pre-
test was powerful enough, no problem would exist, but it 
has been shown that the problem is merely shifted to 
occur at smaller values of the carry-over effect. The 
results for the three-period design presented here show 
that very similar problems occur with that design, 
although these are caused by second-order carry-over 
rather than first-order carry-over. Thus the benefit of 
the more complex design is in making the problems more 
distant, and possibly less likely to occur. However, 
doubt must be cast on the suitability of a test procedure 
invoving a complex of pre-tests and main tests. One way 
of avoiding this is to eschew tests altogether and 
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perform a Bayesian analysis. This option will be explored 
in the following chapters. 
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Chapter 9j Bayesian Analysis of Cross-oyer Designs 
9.1 Introduction 
In chapters 2 to 5, classical analysis of cross-over 
designs with continuous response variables was 
considered. We now consider a Bayesian approach to the 
analysis of cross-over trials. Such an analysiS for the 
simple two-period cross-over has already been considered 
by Grieve[19851, Selwyn et al[1981] and Racine et 
a1[1986]. In all of these, the standard linear model is 
used, as given in 2.2.1, but a prior distribution is 
postulated for the unknown parameters. By assuming that 
the data is normally distributed, the likelihood can be 
written down, and a posterior distribution for the 
parameters of interest can be calculated using Bayes' 
Theorem. This chapter will review the results obtained 
for the simple two-period cross-over, and consider the 
possibility of extending the method to other cross-over 
deSigns. An alternative way of performing the Bayesian 
analYSis using Gibbs sampling will also be considered. 
9,2 Results for the Simple Two-period Cross-oyer 
Grieve[19851 has given a Bayesian analysis of the 
simple two-period cross-over without baseline 
measurements using a linear model which is identical in 
form to that given in 2.2.1 above, with the observation 
fDr subject j in sequence i for period k being expressed 
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in terms of an overall mean, ~, an individual subject 
effect w, a period effect x, a treatment effect ~, and, 
for observations in the second period, a carry-over 
effect a. Kaking the usual assumptions that nl + nz = TA + 
Ta = aA + aa = 0, the analysis is simplified by defining n 
observations on subject j in sequence i (Y1Jl & Y1J2) are 
assumed to have a bivariate normal distribution, with 
E{Y1Jd, E{Ytj2} given by the linear model, and var{YtJd = 
var{YtJz} = O'~ + O'i, and COV{Y1Jl,Ylj2} = O'a 
so that the correlation between the two observations is 
p = 0'41 (O'~ + IYV, and 1 - p2 = IYiO'V (IYa + O'i)2, 
where O'~ = 20'a + O'i. 
Thus the likelihood for this pair of observations is: 
11 (2TTO'.0'2)exp{- (O'~ + O'i) 120'iO'U <Y1jl - E<Y1J,})2 
- 20'V (O'~ + IYi) <Yin - E{YiJ~) (Y'J2 - E<YlJ2}) 
+ (YiJ2 - E{Y1J2} )2]} .•• 9.2.1 
ASsuming that there are n, subjects in sequence i, 
with N = n, + n2, m = N/(nln2), the likelihood for the 
observations on all N subjects can be split into the 
following components: 
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1t = 14(EY1Jl EY1J2 + EY2Jl EY2J2 ) N (1[, lllO'f/8 ) 
l' = 14(EY1Jl EY1J2 EY2Jl + EY2J2 ) N(1' - ~, mrU8) 
ex = ~(EY1Jl + EY1J2 E Y2Jl EY2J2) N (<X, lDO'~/ 2) 
plus quadratic forms SSP ft • «r~X 2 N_ 2 
. ,,9.2.2 
Prior distributions are postulated for ~, 1[, 7, <X, 
cr~, and cr~. As is usual when there is no strong a priori 
information about the parameters, uninformative priors 
are used except for the carry-over effect <x, which is 
assumed to be normally distributed with mean 0 and 
variance «ri. The joint prior density is thus: 
.. 9.2.3 
By giving era different values, a range of prior beliefs 
about the likelihood of the presence of carry-over may be 
obtained. eri = 0 corresponds to a prior belief that 
carry-over is not possible, while cri = ~ corresponds to 
an uninformative prior about the size of the carry-over 
effect. 
Multiplying the prior distribution and the 
likelihood gives the joint posterior distribution. The 
parameters of most interest are T and a, and the jOint 
posterior distribution of these could be found if the 
other parameters could be integrated out of the Joint 
posterior. Unfortunately, it is only possible to 
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integrate out ~ and n analytically, with the other 
parameters having to be removed by the use of numerical 
integration. Thus, exact general results cannot be 
obtained for the joint distribution of T and a, and each 
dataset would have to be submitted to numerical 
integration separately, using a package such as the Bayes 
4 program, developed at the University of Nottingham. 
However, Grieve shows that approximations to the 
posterior marginal distributions of ~ and a, and the 
conditional posterior distribution of ~ given a are 
possible to obtain. These are given as: 
p(a y) = t(&, m(SSP)/[2(N - 2)], N - 2) 
p(~ a, y) = t(f + ~a, m(SSE)/[8(N - 2)], N - 2) 
p(~ y) = t(f + ~a, mf/(8h), f) ... 9.2.4 
where t(8, ;, v) denotes a shifted and scaled t 
distribution with v degrees of freedom, location 
parameter 8, and scale parameter ;~i and 
f = 4 + {(SSE + SSP)2 (N - 6)} / {SSE~ + SSP~} 
h = (f-2) (SSE + SSP)/(N -4). 
9.3 The Two-period Desiin with Baselines 
In chapter 4 it was shown that the addition of 
baseline measurements to the two-period cross-over gave a 
more efficient estimator of the carry-over effect. 
However, from the point of view of a BayeSian analysis, 
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the addition of baseline observations makes the situation 
more complex, since the likelihood of a set of three 
observations on a single subject must now be considered 
as having a tri-variate normal distribution. Writing y 
for the vector of three observations on a single subject, 
i. e. y' = (YiJO, YiH, YiJ2), the tri-variate normal 
distribution has p.d.f. 
. .. 9.3.1 
where p is the vector of means given by the linear 
model, and E is the variance-covariance matrix of the 










Wri ting Yo, yl, and y2 for YiJO, yUl, and YtU, and }lo, }l1, 
and }l2 for the expected values of these observations 
given by the linear model, the exponent of the tri-
variate normal is: 
-1/[20'~<1-p) <1+2p)] {<l+p)( <YO-JlO)2 + <Yl-Jll)2 + <Y:z-Jl:z)2] 
-2p( <Yo-jJ.O) <Yl-Jl1) + <Y1-jJ.1) <Y2-jJ.2) + <Y:Z-jJ.:Z> <Y1-Jll)]} 
... 9.3.2 
Given observations on three periods <baseline and 
two treatment periods), two contrasts between the periods 
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can be defined. For convenience, the usual contrasts for 
linear and quadratic trend are used, so that orthogonal 
effects 1tL, and 1t~ are defined, with nL = no - 1£2, and 1tQ = 
1t0 -21tl + 1t2. Effects ~ = ~1 = -~2, T = TA = -~8 and a ::: aA 
= -aB relating to sequence, treatment and carry-over are 
also defined, together with the estimators: 
j.l = 1/6n{1:Y1JO + 1:Y1Jl + 1:Y1J2 + 1: y2JO + 1: y2J1 + 1: Y2J2} 
't = 1/2n<I:YlJo 1: Y2,l0} 
XL ::: 1/2n<I:Y1JO - 1: yl .12 + 1:Y2JO -1: Y2U} 
1tQ ::: 1/2n{1:Y1JO -21: yl .I 1 + 1:Yl,j2 + 1: Y2jO -21:Y2,jl + 1: Y2j2} 
i ::: 1/2n{-I:Y1JO + I:ylJ1 + 1: y2JO - 1: Y2J ,} 
It can be shown that the likelihood partitions into 
components depending only on }.l, fiL, ft~ and i, i, a, with 
with j.l - N(~, ~~(1+2p)/6n), 
ftL ~. N ( 1tL , ~ ~ ( 1-P ) In) 
and 1tQ~' N(1tQ, 30'~<1-p)/n) 
The term involving i, i, and a cannot be factored, and 
has the form of a tri-variate normal, with mean vector 
p.v ::: (1:YljO - 1:Y2Jo)/N 
p. ... ::: (-1:Yl,jO + 1:Yl,jl + 1:Y2JO - 1:Y2,jl)/N 
p.. ::: <-21:YIJO + 1:YIJI + 1:Y1J2 +21:Y2JO - 1:Y2Jl - 1:Y2J2)/N 
and variance covariance matrix 
155 
~f/N 1 -(l-p) -2(1-p> 
( -(l-p) 2(1-p) 3(1-p> 
-2(1-p) 3(1-p) 6(1-p> 
It is interesting that the mean for ~ in this tri-
variate normal is the contrast between the baseline and 
first period observations, the presence of the carry-over 
effect preventing the use of the data from the second 
period. 
Assuming vague priors for the parameters as before, 
the posterior will be in a similar form to the above 
likelihood, presenting great difficulty in obtaining 
posterior distributions for the parameters of interest. 
Integrating out the parameters of little interest is not 
possible analytically, and, although numerical 
integration techniques might be applied, this requires 
sophisticated computing. This is an example of the 
problems associated with Bayesian analysis, which can 
often lead to intractable jOint posterior distributions. 
There seems to be little pOint in p~rsuing this method of 
approach, as its application to more complicated designs 
is likely to yield still more intractable joint 
posteriors. Fortunately, an alternative approach 
utilising Gibbs sampling has now been suggested, which is 
much simpler to apply. The application of this method 
will now be considered. 
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9.4 Gibbs Sampling 
It is evident that a straightforward Bayesian 
analysis often gives a joint posterior distribution from 
which the marginal distributions of interest cannot be 
derived analytically. In some cases approximate 
distributions can be obtained as above(Grieve[1989]), 
while in others numerical integration techniques would be 
needed (Naylor· & Smith [1982,1988]). A simpler 
alternative to the use of numerical integration 
techniques is to employ a "sampling based approach". 
Gelfand & Smith[1990] and Gelfand et al[1990] have 
investigat~the use of the Gibbs sampler, described by 
Geman & Geman[19841, for estimating the conditional 
posterior distributions in a Bayesian analysis, and are 
enthusiastic about its efficacy. The technique is, 
indeed, remarkably Simple in essence. The conditional 
distribution of a parameter is calculated, assuming that 
all other unknown parameters are in fact known or fixed 
in value. A value of the one parameter which is being 
regarded as unknown at this stage is then simulated, 
taking a previously simulated value of the other 
parameters as their 'true' value. The simulated value of 
the parameter is then used in further simulations of the 
other parameters. Thus the technique cycles round the set 
of parameters simulating each one in turn. This cyclic 
process is repeated for many simulation sets, and Geman & 
Geman showed that under mild conditions the process would 
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converge, allowing the required marginal distribution to 
be estimated from the conditional distributions on the 
ultimate cycle. 
Because of the notational difficulties, it is 
simpler at this stage to think in terms of a particular 
number of parameters 9, although it is not necessary to 
specify the nature of the parameters. We will consider a 
set of 3 parameters 9" 92 and 9s. The conditional 
posterior for 9" given the observations x, and 
considering 9:z and 93 to be known, may be written 
h(S, I 8:z, 93, x). Similar expressions for the conditional 
posteriors of 92 and 93 will also be used. 
The Gibbs sampling procedure will start with initial 
values of 8 1 , 92 and 93, denoted 9fO). These initial values 
will be changed by Simulating a new value at each cycle 
of the iterative process. The value for 9, simulated on 
cycle k will thus be denoted 9lk >. The process of Gibbs 
sampling then proceeds as in fig 9 below. 
Gelfand et al[1990] suggest that convergence of 
the process can be judged by plotting the ordered 
parameter values from successive cycles, which will lie 
approximately an a line of slope 1 when the process has 
converged. Assuming that the process has converged after 
k cycles, the marginal posterior distribution can be 
estimated using the 8(k) values from the simulation sets. 
Let the values for the ith simulation set be denoted 9'i, 
92' and 8 3t • In order to estimate the marginal posterior 
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for 9" we will use the fact that the form of the 
conditional posterior of 9" given a value for 92 and 93, 
is known, < h<9, I 92, 93, x) ). Using 921, 931 as the 
"known" values of 9 2 and 93, we can calculate ordinates 
of the posterior for 9,. Because the values of 921 and 931 
will be slightly different for each simulation set, the 
calculated ordinate for a particular value of 9, will 
vary. The overan estimate of the ordinate of the marginal 
posterior of 9, is taken as the average of the estimates 
from the individual simulation sets. 
Sequence of Operations in Gibbs Sampling 
Start cycle k with values 9t k- n , 
Simulate a value from h(9, I 9~k-1>, 
- simu lated value is e fk) 
Simulate a value from h(8:z I 9lk), 
- simulated value is 9~k) 
Simulate a value from h(93 I 9f k), 
- simulated value is 9~k) 
In order to illustrate the technique, its 
application to a very simple situation, for which the 
marginal posterior distributions can be derived 
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analytically, will be considered, before the technique is 
applied to the more complex situations which arise in the 
analysis of cross-over designs, 
9,5 A Simple Example 
Consider a situation in which a random sample of n 
observation is drawn from a normal population whose mean 
and variance are unknown, The two unknown parameters, the 
population mean, and the population variance will be 
denoted 9 1 and 92 respectively, while the sample 
observations will be denoted X1, "" Xn, The likelihood 
is then given by 
L = (2lT9 2 )-"n exp{ -1: (x, - 91)2/282} 
If independent vague priors are specified for the two 
parameters, with a uniform prior for 61 and a prior for 
62 proportional to 1/62, the joint posterior is 
proportional to 
(92) -"(n-+:2) exp< -1: (x, - 9 1 )2/262} 
Writing 1: <x, - 61)2 as (n-l)s2 + n(x - 91)2, where x is the 
mean of the sample and S2 the unbiased estimator of the 
population variance from the sample, the joint posterior 
can be re-written 
(62)-I"n-+2) exp< -[ (n-l)s2 + n(x - 61)2] 1262} 
Treating 62 as a known constant 1 the conditional 
posterior for 8, is 
p(8,1 8 2 , x) ex exp< -n(x - 6, )2/262} 
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multiplying this by the constant (82)-~' normalises the 
expression for this conditional distribution, showing it 
to be the normal distribution with mean X, and variance 
6 2 /n. II 6, is treated as a constant, the conditional 
posterior for 6 2 can be obtained 
p«(hl 8" x) ex (82)-~(n+2) exp{ -[ (n-l)s2 + n(x - 6,)2] 126:z} 
This indicates that [(n-1)s2 + n(x - 8,)2]/82 has a chi-
squared distribution with n degrees of freedom. 
Having derived the conditional posterior 
distributions, the Gibbs sampling can be instituted. 
Adapting the general method given in fig 9 to this 
specific example, gives the sequence of steps illustrated 
in fig 10 
Gibbs Sampler for the Simple Example 
Start cycle k with values 6\k-'), 8~k-') 
Simulate a value from N(x, 8~k-1)/n) 
- simulated value is 8\k) 
Simulate a value from the chi-squared distribution 
with n degrees of freedom = en 
- [ (n-1)s2 + n(x - e\k»2] len is eik) 
Assuming that the process has converged after k 
cycles, the e(kl values for the ith simulation set will 
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be denoted 811 and 921. The conditional posterior 
distribution for 81 given 821 is a normal distribution 
with mean x, and variance a21/n. Let the ordinate of this 
an ordinate can be found for each simulation set, and the 
average of the ordinates given by all the simulation sets 
is used as an estimate of the corresponding ordinate of 
the posterior distribution of aI, 
is the number of simulation sets. This allows us to plot 
the shape of the marginal posterior distribution, and 
calculate approximate "confidence" intervals for 91. 
For a simple situation such as this, convergence is 
achieved qUite quickly, with about 25 cycles proving 
sufficient. The ordered values of 81 and 82, from which 
convergence can be judged, are plotted for cycles 1 & 2, 
12 & 13 and 24 & 25 in figs. 11, 12 & 13 
In this simple case, the form of the marginal 
posteriors is easily obtained analytically, <see eg 
Lindley[1965J), the marginal posterior for 81 being such 
that n~(81 - x)/s has a t-distribution with n-1 degrees 
of freedom, with the marginal posterior for 92 being such 
that (n-1)s2 /82 has a chi-squared distribution with n-l 
degrees of freedom. A program was written to perform the 
Gibbs sampling proceedure for this simple example, using 
HAG routines to simulate values from the required normal 
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Convergence of the Gibbs Sampler for the Simple 
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the marginal posterior distribution of 91, together with 
the t-distribution which is the theoretical form of the 
posterior are plotted in fig 14, showing good agreement 
between the Gibbs sampling and theoretical results. 
9,6 Gibbs Sampling for the Two period Crgss-gyer 
The analysis of the two-period cross-over using 
Gibbs sampling described here follows the method given by 
Gelfand et al[1990] I who give several examples of the 
application of Gibbs sampling, including the analysis of 
a two-period cross-over with missing values, but without 
carry-over. Initially, details of the analysis with no 
carry-over in the model will be given, and this will then 
be generalised to include carry-over. The methods are 
then used to analyse the enuresis data given by Hills & 
Armitage[1979], which has been extensively investigated 
using classical methods <Poloniecki & Daniel[1981]), and 
was also used by Grieve[1985] as an example in his 
Bayesian analysis. A listing of the data 1s given in 
appendix F. 
The linear model without carry-over will be as given 
in chapter 2, except that the constraints on the 
parameters have been incorporated so that, for the period 
effects, ~ = ~1 = -n2, and for the treatment effects, T = 
TA = -Ta. As before, the parameters ~ and w represent the 
overall mean and the subject effect, respectively, with e 
representing the error term. The model for the response 
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for the jth subject in the ith sequence for the kth 
period is thus: 
wand € are random effects with variances ~~ and ~i, 
respectively. The two observations on a single subject 
therefore have a bivariate normal distribution with mean 
x'Ja, and variance-covariance matrix t, where a' = 
[~,~,T], the vector of model parameters, and X'J is the 
appropriate design matrix. i.e. 
I = (~a+~i ~a \ being the same 
~a ~3+~il 
for all subjects 
Two new variables, ytJ and yt .. are defined as 
fbllows: 
These new variables have the advantage of being 
orthogonal, so that the bivariate normal distribution of 
yt.t and ytJ is relatively simple. Thus 
(
Yi .I) ~. N (n:+T) ~ (~i 0 \ and 
ytJ Jl 0 ~~) 
where ~~ = 2~~ + ~i 
Prior distributions are now specified for 8, ~i and 
~~. 8 is assumed to have a trivariate normal 
distribution, and the two variances are assumed to have 
inverse gamma distributions. The distributions are 
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assumed to be independent, so that the prior distribution 
is given by: 
f(e,O'~,O'~) = N(J(,C)IG(~d •• ~d.v.)IG(~d2,~d2v2) 
This distribution is subject to the restriction O'~ , O'~, 
which is a consequence OI the definition of O'~. 
Defining S8, = 2I:{Y1J -(1[+'T)/2)}2 + 2I:<Y2J - (1[-'T)/2}2 
and SS2 = 2I: I: {ytJ - JJ.}2 
wi th X' S-I Y = I: I: X1 J I-1Y1J , X' S-'X = I: I:X'JI-'X6J 
and :0- 1 = XI g--'X + C-I, it can be shown that the Gibbs 
sampler for O'~, O'~, and e is specified by: 
O'~IY,e,O'~ = IG{~(n+d.), ~(SS, + d.v.)} 
O'~IY,e,O'~ = IG{~(n+d2), ~(SS2 + d2v2)} 
9IY,O'~,O'~ = N{D(X'S-'Y+C-IX).D} 
Details of this derivation are given in appendix D. 
The Gibbs sampling process for this example is 
illustrated below in fig 15. With no carry-over in the 
model, the process converged quickly, and was relatively 
insensitive to different initial estimates of the 
parameters. The obvious initial estimates are those 
derived from the usual analysis given by Hills and 
Armitage[19791. and quoted in chapter 2 above. The 
estimate of the posterior distribution of the treatment 
effect obtained agrees with that given by Grieve when 
carry-over is assumed to be zero. A plot of the estimated 
posterior, is given in fig 16 together with the estimated 
posteriors when there is carry-over in the model. 
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Fig 15 Gibbs Sampler for the Two-period Cross-over 
Calculate SSI & SS2 using current value of e 
Simulate a value from the gamma distibution with 
parameters n+d. and SSI+d.v.. The new value of O'~ is 
the reciprocal of this simulated value. 
Simulate a value from the gamma distribution with 
parameters n+d2 and SS2+d2v2. The new value of O'~ is 
the reciprocal of this simulated value. 
Calculate D using the new values of ~~ and ~~ 
Simulate a value from the tri-variate normal 
distri bution with mean D(X' S-lY+C-lx), and variance D. 
Simulated vector is new value of e 
9.7 Addini Carry-oyer to the Hodel 
The addition of carry-over to the above model and 
the application of the Gibbs sampling approach is now 
considered. The overall form of the Gibbs sampler is 
unchanged, but 9 is now a vector of four parameters. 
~,n,7 and a, where a is the carry-over effect, with aA = 
-aB = a. Details of the derivation of the conditional 
distributions are given in appendiX D. Adding carry-over 
to the model increases the uncertainty about the size of 
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the effects, and the prior variances needed to be 
increased from the value used when there was no carry-
over in order to allow the sampler to move to its optimum 
solution. The estimated posteriors for ~ and a are 
plotted in fig 16, and agree very well with the results 
given in Grieve's paper, where an almost identical plat 
is gi vent 
9.'8 Three-period Desiins 
The sequence of operations in Gibbs sampling given 
in fig 9 could be applied to any experimental design, 
including any of the crass-aver designs described 
previously. For each design it is necessary to derive the 
conditional distributions. Fallowing the lead given in 
Gelfand et al[19901, this is simpler in terms of 
orthogonal functions of the observations on each subject, 
rather than the observations themselves. For the three-
period design with sequences ABB and BAA, the orthogonal 
functions 2YiJl - YiJ2 - ytJ3, which is used to obtain 
estimates of the treatment effect in the conventional 
analysis, and yiU - YU3, used to obtain estimates of the 
first-order carry-over effect, together with the total of 
the three observations an a subject <yu1 + yiJ2 + Y1.t3) are 
those which seem most appropriate. These have been used 
to derive expressions for the conditional distributions, 
and details are given in appendix E. The vector of model 
parameters 8 can be increased to include a group effect 
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Fig 16 
Estimated posterior for the enuresis data . 


































































(~), two period effects (~1 & ~2), and, if required, 
first and second-order carry-over effect <a,~). The Gibbs 
sampler for ~~, ~~, and 9, where ~i = 3~3 + ~~ that 
results is essentially the same in character as that 
described for the two-period design, with simulated 
values for ~~ and ~~ being obtained from inverse gamma 
distributions, and simulated values of 9 being obtained 
from a multivariate normal distribution. 
A FORTRAN program was written to apply the Gibbs 
sampler, both with and without second-order carry-over in 
the model. This was applied to the data for the ABB 
design, from Ebbutt[1984J. 
9.S,! Results 
In his paper on three-period cross-over designs, 
Ebbutt[19841 considers a set of data from a trial 
comparing two treatments for hypertension. The trial 
consisted of four sequences, ABB, BAA, ABA & BAB, but 
only the data from the ABB & BAA sequences have been used 
here. Systolic and diastolic blood pressure was recorded 
for each patient in each treatment period, and a baseline 
observation was also taken. Only the systolic blood 
pressures have been used here, and a listing of these is 
given in appendix F. Using the data from the three 
treatment periods, estimates of ~, a and ~ are 2.96, 
1.336 and 8.116, repectively. The estimates of T and a 
are obtained using the within-patient comparisons Hu = 
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2Yij, - yiJ2 - yiJ3 and KiJ = Yij2 - Yij3 respectively, and 
would be expected to be more accurate than the estimate 
for j3 which uses the between-patient comparison 2YiJl + 
yiJ2 + Ylj3. However, the estimators of 1" and a are only 
unbiased if j3 = O. The variance of the estimator of j3 is 
large, and in a formal test, the hypothesis j3 = 0 would 
not be rejected. A better estimator of ~ can be obtained 
by using the baseline observations, and this gives j3 = 
-2.86. Corresponding estimates for 1" and a are 2.246 and 
-0.094 respectively. The Gibbs sampler was run twice 
using each of these two sets of estimates, and the 
estimated posterior distributions are given in figs 17, 
18, 19 & 20. Figs 17 and 19 give the estimated posteriors 
for 1" and a when there is no second-order carry-over in 
the model. It can be seen that the dif'ferent starting 
values make very little difference to these results. Figs 
18 and 20 give the estimated posteriors for 1", a and .13, 
and show a marked difference, both from the posteriors 
when there is no second-order carry-over, and from each 
other. Clearly, adding second-order carry-over to the 
model introduces a great deal more uncertainty, and this 
necessitates an increase in the prior variances. Although 
the program was run several times with increasing values 
of the prior variances until the solution appeared to 
stabilise, it may be that the optimum solution had not, 
in fact, been reached, and that the process had 





Fjg lZ : Estimated posterior distribution for ~ & a , 













































Fig 18 : Estimated posterior distribution for T, a & ~. 
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fig 19 : Estimated posterior distribution for ~ & a , 







































































Fig cQ : Es timated posterior distribution for ~, a & ~ . 




































posteriors for ~ are centred at values relatively close 
to the initial estimate, indicating that the process has 
~ 
not moved far. On theAhand, the centres of the posteriors 
for T and a are not particularly close to their starting 
values, and the estimates of T are fairly similar. This 
may just reflect the fact that the data gives most 
information about T and least about ~, and suggests that 
the process had not properly converged. 
9.9 Effectiyeness of Gibbs Sampling 
Gibbs sampling was found to work well for the two-
period cross-over, and be relatively simple to apply. 
Using a model without carry-over, the computations were 
completed quickly, with rapid convergence, unaffected by 
the initial parameter estimates. Once carry-over was 
included in the model, the computations took much longer, 
and convergence could be adversely affected by 
inappropriate initial estimates of the parameters. 
However, it was found that use of the "obvious" initial 
estimates, from the Hills & Armitage estimators, 
generally avoided problems with convergence, and there is 
every reason to believe that the process will work well 
when such initial estimates are employed. Another 
critical factor in the success of the procedure was the 
choice of the variances of the prior distributions for 
the parameters. If these are too small, then the process 
is unable to move far from the initial estimates, while 
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if they are too large, the extra variability causes the 
condition that one of the simulated variances be larger 
than the other (a consequence of the fact that the second 
variance is the sum of the first and other variance 
terms) to be violated frequently by the simulated values. 
When this happens, another attempt at simulating suitable 
values must be made, and the larger the prior variances, 
the more likely it is that the simulated variances will 
violate this condition, necessitating more passes through 
the simulation loop to obtain acceptable values. This 
increases the computing time, which can quickly become 
u ,,_acceptably long. In some ways these two problems are 
related, because "good" initial estimates will be close 
to the optimal, and will not require the solution to move 
far. It is clearly good practice, however to gradually 
increase the prior variances and confirm that the 
solution remains stable. 
It should not be thought that the Bayesian analysis 
overcomes all the difficulties of the classical analysis. 
Rather it is that, with a posterior distribution for the 
treatment effect, the uncertainty about its value is 
included, rather than quoting a, pOSSibly misleading, 
point estimate. If some measure of the centre of the 
posterior distribution were to be quoted on its own, this 
would be as inadequate as the classical point estimate. 
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9.10 Discussion 
Bayesian analysis has been suggested as a way out of 
the problems caused by carry-over, because it provides an 
overa) picture, in the form of the posterior 
distributions, of the position regarding the estimation 
of the treatment and carry-over effects. It is clear, 
however, that the difficulties with integrating out 
unwanted parameters to obtain the required posteriors 
make the direct application of Bayesian methods very 
difficult. The method of Gibbs sampling overcomes these 
problems by obtaining an estimate of the posterior 
distributions indirectly, using a sampling approach. It 
is relatively easy to apply to complicated designs, and 
is not too expensive in computing time, given the 
powerful machines that are currently available. As with 
all simulation methods, however, there is a fine line 
between the method working well and providing a good 
estimate, and between it failing to converge, or 
performing badly. It appears that the choice of the 
initial estimates, and the prior variances are the 
important factors in this. In this investigation it has 
been found that the estimates from classical methods 
(e.g. Hills & Armitage for the two-period design) are 
generally good initial estimates, while the appropriate 
values of the prior variance have been determined by 
trial and error. There is scope for further work on the 
method in order to develop rules of thumb for these, but 
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this would require work with a large number of data sets, 
in order to obtain a general view of the situation. 
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Chapter 10j Discyssion 
10.lintrodyction 
This thesis has been concerned with the problems 
caused by carry-over in cross-over designs, and has 
suggested ways of dealing with these problems. The 
difficulties that carry-over cause are best understood in 
relation to the simple two-period cross-over design, 
because this is the simplest such design, and the most 
widely used and studied. One solution to the problems of 
carry-over is to use a more complex design rather than 
this simplistic design, while another 1s to use a 
different form of analysis for the design. Both these 
options have advantages and disadvantages which will be 
briefly reviewed in this chapter. 
10.2 The Problems of Carry-oyer 
Chapter 2 covered the nature of carry-over, and the 
problems it causes in the analysis of the simple two-
period cross-over. The technical details of these 
problems are explained in more detail in chapter 8, where 
the power of the test procedure, and the bias in the 
estimation of the treatment effect are explored. The 
uncertain nature of carry-over effects contributes to the 
difficulty in dealing with them. The simplest type of 
carry-over, in which the active compound in a drug 1s 
still having an effect in the next treatment period, 
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should be very easy to avoid, while any psychological 
effect of a treatment is at least understandable, but 
more difficult to counteract. As Freeman[19891 has 
pOinted out, true treatment-period interaction, implying 
that a treatment has different effects at different 
times, makes any judgement of the size of a treatment 
effect impossible, whether a cross-over design is used or 
not, because the result will, apparently, depend on when 
the experiment is performed. 
10.3 Alternatiye Designs 
Chapter 3 reviewed the considerable literature on 
the design of cross-over trials, although this thesis has 
only considered designs for two treatments, because 
clinical trials most commonly involve such a comparison. 
Three alternatives to the simple two-period design were 
dealt with in detail. These are the "complete" two period 
design, with four sequences AA, BB, AB & BA, shown by 
Laska et al(19831 to be the optimal two-period design, 
the three-period designs with two sequences ABB & BAA, 
shown by the same authors to be the optimal three-period 
design, and the three-period design with four sequences 
AAA, BBB, ABB & BAA. This last design does not seem to 
have been seriously considered before, most authors 
rejecting the use of a sequence of the same treatment for 
a cross-over design, despite the optimality of the 
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"complete" two-period design. This seems unnecessarily 
restrictive, and the design is worthy of consideration. 
All of these alternatives involve some cost, but 
this 1s sometimes slight, as it is not necessary to 
increase the number of subjects in order to obtain a 
better estimate of the difference between the two 
treatments than can be obtained from the simple two-
period design. With the four sequence designs, this means 
that there will be a smaller number of subjects in each 
sequence, which might be a problem if there was a high 
drop-out rate, although such a phenomenon would be rather 
alarming anyway. With the three-period designs, there is 
of course an extra treatment period to adDdnister, 
suggesting that the trial would last longer which might 
increase the drop-out rate. However, because these 
designs cope much better with carry-over, especially 
first-order carry-over, there is less need for a "wash-
out" period between treatments, and so the overall length 
of the trial may not be much longer than a two-period 
design with wash-out periods. The .. complete" two-period 
design is the least demanding alternative, only requiring 
that the subjects be organised into four groups rather 
than two. Given the benefits in terms of the improved 
estimation of the treatment difference, this is well 
worthwhile. 
184 
10,4 Alternatiye Analyses 
Much of the thesis is concerned with the statistical 
analysis of cross-over trials, and how this may be 
improved, Xethods for both binary and continuous data 
have been considered, with attention being given to 
classical and Bayesian methods. Almost all analysiS 
options have been considered previously for the simple 
two-period cross-over, but application to the other 
designs has often not been discussed before in detail. In 
particular, results for the ABB, BAA design for binary 
data is new, (Xorrey[1989]), as is the Bayesian analysiS 
using Gibbs sampling. Indeed, the consideration of the 
efficacy of Gibbs sampling for the analysis of cross-over 
designs undertaken in chapter 9 has not been performed 
before. The calculations for the power of the test 
procedures for the ABB, BAA design contained in chapter 
8, have also not been publicised before. 
There is considerable scope for further work, both 
in considering other cross-over designs with, for 
example, more than two treatments, and other types of 
data. Although non-parametric methods have not been 
mentioned in detail in the thesis, most of the tests for 
continuous data involve a comparison of sets of contrasts 
from the different sequences, which could be carried out 
by a non-parametric method as easily as by a parametriC 
method. It would also be possible to modify the Gibbs 
sampling methods to non-normal likelihoods, although this 
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would be less trivial. Analysis using multivariate 
methods has not been considered, although this could be 
expected to mirror the analysis for continuous data. 
Perhaps the most difficult area that still ,needs to be 
explored in detail is the analysis for ordered 
categorical data. In general, cross-over designs attempt 
to extract a great deal of information from relatively 
few observations. With ordered categorical data, the 
observations may be regarded as being one stage removed 
from an underlying, unobservable, latent variable. Thus 
the observations effectively indicate that the latent 
variable is in a specific, unknown, range. Given the 
difficulties of performing the analysis with continuous 
data, equivalent to observing the latent variable, it is 
not surprising that analysis is intractable when the 
latent variable is not directly observable, and it seems 
doubtful whether a really efficient analysis would ever 
be possible. 
10,5 Cross-oyer Designs and Clinical Trials 
The particular problems of clinical trials arise 
from the fact that the experimental units are people. The 
large variability of the experimental units is one 
consequence, while ethical issues relating to the 
treatment of subjects cause other problems, It is 
generally regarded as unethical to treat more subjects 
than is absolutely necessary with an inferior treatment 
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in order to provide convincing evidence that would 
determine good prescriptive practice. Thus a clinical 
trial should add to the current state of knowledge, 
rather than duplicating past results, or at least provide 
substantial weight to a previously tentative conclusion, 
but in the process it should minimise the number of 
subjects that receive an inferior treatment. At first 
sight, the potential gain in precision of a cross-over 
design would seem to be beneficial, but if the problems 
of carry-over arise these potential benefits are lost. 
Indeed, the potential for a misleading estimate of the 
treatment effect that arises from the suite of pre-tests 
and main tests commonly used for the simple two-period 
cross-over is a marked disadvantage. Given the problems 
with carry-over, the use of the simple two-period cross-
over is hard to justify, as the results are unlikely to 
be completely convincing to any-one familiar with them. 
This b~y of people is, however, unlikely to include many 
physicians, who are more likely to be impressed by the 
intuitive appeal of the cross-over design. Fortunately, 
there are cross-over deSigns, notably the "complete"two-
period design, which do not suffer from these 
disadvantages, and could usefully be employed in clinical 
trials. Although physicians would need to be informed of 
the virtues of this design, it could be said to be a 
combination of the parallel and cross-over deSigns, 
combining the benefits of each. 
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10,6 Concluding Remarks 
It is likely that the alluring concept of "using a 
subject as his own control" will ensure that cross-over 
designs will continue to be used for clinical trials. It 
is unfortunate that the appeal of the designs is so 
intUitively clear, whereas the drawbacks are more 
difficult to comprehend. This is compounded by the use of 
the word "carry-over" for the factor that causes all the 
problems, leading to the impression that such effects can 
be avoided by an interval between the treatment periods. 
Most unfortnate of all is the fact that the design which 
has become most commonly used, the simple two-period 
cross-over, is badly affected by the problems of carry-
over, when there are other, almost equally simple designs 
which do not suffer from the problem to the same degree. 
In particular, the "complete" two-period cross-over would 
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Probabilities 
Appendix A ; Calculation of Xyltiyariate Normal 
Probabilities 
IntrodyctiOn 
In order to calculate the power of the test 
procedures for cross-over designs where a sequence of 
pre-tests and main tests are employed, calcula.tion of 
bivariate and tri-variate normal probabilities is 
required. The purpose of this appendix is to describe the 
methods that were used to perform these calcul~tions. 
Biyariate Normal Probabilities 
Various methods of calculating bivariate normal 
probabilities have been described, some of which apply in 
special circumstances, but one of the most useful methods 
is given by Owen[19561, and has been used in this study. 
Defining B<h,kiP) to be the bivariate normal integral for 
the volume X < h, Y < k when variates X and Y have a 
bivariate normal distribution with E{X} = E{Y} = 0, 
Var{X} = Var{Y} = 1, and Cov{XY} = P, and G(z) to be the 
probability that the standard normal variate Z takes a 
value < 2, Owen showed that: 
B<h,kiP) = ~<h) + ~<k) - T<h,an) - T<k,ak) - b 
where the constant b is 0 if hk ) 0 or if hk = 0 but h+k 
~ 0, and ~ otherwise, and the function T<h,a) is an 
integral defined by Owen, with an = «k/h) - p)/r , 
~1 
ak = «h/k) - p) Ir where r = '" <1 - p2). Owen also gave a 
series expansion for the integral T(h,a), which rapidly 
converges for small values of a and h. Donnelly[1973J has 
given a Fortran program for calculating bivariate normal 
probabilities which evaluates this infinite series, and a 
modified version of this has been used for the 
calculations, this forms the subroutine "BCAL" in the 
programs to calculate the power. A standard NAG function 
(S15ABF) was used to evaluate standard normal 
probabilities. 
Iriyariate Normal Probabilities 
In order to calculate trivariate normal 
probabilities, a method described by Steck[19581 was 
applied. If X,Y & Z are three variables having a 
trivariate normal distribution with E{X} = E{Y} = E{Z} = 
0, Var{X} = Var{Y} = Var{Z} = 1, and E{XY} = P12, E{XZ} = 
P13, E{YZ} = P23; the probability that X < h, Y < k, and Z 
< m is C(h, k, m; P12, P'3, P23). This probability is defined in 
terms of the G and r functions given above, and a new 
function, S(h,a,b), which is itself a univariate 
integral. Daley[1974J has cOmDented that computation of 
this integral by Gaussian quadrature gives acceptably 
small errors, so a NAG routine (D01ARF) was used to 
perform the evaluation of the S function, and hence to 
obtain trivariate normal probabilities. Calculation of 
the S function is performed in the subroutine "SCAL" in 
A-2 
the program to calculate the power for the three-period 
cross-over design. 
C (h, k, mj pa':2, P13, P23) is only defined for two cases. 
Case 1 applies if h,k, & m are all positive or all 
negative, and case 2 applies if h & k are positve and m 
negative or h & k negative and m positive. It is possible 
to interchange the variables, and the corresponding 
correlations, in order to ensure that it is always m that 
has a different sign. Because C<h,k,m) is defined as 
p<X<h, Y<k, Z(m), some re-adjustment needs to be made if 
a probability such as p<X(h, Y<k, Z>m) is required. 
Expressions for the required probability can be found by 
using the fact that, because C(h,k,m) applies to 
normalised variables X, Y & Z, C(h, k, mj Pl:2, P'3, P:2:a) = D(-
h, -k, -mj Pl:l, P13, p:u), where D<h, k, m) = p<X)h, Y>k, Z)m), 
and the relationship given by Steck that if h,k,m are all 
non-negative or non-positive. c(h, k, mj P'2, P'3, pu) = 
B(h, kj P12) - C(h, k, -mj P12,-P'3, -pu). 
A-3 
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Appe nd i x B ; Program to ca l culate the power for the two-
period cross-over . 





.. __ .. 
i n t e 8 e i- i f a. i i , i I ~. , j i ~ . 
double prec i s ion n, rn ,r12,r32, r ,d,8, v l ,v2,v3,v4,v5,v6,h, k ,~ Jw , 
lb i v,t,x,s15a.bf,t~1,tm2,res(17,17) ,t hat,x ; nc 
cc· m~n ·:.n i fa i I ,to iv,t 
re ad(S, 10) n,zal,:::a2,za~: 
10 format(4d15.8 ) 
12 r n=~q ( t (n ) 
r12=sqrt (1 .2dl) 
r32=sqrt(3.0dO ) /Z . OdO 
t-= t-::2 
d::l . 0 ,j O 
3= - 4.21~ O 
d.:. ~:O i \ P = 
3=3+0 .2dO 
; . ; 
~ , "11 
~I (I W = 1 . 0 ,j 0 
v2=za.2- r n*d/2 
v:;; = z a.2+~· ,,* tj / 2 
',i 1 = :. Q. l - ;-n '* S / r 1 :: 
·,, 4=::: c.. ~ + t-n*s /t-1.2 
~~= :a3- (d-g/2 )*rn 
v6:::-za3- (d-s / 2l *rn 
;. ~ = \/ 1 
; f a i ! =0 
~, = s 1 : .a. b of C, , i f' a. i I ) 
~ • • :' It; ::: p .:, '¥., - P 
tmJ. :::~, 
I~ ::: \/2 
ii c.. i l= C 
~.::. S 15 ab f (;.; , i f a. i : ) 
~, (I I", = P (; W - ' P 
( a ll be il.! (v i,l2, r) 
p (l w=~.o '¥.·+b i v 
i fai 1=0 
p=s i5abf( x , i fai l) 
pvw=pow+p 
ca l ! heal (v1 ,-v3,r ) 





call bea l (-v4, v2 , r) 
pow=pvl"l-b : v 
ca.l : bea l (-v4 ,-v3, r) 
~Iow=po '",+b i v 
I~:: - v4 
ifai 1=0 
P = s 15 at. f (x , i fa i I) 
t rn l =tm1-p 
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i h i 1 =0 
p=s1!:'abf (::, i fa i I) 
tm2=1-p 
i fa i : =0 
~,= s 15 ab.p (:.:, i fa i I ) 
trn2=tm2-+p 
pO .... =~.Ij .... +tml *tm:: 
thai;;=tr;.l* (d-Sf;:) + (l-ti.l1j *d-O.5dO 
w r ite(.~.,29 ) s,tml,that,po'..' 
29 format (5d15.8) 
:}) cc,nt i li ue 
s t)~: 
,j o 40 i l~, = 1,17 
do 40 jlp= 1, 17 
..,, ~. ; t e (6 , 5:») r es ( i I ~, , j i ~, ) 
< ~ f orma~( 13h ~~ eat diff = , diS.8 ) 
50 fO ( i.lat(d 15.S) 





sut,~-o :Jt ; ne bea. ! CCth 2, bk2,b rZ) 
i ritner ~ fa i i . 
\ol ~ \ _ ! 1 _ ,_. d (, u:, I e p. e c is i ;) n b ~I , t. :-:: , b t" , q r , b ; \i , P , "-h , a ~:: , -;; , s 15,,-b ? , :.: , u 11;';: , D ;:: ;;.: , t, r .:::. 
[ ·)ifi:l\·)rl i f"a i : ,b iv ,t 
b i '-.'= O. Od :) 
bh '::b h2 
bk =bk2 
bt=br2 
q "' =sG ~·t (l-bn·t.r ) 
>~:: b h 
if a i I ::(i 
p=s15a.bf' (}:, i.fai I) 
biv=t. iv+p 
x=bk 
i fa i 1=0 




call teal (bh,ah) 
b iv=biv-t 
ak= (bh / bk-bt-) Iqr 
.:: a. I I tea. I (b t:: , a. k) 
b iv=biv-t 
if (bh*bk> 110,100,120 















c sub r outine to cilcu l ate t-fun:tion 
c 
subrclutine tea.l (th2,ta.2) 
integer ifait,flg 
double pr2cision th,ta,twopi ,con,gw,t,sgn,g2,hZ,aq,h4,ex,w2,ap, 
ls2,sp,sl,sn,conex,cn,x,p,s15abf,b,thZ,ta2,biv 




con=twop i *ld-15 / Z.0dO 
b= O. ().:o 
f' \ 3=0 
sl=O.OdO 
ssn=-1.0dO 
190 th= - t h 
i .f::. i \ =: ..
;! = ; 1 : ' ~ D f (~.~ , i -f a. i !; 
wh=t h 
t=(l.O.:; :) 
if (ta.) 21(1 , :~:: \) ,22 \:': 
'21 0 t a=- to. 
fl g:: l 
220 it' (da. t ~(ta)-1. '·:).:C ) 270 ,2:::;(: ,240 
230 t=ta*3~1(1.0dO-3w)/2. 0dO 
24;) 5:3 n= - :;sn 





~, = s15a.uf{;" ifai i) 
32=~, 
ta,=1.0dC/ta 



















































Q.~! = - a.~,:O: . a.q 
290 cn=~p*s:! (sn+sp ) 
si=sl+:n 
-- - '- - .. . .. "_. 
- _ _ oj __ ' ~' . '_ .. .. _ ~ . . . ..... _ .......... ~ • • _, _ . - • 
j .? (da.bs (en) -cone:.:) :300,:300,2::;,) 
::::00 t= (d<;.i; ... n <ta.) -ta-x·s 1) /tIoJt:lp i 
:310 t=b- ssn*t 
if (fig) 330,330,315 
315 t=-t 
~:.::o t=O.OdO 
:::::::: :) retur·n 
en d 
B-4 
... _--_ . . _------- - -_ ... _--._- "--, ,... -,~-~ -- _ .... ; . . . 
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Appe ndix C ; Program to calculate the power for the 
three-period cross-oyer 
c ~,rcI8ramm2 to ca.icu \ate th2 power for the three=p2 r ic.,j cn,s;;-e,ver 
c 
c 
integer ifai l ,i 
double precision ans,b iv,cval ,n,p,~cw,prl,pr2,~r3, 
lq44,ret,rq33,rq44,rtt,rn,rn3,t,tre,vl,v2,v3,v4,v5, 
2v6 ,v7,v8,v9,vl0,s15abf,x,z2r,d,f,9,rrn,p k l,pkZ,~k3, 
:;: ,j hat, te m 
(lmmon/b:ockl / ans,b i v,cval, t 
ret=dsqrtC11.0dO/12. 0dO) 
rtt= dsq r ~(3.0dO)/2.0dO 
rq33=1. C d O/ ~sq r t(33.0dO l 
t :. e: =:;: • (> ': G / oj s q r t (11 .0 dO) 
rq4~=1.0dO/ cisq r t(44. 0 dO ) 
r2ad(5,1 )) n,:al,za2 ,za~,:~4,:a.5 
10 f o r~~t (6 di O .4) 
·L l f CI nn~ t (2 .j ~ 0 . 4: 
< 12 f (. ~. mat (:;: h er y 1 = ,d 10 • 4 , ;:.: , cry 2: = ,d 1 0 • 4 ) 
w:·· i te (6,* ) n 
~ri te(6,*) :a l ,:aZ ,: ~3,: a4,:a.5 
wr i te (6,4:Z) S,f 
c d= tr eat dif f , f=ca r r y 2: dif r , g=ca. rry 1 dif f 
c 
c 
t· n = Ij S q r t (n) 
rn3=dsq r~ ( n/3. 0dO l 
,-rn=1.0.: ·)/r n 
f =5. O.j ;)*r t"r, 
:3 :~ -5. Od C*rr n 
!,oJ t- i t e (.:, , '* ) :3 , f 
d = - :;'1. 2d(:''*-r r n 











vlO=za5- (d-f 14.0dO) ~2.0dO*rn::: 
pow=O.OdO 






i fa i 1=0 




---~---- -- _ .. .. -.- .. """"- " . 












• - - -- ........ - -"'. L.. - .... _ • • o, _ .... '- . . . ...:... ' , • to. .... . . _ ..... _. .. •• 
i fa i 1 =0 
p=s15abf (x , ifai I) 
p r 1 = P t- 1 - ~, 
pkl=prl 
:.all bca. ! (v2,.v:O, t-q~!:;: ) 
pr-l=pt-l-a.r:s 
ca l l bca.1 (v2,vS',rq3:3 ) 
pd:pt- l+~ns 
ca i I bca.1 (v1 , v10 ,rq:::::::) 
prl::.prl+ans 
c ii!' to c a I (v 1 , \19 , r q ::::::;:) 
p i -l=~.~-l-"-ns 
( ca.:cu : ltion of pr oL U siS, ~ not s~S 
c 
c 
iia i I =\) 
~i =:.: : iab f L .. ~ , i fa.: i ) 
p k::'=~. 
j f~ i 1=0 
p:: S : 5 Q.b ·f' (i'~ ' , 'f Q. i I ) 
P k :> ~, k :: ,- ~, 
L: Q. ; I b c a. i ( \/;: , \l~· , ~ .. e t ) 
P ~:: :: = ;'1 ~:: 2: - "- II S 
:a. :! b:;. : !vJ.,v4~ret :~ 
~, ~ :: := , ~1 ~:: 2 -r ~rl '~ 
~~ I t bca. i \v2, 1../3 , t· et > 
p ~" 2:. ~\ k 2: -+ a rl .~ 
(<..11 bca l (vl,.v3 ,re t ~ 











(a l l tr i c a I (v 1 ,v3, vt., ret, tr e ,rt t ,0, 1) 
pr2=c:val 
C ii.1 I t ric a.1 (v 1 ,v3, v6, ret, tr e , r t t ,0,4) 
p,-2= pr2+c:va I 
call trica.1 (vl,v4,v5,ret,tre,rtt,O,3) 
pr2=pr2+cva! 
call trical (vl,v4,v6 ,ret,he,rtt,1,2:) 
pr2=pr2+cval 
cal I tr i c a I (v2, v3, v5, ret, t r e ,r t t ,0,2:) 
pr2=pr2+cva! 
c a. \! t t- 'I ca l (v'., "" ' - .... t - -~.- 1 '"". \ ~,v.,j, Vt, , t e ", t e ,t V", , ..:' I ~r2=pr2+cval 
ca.ll trica.1 (v2,v4,v5,ret,tre,rtt,1,4) 
C- ·-:· , ... 











p l"2~~, t";::+ C va : 
co.ll tr i ca l (v'::- v4 v ': r"" "t"" t"~ ;" ~ 1 \ 
-, , '- ' , ~I.t,v 1;, w~, .L ,"' 1 
pr2=~r2+cva \ 
c calcu lation of p r o~ U s i g, R not s iS, T siS 
c 
c 
call tr i cal (vi ,v4,v7 ,ret ,rq44,z2!'" ,0,1) 
pr3=cva\ 
call hical (vi,v3,v7,ret,rq44,z2 t",0,l) 
pt";::= t' r3- c va. l 
cai I tr i cal (vl,v4,v:::,ret, t"q44,z2r,C.,4 ) 
pr3=pr3+cva. 1 
call h i ca. ! ( v l,v:: , vS,r2~, :"q44,z~r,O.4 1 
pr ::;:= t' r3- eva I 
ca : I tt-ica.l (.'2, v4, v7,n!t,rq44,::2t",O,2) 
~l t- ::;: = ~. r ;::+ c va. l 
( a i I t r-i :a.l (,.' 2,v :;: , v7,re t , r q 4~,z2r, O ,2. ; 
pr ;:= p r ::;:- eva I 
. c. a. \ \ tr i C 0. 1 (v2, v 4 , v::: , ret, rq 4'; , :: 2 r , 1 , :;: ) 
pr :;:: ;:. r3+cva I 
: 2.1 1 t ( ; c a. l ( 'v':, \ !:;; , v ;:~ , ;-e t , r q 4 ~ , z ~. :' , 1 , :;: ; 
p ~- ~~ :: ;J r~: - c \/ a ~ 
~; ·)w ~ ; . i" 1 + ~. ,-::. +;, r:;: 
i f (i. n; . l ) 3.) t (, 
.~ . ,: ~:J C (I r, 't i Ii U ~: • 
. j h a. t =- ,~ h a. t. - ;) • 5 d 0 
~ f ( ~ .. ) w. 1 t . 1 • (} d (.:) 
p c· .... :: 1 . (\;: 0 
42:, cont i rlue 
tern = d " r t"ri 
A .~ •. - \ 
"'·L'.' 
It .",": t: 
.,...:.., ._, 
wr ite(6,430) tem ,p k:,dha t ,po~ 
420 format C4j15.S) 
11 f (lt"fnat (!7h ~'OWH ,d15.~: ,3h ; , :;:(d 15 . : : ,4 :-:) ; 
12 forrnit ~ 11h delta ~st ,4(d15.8,4x)) 
9 for mat (5h d = ,d15.8,5h f = ,d15.8,5h 9 = 
8 cont inue 
st (IP 
en ,j 
.J -i e ,- .\ 
, '..i ~ ".' .. .:,. J 









subroutine trical (ht,kt,mt,rt12,rt13,rt23,ia.,ib) 
i r, t e '3 e r if a ii, i n d • i a. i b , i d , i p I 
d I) ubi e pre I: i 5 i I) n a1, a2 , a3 , b 1 , b 2 , b 3, c 1 , c 2 , c 3 , d 1 , d 2 , d:;: , f 1 , f: , f 3 , 
lel,e2,e3,e4,e5,e6,h,k,m,r12,r13,r23,rcl,rcZ,rc3,biv,del,gt,tt,st, 
Ztri,ans,t,x,xxl,xxZ,cval,p,s15abf,ht,kt,mt,rt12,rt13,rt23 
commo n/blockl/ans,b ~ v,cval,t 
c ommo nf b I 0 C k2i h, k , tTl, rl2, r13, r2:3 
tri=O. OdO 
id=O 
C' .-. , -.':' 











~~::: k t 
rn= :n t 
r Z::::= rt23 
if (ia..eq.O) goto 12 
h=- h 
k ='-k 
m= - rn 
; p != l 
c n (J w m 0 r e -( t h a. n >. i b = 1 f c.;· a. I I < i!:l :: 2 f' CI r x:> i b:::3 of (I r y> i b:: '1 f <:: r Z >-
c 
c 
12 got o (15,D, 14,1:' ) , i b 
1:::: i ~I : =: 
cc. i: swD 
3Ci t; O 15 
1< : ~ , ! <: 
c a.: : sw::'J 
( n,:.w a. : i < (1/'. (I n : .,,, Z.> 
[ 
c 
if (h.lt. ~)) i nd::lrd +l 
if (k . i t. O) i n d = i n \~ + 2 
i f ( i nd ' 8t.4 ) irl l~ = ::: - i nc: 
i p := 4 









· -- ...... 
:f ( i b.eq.1) gc.t o :;:1) 
S·:. t .) (2 1,20 ,20,22), i ne 
::0 j.j =l 
ipl =5 
21 ca.l ) be a. 1 (h, k , t"12> 
tr i =b i v 
i p I =,;. 
got!) 30 
21caI 1 cs::: 
ind=l 
ip l=7 
:;:0 goto (40,32,33,34), i nd 
32 c a II 51.113 
i P I =(;: 
sot !) :::4 






















~ - ~ ~ -- - . . ". . ... ~ - . ........... . . ..... . - ~ - '-- - ." . 
e l l I t ~ - I (h I.- - 1 --:- , d. 1 1.. 4,1 ,~. , I ..I.":" i 
i p ! =9 
if (ic.eq.1> go tc, :::: ' 
tt-i=biv 
9 i) t ( I :: ,~, 
:~:5 t r i = t r i - b i v 
i p : =10 
:36 cal I c s~: 
i~ll ::l 1 
40 xd=1.0jO 
:·: !·~2= 1. Od O 
e1=k-IH'r-12 
e3=h-m*r13 
e4= m- h* ;-' 13 
e5= h-k* r 12 
c !~, = k -m* <:::;: 
O=1.0,jO-d2.* r 12 
f 2=1.0dO -r2:3* ;- 2~: 
n=1.0dO-r1:3*d :3 
n 1 =r 12- d ::;:* ;·-:::;: 
t-e;:: r D- r 12*r 2 ::;: 
r c :;::: r- 2: :~: - ;.-12 * r 1 :;: 
a. ~. :. e i / (h x s q r t ( f 1) ) 
~:::'=e2/ ( k ~- s- q ;-t (f2 » 
a3=e3! (m . sqrt (f3 ) ) 
L. 1 :: e 4 / (h ~- :; q ~- t (n) I 
c 2::'25 i (kx--:, q r ': ( f 1) ) 
( ::;: :: e U ( IT! "' :; q :- t (f 2) ) 
de: =sq r t(fZ- r lZ* r cl- r 13*r c2: 
t,l = (f 1* 24- i" C 3·):· e 1 ) / (e 1 *.~ 2 i ) 
dl =(f3*el-rc3 t e4 ) / (e4*de : ) 
b2= (f2*e5-rc2Ie2)! (e2*de~) 
~2=(fi* E :-rc:~~5~1 (e5*det l 
b3=(f3*2 6 -rclI23)/ { e3*~e l) 




if «x:-;1*><>:2) .ne.l.0dO) 30teo 100 
ifa.i 1=0 




if «x :<1* ;,x2) . ne .1.0dO) sot.:, 105 
~.~ =k 
i hi 1 =0 
c-; 





-..... - . -.. ~.~ . -- . -__ . _·, · __ ....... ·_·.,·c_ ""'" 
p=:;15il.b ·r (::, i fal I) 
3t:3t ... ~' 
101:, :<:< 1 = d;; i gn (:-::-:1 ,a:;:) 
xx2=dsi gn( xx2 , c3) 
. . .. ,. ..- -... ~ .. .. .... .... - .. 
if « ;{xl -l1 ::x2) .ne.l. 0dO) gc,t o 11 0 
~.~ = rn 
ifc. il =:) 
p = s 15 a b f (}: , i fa i I ) 
gt=gt+p 
110 9t=3t/2.0dO 
















call teal <rl,al ) 
tt= tt+t 
call teCi.l (h,el) 
t~=tt+t 
c a i I t eal 0-. , a.2) 
tt = J~~. +t 
call t ea l (k ,c Z) 
tt=tt+t 
call tea t (m,a.:;:) 
tt=tt+t 
cal ! teal (m,e :;;) 
t ':=-tt+·: 
ca. t I sca ~ (h ,'-.l, bl ) 
st =; t +a. n:. 
c. a ll sea! (h , c:. , d) 
st::::;i+a.ns 
e do : I ~ Co a \ (k , a.2 , b2) 
s t =s t+a.ns 
cal i se a l (k ,e 2,dZ) 
s'-:=;t+an s 
ca. l I sea. l (rr. , a:;:,t, ::::) 
s t = s t + a. r. s 
ca.ll sca t (m,c3,d3) 
st=st+ans 
[va.!=gt-tt/Z.OdO-st 
i ~, I =20 
i f (id.eq.U goto 120 
if (tri.ne.O) cval=tr i -cval 
got(l n o 
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i ra i ! =0 
~, =sI5c..bf (): , i fa i !) 
b i v=biv+~, 
;{:::bk 
i of", i 1=:) 
p=s15a.bf (x , i fa i I) 
biv =b iv+p 
b iv=biv/2.0dO 
a ~I = (b k / b h - b t' ) I q t-
cal! teal (bh,ah) 
biv=biv-t 
ak=(bh/bk-br ) /qr 
Cd. I I tea: (b k , ak) 
biv=b iv-t 
if (bh*b kl 11 0 ,1 ~.)(l,120 
100 if (b h+bk) 110, 120, ~20 
110 biv=biv-0.5dO 
120 ans=biv 
ret ur n 
e-nd 
sub r 0) ut i n ~ t ;: a. i (t h:: , t <..2 ) 
in:e3er ifa i! , f : g 
': ,) \.I b i e ~, n ' c is ; (: r: t h , t a , ":; 1,0.' (; P : , :: .) f I , 3 \oJ , t , '.; t , :.,; r; j 3;: , h;: , a. q , : i ~ , c:' :.:. , "":: , a~, , 
1- .-. - -' ~ . - , - .. - - 1:= - t" ~ - ,. .. ~ .-. .;. ~.-:- t , ; ·· , tI~ - " - ! .~ - , s ~ , ~ .,;. , ;:) n ~ C i) n t:' , ~ , '- n , ;.~ , f-I , ':. ... . _ l c... ( . , u , ci n :;, 'j \,. I \ ~ , \,. C!._ , i ", wi i ~ \.. .. c... I 
( ':> [(1:[1 0 n / t. ! ;:. c k : / a.n s , to iv , :: \' a. I I t 
t ~l:::t r. 2 
~ :"';(i p i =6.::::3 1 ;:: 5:30717 ';·S : ~7d( 1 
co)n= t w opi*1~-: 5 ; 2. 0dJ 
b::(. . O,j'::' 
f i 3=O 
.~ 1 = ~) . Oi:iO 
s S r: = ... 1 • ~) l~ 0 
i f (t h ~· 190 , :~:O ~) , 200 
l 'X ) t h= -th 
t=O.OdO 
if (ta) 210,320,220 
210 ta=-ta. 
f13=1 






----. -- -- ...... ~ 






sub ro ut i ne t o swa? \1 \! 1\ u.:: a:. 
sub rc, ut ; ne sloll:::: 
d o ~ ~ l e pr e: i s ion h, k ,~,r12,r13!r23,tm s 
commo n! bloc k2/ h,k,m,r12,r13,r23 








C subroutine to siolap y & ~ 
c 
c 
sutot-out i ne sl..' 2~: 
double prec i s i on h, k,m,r12,r13,rZ3,tms 
common!bloc k2/ h, k ,m,r12,r13, r 2:::: 




t- 2t ui·-n 
2 r. d 
c sub :· (,u ~; i rJe t(! cha;'13 2 s j Sit ( ! f z an d rl :3,t· 2 :=~ 
c 
c 
SL:k (,ut i ne cs :: 
d 0 u~12 pr ec i si on h, k , ~ ,r12,r 1 3,r23 
C I) mrr, ,) f : / t- ! (I C k 2: i h , t.: , ril , r 12 , r 1 :::; , t-2:::: 
rn :: -. in 
r 2:::::: - r2: :::: 
1"2 tU t" n 
end 














subroutine bca. l (bh2,tJ kl,br2) 
inteser ifatl 






























. ~ ,- -_. -- ...... . -' - . .... - .... . ..... " •. _.... ' . :', __ •• ..i_ ~ ...... " . .• ....._. __ ._ .. 
x=wh 
~. ::. S 1 5 a tJ f' (;< , i f a. i I ) 
32: ::.P 
t a::.l. 0c(i / ta 




e :: :..je 1;~' (-h4) 
1oi2 =- h4*e ;.: 
ap=1 .0dO 




se,t o Z·?O 
2;::0 srl=Sp 
sP=s~' +1.0dO 
s2: =s2 -w 2: 
w2:=w2*h4/ ·=.p 
ii~' = - a~'*aq 
290 cn=i~*;Z/ (s~~sp ) 
'O.l=sl+ :: n 
i f (da bs (En) -ccl ne }~:' :;:OG , :-;:OO,2!:::) 
:~: :) :) t= (datan (ta) -t axsi) / t\." ,)~, i 
31 0 t = b ~. :; 3 ; 1 * ·t 
i f (-[! S) ;;:::::') \ ::;::3(, , :315 
:~: lS t:: -t 
j(.t t) 330 
32') t =() . O,j <) 
::;:::;:0 t- e tunl 
2 n (~ 
Sl;kcut i n2 SCi. ] (s h,s3 , b) 
~ :) L: =: I e pre [ j S : (i n a, a. ~ , 5 a.;: , a. i: c , b , ;-e ! ace , S , h ~ I , fun , s 1 5 d. L f , a 1 ~ : '1 <.. ,: :::9 (» , 
It,tt,st,ans,sh,s3,biv, cv a.! 
~ :: t e ~. n a 1 fun 
i ;1 t e 3 e c- i ~. ~ no , r;, i f a i I 
c ,:' rnrrlt:'n/ b I (Ie k 1 I a. n s, b iv ,.: 'I e. I ,t 
(omm on/b l ock3 / S, hh 
r e I acc= ::) .O.jO 
ab=.a.:=1 . i).j-5 
i ~'at" ro=O 




cal I d01arf(a,b,fun,relacc,absac,O,lparm,acc,ans,n, 
1a lpha., ifa.i I) 
i f (lfa.ll.eq.O) gote, 400 
(:- '-
-- - _ _ ..1 _ '-__ .... . ___ • 
c 
....... ..... \:! rt~-e rC -,'? t:}I))- I 'l a 'rl ~ 
stop 
400 retunl 
•• ' , _ "": A.,!. _ '.~ ... :. ~ • • . • " " . " _ _ .' 
';1';'9 format (22h dOla. i-f hi I s. i fa i I = ,i2: ) 

























double ~ r ecisi o n funct i on fun (x) 
do~ble precision x,ta,z,ql,g,hh,s15abf 
~omm0n/b l ock3 ! S,h h 
integer- ifai: 
ta=dsqrt (1+S*3*(1+x*x)) 
;:: = ~I h*t a 
i fa i I = 0 
ql = s15abf' (z, ifai l) 
fur'=ql1 (2i13.14159:}~ta.i\ (1+ :-:*;{)) 
retun l 
e rl oj 
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Derivation of Posterior Distributions for 
the Two-period Cross-over 
AppendiX D i Derivation of Posterior Distributions for 
the Two-period Cross-oyer 
Posterior Distribution of e 
Results given in Lindley & Smith[1972J and 
Smith[1973J state that if Y is a vector of observations 
and e a vector of unknown parameters such that 
Y _. N(Xe, S), where X is a design matrix, and S is the 
variance-covariance matrix of the observations, with 9 
having a prior distri bution specified by 9 ft. If (11, C), then 
the posterior distribution of 9, given X, S, 11, C and Y 
is N(9*, D) with 
e- = D(X'S-'Y + C-'X) and D"" = X'S-'X + C-' 
Since the observations on different subjects are 
independent, the variance-covariance matrix of the 
observations, S takes the form S = to. . 0 
o to. . 0 
O. • 0 t 
where I is a pxp variance-covariance matrix for the p 
observations on a single subject, and 0 is a pxp matrix 
of zeros. Similarly, the design matrix X will consist of 
nl sub-matrices X, followed by nz submatrices Xz for the 
observations for subjects in sequences 1 and 2 
respectively. Hence X'S-Iy = I:Xll:-IYi, and X'S-IX = tXII-IXt 
For the two-period cross-over without carry-over 8' = 
(~'~'~), with ~, = -~2 = x, and ~A = -~. = ~, and 
D-l 
x, =C 1 J L =C 1 -1) -1 
-1 1 
and I 
=c: 2) so that I-I = (1/ ..... ~) ( .. , 0' .. 
0'1 -O'a 
where O'i = O'~ + O'~ and O'~ = 20'~ + O'i 
Hence, for a subject in sequence 1: 
=(YIJI + Y1J2) IO'~ 1 X' I-IX = 
<Y1J1 - Ylu)/O'i 
<YiJl YiJ2) /O'i 
11 <O'iO'n (20'i 0 
o 20'/-
o 20'/-
and for a subject in sequence 2: 
+ Y1J:2) /O'~ X· I-IX = 0 X' E-'Y = \ ( y", 
< yl J 1 - Y1J:2)/O'i 
11 (0'1 .. » (2'" a 
o 20-/- -2O'i 
<-yaJl + Y1J:2) /O'~ 0 -20'/- 2O'i 
so that X· S-IY = 
and X· g-IX = 2 (nl + n2) IO'~ o o 
This allows the calculation of Drl. and hence D, by 
the use of a NAG matrix inversion routine, <fOlaaf or 
f01acf) so that the mean vector Q* of the posterior 
~ b«. ~\CN\"l~. 
distribution for SA Values from this posterior 
distribution are simulated using the NAG routines g05eaf 
and g05ezf. 
D-2 
Posterior Distributions for qj & qi 
New variables, ylJ and ytJ are defined as follows: 
These new variables have the advantage of being 
orthogonal, so that the bivariate normal distribution of 
ylJ and ytJ is relatively simple. Thus 
(Yi J) ... N (11+1') ~ (O'~ 0.) and ytJ }J. 0 O'~ 
where O'~ = 20'a + O'~ 
Using 1:"8 and 1:B" to denote the summation over subjects in 
the AB & BA sequences, respectively, the likelihood for 
the 2N observations on the N subjects can be written in 
terms of these new variables to give : 
Given that the prior distribution of 8, O'~, and O'~ is 
given by: 
where IG<~,~dv) denotes the inverse gamma distribution 
with parameters ~d and ~v, which has a pdf given by: 
D-3 
The Joint posterior distribution is proportional to 
the product of the prior and likelihood given above. The 
conditional posterior distribution of one of the 
parameters, given the values of the others, can be found 
by treating all these other parameters as fixed in the 
expression for the joint posterior. Thus, the posterior 
distribution for ~~, given the values of ~~, a, and the 
observations Y can be obtained by picking out the terms 
involving ~i, and ignoring those that do not. This gives: 
(~il Y, a, O'~) ex (O'V-Otd.+NI2+1) 
*exp[-(d·v· + 21:A8{Y'i.t - (1t+'T)}2 + 21:ludY'iJ - (1t-'T)}2)/2~i] 
Defining SS1 = 21:AB{Y1J -(X+T)}2 + 2l:8j1dY2J - <1t-T)}2, 
this may be written: 
Hence, the conditional posterior for ~~ is an inverse 
gamma distribution with parameters (d. + N)/2 and 
<d.v. + SSt) 12 
Similarly, treatin~ all parameters except ~~ as 
fixed, the conditional posterior for O'~ is obtained: 
(~~I Y, a, O'i> ex (O'~)-(Itd~+NI2+1> 
*exp[ - <d2 v 2 + 21: AS {yl.t - J.l} 2 + 21: .,dylJ - J.l} 2) / 20'~] 
D-4 
conditional posterior for ~~ may be written: 
making the conditional posterior for ~~ an inverse gamma 
distribution with parameters (dz + N)/2 and <dzvz + SSz)/2 
The Gibbs sampler for ~i, ~~, and 8 is thus specified 
by: 
~iIY,9,~~ = IG{~<n+d.), ~(SS, + d.v.)} 
~~IY,9,~f = IG{~(n+dz), ~(SS2 + d2v2)} 
81 Y, ~j, ~~ = N{D(X'S-'Y+C-'X). D} 
Addini Carry-oyer to the Hodel 
(O'i , O'~) 
(O'i , O'~) 
The addition of a first-order carry-over effect a = 
aA = -as, makes comparatively little difference to the 
above derivation. 9 is now a vector of four parameters ~, 
n, T and a, and the design sub-matrices X, and Xz now 
have four columns, with 
X, =(1 1 1 
1 -1 -1 
L =(1 1 -1 0) 
1 -1 1-1 
The variance-covariance matrix t for two observations on 
the same subject is unchanged, so that X't-'Y has an 
extra element, to become a 4xl vector, while X'E-'X has 
an additional row and column, becoming a 4x4 symmetric 
matrix. The additional element for X'~'Y is 
D-5 
U-EASYIJ + E9AYiJ)<.l20'~]/O'i + 1) + O::AlilylJ - ~9AyrJ)}/0'~ 
and the additional column (and row) of X'~lX is: 
( n 1 - n2) I 0' ~ 
( n2 - n 1 ) 10' f 
- (n 1 + n2) 10' i 
{(nl + n2)O'H / (O'iO'~) 
These changes affect the matrix D, and hence the mean and 
variance of the posterior distribution of 6, which is now 
a quadri-variate normal distribution, but the form of the 
mean and variance of this distribution is as before. 
The means for Y'i.i and y2J are now 1t+T-~ and 'JI-1'+~cx 
respectively, and the means for ytJ and Y2~ are }J+~cx and 
}J-~cx respectively, but the variances are unchanged. Hence 
it is necessary to re-define SSI and SS2 as follows: 
SSI = 2~A.{Y'i.i <1t+T-~>P + 2l:8~dY-2J- ('JI-1'+~cx)}2 
SS2 = 2l:A.{yt~ - (J.1+~)};Z + 2l:8"{Y2j - (}J_~CX)}2 
With these changes, the expresssions given above for the 




Derivation of Posterior Distributions for 
the Three-period Two-sequence Cross-over 
Appendix E i Deriyation of Posterior Distributions for 
the Three-period Two-sequence Cross oyer 
Posterior Distribution of e 
For the three-period deSign, it will still be 
assumed that the observations have a multivariate normal 
d1str1 bution <Y -- N<Xe, S», and that the prior 
distribution of e is also multivariate normal 
<8 - N(X, C». Thus the expression given for the 
posterior distribution of e given X, S, X, C and Y given 
in appendix D still applies. e is now a vector of six 
parameters, it now being possible to include a sequence 
effect in the model, and two period effects are reqUired. 
n3 = -(nl + n:z). ~ and a are as defined before for the 
two-period design. 
The design sub-matrices Xl and X2 are now 3x6 
matrices: 
x. = \: 
1 1 0 1 
:r
nd X:z = 
(: 
-1 1 0 -1 0 
1 0 1 -1 -1 0 1 1 -1 
1 -1 -1 -1 -1 -1 -1 -1 1 1 
and 1: = O'~ O'a 
') 0' .. O'a O'i O'a 
:2 :2 O'~ 0' .. 0' .. 
so that I-I = (1/ O'iO'i) O'~ -O'a -O'a 
E-l 
where ~i = ~~ + ~i, ~~ = 2~~ + ~~ & ~~ = 3~ci + ~f 
Hence, for a subject in sequence 1: 
X'I-IY = <YIJl + ylJ2 + Y1J3)/~~ 
<YIJI + ylJ2 + YIJ3>/~~ 
<YIJ1 - YIJ3)/~1 
<Y1J2 - YIJ3)/~i 
<~iYIJI - ~~(YIJ2 + Y1J3»/<~iO'~) 
<YIJ2 - YIJ3)/0'1 
and X'I-IX = 1/ <~i~~) 30'f 30'f 0 0 
30'i 30'2. 0 0 




and for a subject in sequence 2: 
X'I-IY = <YIJ1 + YIJ2 + yq3)/~i 
-<YIn + YlJ2 + YIJ3)/0"~ 
<Y'P - YI13)/O'i 




(-O'iY1JI + 0"~(Y1J2 + Y1J3»/(O'iO'j 
(-YIJ2 + YIJ3)/O"i 








o o 0''; 20'/ o -20'/ 
0 
O'i -O'i -20'~ 0 (30'i+80'3> 0 
o 
E-2 
so that X'S-Iy will be: 
LL (YIJI + ylJ2 + YIJ3)/O'~ 
u: (Y1J'+Y1J2+Y1J3) - I (Y2J'+Y2J2+Y2J3)} IO'~ 
1:1: (YIJl - YiJ3) IO'~ 
II <YiJ2 - YiJ3)/0'~ 
O'U <Y1Jl-y:tJ1> - O'~l: <Y1J2+yq3-Y:ZJ2-y:z.t3> I <0'10'~) 
{l: <Y'J2-Y1J3-Y:ZJ2+Y:ZJ3)} IO'~ 
while X'S-IX is: 
3 (n,+n:z) 3 <n1-n:z) 0 0 - (n,-n:z) 
3 (n,-n:z) 12 3 <n1+n:z) 0 0 - (n1+n:z> 
0 0 2 (n,+n:z) (n,+n:z> 2 (nl-n2) 





- <n,-n2)O'i - (n,+n2)O'i 2 (n,-n:z)w 0 (n1+n:z) (30'j+80'c.n 0 
o o o 
all terms in rows 1 and 2 of the above matrix are divided 
by O'~, all terms in rows 3,4 & 6 by O'i and all terms in 
row 5 by O'jO'i. 
These expressions allow the calculation of Dr1 and 
hence D, as before so that values of the conditional 
posterior for 8 can be simulated. 
Posterior Distribution of gj & g~ 
As before, new variables are defined which will be 
orthogonal. For the three-period design these variables 
are: 
yf.t = (2YIP - yiU - Y&33)/2J3 
YI.l = ~(YiJ2 - YU3> 
E-3 
These three new variable have a tri-variate normal 
distribution, for a subject in the ABB sequence, the mean 
vector is: 
while for a subject in the BAA sequence, the mean vector 
is: 
{31t1 - 41"} 12J3 
for all subjects, the variance-covariance matrix is: 
~ (O'i 0 0 
o O'i 0 
o 0 O'i 
where O'~ = 30'~ + O'i 
In terms of these new variables, the likelihood can be 
written: 
*exp[-I;" •• {yt" - (3}J+3)'-1')}2/O'j] 
*exp[-L6AI\{yt" - (3}J-3)'+1')}2/O'j] 
E-4 
The prior distribution for 8, ri, and r~ is given 
by: 
f (8, ri, r~) = N(X, C) IGOf!d., ~d.v.) IG(~(h, ~d3v3) 
Hence, defining 
SSI = 2EAB.{ylJ - (31t1+4'TP + 2l:BAA{y'fJ - (31t1-4'T)2 
SS2 = 2E" •• {YiJ - (1t1+21t2+2cx)}2 + 2l:8",,{YiJ - (1t1+2'Jt2-2cx)}2 
SS3 = 2l:" .. {ylJ - (3}J+3'¥-T)}2 + 2l:~{ytJ - (3}J-3'¥+T)}2 
it is found that the Gibbs sampler for r~, r~ and 8 is: 
rflY,8,r~ = IG(~(N+d., ~(SSd3 + SS:z + d.v.) 
r~ly.a.ri = IG(~(N+d3, ~(SS3 + d 3v3) 
alY,ri,r~ = N{D(X'S-IY+C-IX),D} 
subject to the restriction that ri ~ r~ 
Adding Second-order Carry-oyer to the Model 
The addition of the second-order carry-over effect ~ 
= ~A = -~B to the model increases the size of a and the 
design matrices Xl and L, and hence X' S-ly and X' S-IX. The 
mean vectors of y*, y- and y. also change, necessitating a 
corresponding change in the definitions of SS" SS2 and 
SS3. These changes are similar to the changes caused by 
introducing first-order carry-over into the two-period 
design, and, as there, do not affect the form of the 




Appendix F Datasets 
Hills & Armitage Enyresis Data 
This data set is given in Hills & Armitage[19791, 
and has been widely used as an example of a data-set from 
the simple two-period cross-over. The data comes from a 
trial of a new drug for the treatment of enuresis, in 
which each of 29 patients were given the drug for a 
period of 14 days and the placebo for a separate period 
of 14 days, with the order of administration chosen 
randomly for each patient. The response recorded is the 
number of dry nights out of 14 for each treatment period. 
Group 1 . drug, placebo Group 2 . placebo, drug . . 
Patient No of dry nights Patient No of dry nights 
Number Period 1 Period 2 Number Period 1 Period 2 
---------------------------------------------------------
1 8 5 2 12 11 
3 14 10 5 6 8 
4 8 0 8 13 9 
6 9 7 10 8 8 
7 11 6 12 8 9 
9 3 5 14 4 8 
11 6 0 15 8 14 
13 0 0 17 2 4 
16 13 12 20 8 13 
18 10 2 23 9 7 
F-1 
19 7 5 26 7 10 
21 13 13 29 7 6 
22 8 10 
24 7 7 
25 9 0 
27 10 6 
28 2 2 
Ebbutt's three-period data 
In his paper on three-period cross-over designs, 
Ebbutt[19841 analysed the results of a trial which 
compared two treatments for hypertension. The trial had 
four sequence groups, ABB, BAA, ABA & BAB but only the 
data for the groups receiving ABB and BAA have been used 
in this thesis. SystoliC and diastolic blood pressure was 
measured in each treatment period, and there was also a 
baseline measurement. Only the data for systoliC blood 
pressure has been used, and these data are given below 
for the ABB and BAA sequence groups. 
ABB Sequence 



















190 170 170 160 
170 174 132 130 
185 175 155 155 
180 154 138 150 
160 160 170 168 
170 160 160 170 
165 145 140 140 
168 148 154 138 
190 170 170 150 
160 125 130 130 
190 140 112 95 
170 125 140 125 
170 150 150 145 
158 136 130 140 
210 150 140 160 
175 150 140 150 
186 202 181 170 
190 190 150 170 
BAA Sequence 























180 180 165 160 
200 170 160 160 
166 140 158 148 
188 126 170 200 
175 130 125 150 
186 144 140 120 
160 140 160 140 
135 120 145 120 
175 145 150 150 
150 155 130 140 
178 168 168 168 
170 150 160 180 
160 120 120 140 
190 150 150 160 
160 150 140 130 
200 175 180 160 
160 140 170 150 
180 150 160 130 
170 150 130 125 
165 140 150 160 
200 140 140 130 
142 126 140 138 
F-4 
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Binary Responses and the Three-period Cross-over 
a.H. MORREY 
Leicester Polytechnic, School of Mathematical Sciences, England. 
Summary 
Problems with carry.overeffects in the simple two-period cross-over have lead to interest in more 
complex cross-over designs. A method for analysing the optimum two·treatment three-period 
design with binary response variables is given by making a simple extension to Gart's logistic 
model. The method gives independent tests for, and estimates of the difference in treatment and 
first-order carry-over effects. An example of the analysis is given, using the loglinear models 
facility in GLIM. 
Key words: Cross-over designs; Carry-over; Binary response variables; Logistic 
models; Log-linear models; GLIM; Clinical trials. 
1. Introduction 
The two-treatment, two-period crossover design has . frequently been used in 
clinical trials to compare the action of treatments which relieve a condition. Some-
times the response observed is dichotomous, typically that the treatment is a 
'success' or a 'failure'. Analysis of such data has been considered by several 
authors, with one ofthe best known expositions by G ART [1969]. Gart uses a logistic 
model for the probability of success in each period with each sequence of treat-
ments. The model uses the parameters 
{J, = effect of ith subject 
A, = period effect 
~ = treatment effect 
Note that p, is the average effect of subject i while the period and treatment effect 
are regarded as deviations from this average with the usual restrictions Al +A,2 = 0, 
8..4 + 8B = 0 so that A = Al = - A,2 and ~ = 15..4 = - c5B. Hence, for patient i in sequence 
one, who receives treatment .A follows by treatment B: 
P (success in period 1 (treatment A)) 
l,+'-+6 
l,~A-6 
P (success in period 2 (treatment B)) = tJ -),-6 
1 +e ( 
40 :Blom. I. 31 (1989) 5 
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Similar expressions can be obtained for subjects in sequence two, who receive 
treatment B in period one and treatment A in period two. 
Writing 0 for 'failure' and 1 for 'success', there are four possible patterns of 
response: 0001 1011. The observed frequencies of these four patterns in sequence 
one will be denoted noo, nOl, nlO and nll respectively, while the observed frequen-
cies in sequence two will be denoted n~o, n~l' n~o and n~l' It is helpful to form a 
score defined as response for period 1 minus response for period 2, which yields 
scores of + 1,0 and -1. For sequence one, a score of + 1 favours treatment A, 
while a score of -1 favours treatment B, with a score of 0 indicating no preference. 
For sequence two, scores of + 1 favour treatment B, and scores of -1 favour 
treatment A. 
The logistic model can be used to obtain expressions for the probability of any 
one of the four patterns of response, and when this is done it is found that apart 
from the normaliSing constant required to make the probabilities sum to one, only 
the probabilities relating to the patterns 01 and 10 contain the parameters ~ and 
A. Thus it seems reasonable to concentrate on those subjects who respond differ-
ently to the two treatments, obtaining a score of + 1 or -1. 
For a subject who experiences success on one treatment and failure on the other, 
the conditional probabjJities of success on treatment A given only one success and 
success in period one given only one success are independent of the subject effect 
{it, and these conditional probabilities can be used to give tests of A = 0 and ~ = O. 
The two-period crossover design becomes difficult to analyse if there is any 
treatment-period interaction. For the two-period design such an interaction is 
usually represented by different carryover effects of the two treatments. Analyses 
of the two-period crossover with continuous data (GRIZZLE [1965], HILLS & 
ARMITAGE [1979]) test for such a difference in carry-over before testing for a 
difference between the treatments because the test for treatment differences is 
only valid if there is no difference in the carry-over from the two treatments. In 
Gart's logistic model there is no parameter to represent carry-over, and so no 
way to test for it. 
2. A Three-period Crossover Design 
Interest in two treatment crossover designs with more than two periods was stimu-
lated by a paper whioh reviewed the properties of such designs (KERSHNER & 
FEDERER [1981]). This suggested that the three-period design in which two treat-
ment groups receive the treatment sequences ABB and BAA respectively is 
particularly efficient in giving estimates of the treatment and carry-over effects. 
It has since been confirmed that this design is the optimal three-period design 
when oarry-over is present (LASKA, MEISNER & KUSHNER [198S]). 
Analysis of this design with a continuous response variable has been dealt with 
elsewhere (MoRBEY [1984], EBBUTT [1984]) and the purpose of this paper is to deal 
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with the analysis of the design with dichotomous responses. Following Gart, a 
logistic model is adopted, but this now includes two parameters for periods (AI, ).2) 
and a term for the carry-over effect of a treatment from one period to the next, 
represented by the parameter c. 
These period and carry-over effects are again regarded as deviations from the 
average subject effect with restrictions AI+A2+As=0 i.e . .As= -AI-Aa and 
CA+CB=O i.e. C=CA= -CB· 
:F'irst-order carry-over takes up one of the two degrees of freedom for treatment 
Xperiod interaction in the three-period design, so there may still be- aspects of 
treatment X period interaction not allowed for in the model. However, it is hoped 
that first-order carry-over would form a major part or any treatmentXperiod 
interaction, and that any remaining interaction would be comparatively uninter-
esting. It would certainly be difficult to interpret. 
Using this model, the probabilities of success in each of the three periods for 
subject i in sequence one are: l,H1 +cI 
P (success in period 1 (treat A)) = /I +.t +cI 
1 +e' I 
Similar expressions can be obtained for a subject in sequence two. 
There are now eight possible patterns: 000, 001, 010, 011, 100, 101, 110, 111; as 
before, the observed frequencies of these patterns will be labelled nooo, nOOl etc. 
for sequence one and n~oo, n~Ol etc. for sequence two. It is again useful to define a 
score, and consideration of the analysis for the design with continuous response 
variables suggests the combination twice period 1 minus period 2 minus period 3 
might be useful. Such a combination yields scores of - 2, - 1, 0, 1 or 2, and pro-
duces a logical ordering of the eight patterns, as shown in table 1. The model can 
be used to give the probability of any of these patterns, and the probabilities for 
subject i in sequence one are also tabulated in table 1. Corresponding probabilities 
for a subject in sequence two would differ in the sign of the terms in fJ and c. 
It can be seen from table 1 that apart from the normalising constant, the term 
for carry-over occurs only in the patterns giving a score of -lor + 1. Thus, by 
concentrating on subjects who obtain a score of -1, or on those who score + 1, it 
may be pOSSible to o,!>tain a test for carry-over. Note that the patterns giving scores 
of -1 and + 1 are of two basic types: type R have a success in period two (010 or 
110), while type S have a success in period three (001 or 101). 
e,h+c 
(1) for sequence 1. p (type R pattern/score = -1) =""7-::-:--~-
eJ.2+o + e-J.t-J.2-C 
(2) for sequence 2. p (type R pattern/score = -1) 
40· 
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Table 1 
Soares for eaoh pattern, and probabilities for subjeot i in sequenoe one. 
Note: k=[l +exp (Pi +1.1 +15)] [1 +exp (PI -1-1.2 -15 +c)] [1 +exp (Pi -AI -1.2 -15 -c)] 
soore pattern observed implication for Probability for subject i 
frequenoy in sequence 1. 
seq 1 seq 2 sequence 1 sequence 2 
n011 
most most 1 
-2 011 non favours B favours A k exp (2Pt- At- 2t5) 
nOlO 
1 
010 nolO k exp (Pt -1-1.2 -15 -I-c) 
1 favours B favours A 
001 nool nool 
1 k exp (P, -AI -1.2 -15 -c) 
000 nooo noon 
1 
k 
0 no preference no preference 
ntH 
1 
111 nUl k exp (3P,-t5) 
110 nllo n'11o 
1 k exp (2Pt -1-1.1 -1-1.2 -I-c) 
1 favours A favours B 
niDi 
1 
101 nlOl k exp (2P,-A2- C) 
nioo 
most most 1 
2 100 nloo I favours A favours B k exp (Pd-AI -1-15) 
Clearly, the above expressions are identical if there is no difference in the carry-
over effect of the two treatments, making c = o. Thus a test for carry-over can be 







Alternatively, considering only subjects who score + 1 : 
(3) for sequence 1: p (pattern type R/score = + 1) 
(4) 
eA2- C 
for sequence 2: p (pattern type R/score = + 1) = A C A A + e. +e I • C 
These oonditional probabilities are identioal to the previous two, providing not 
only an alternative test for carry-over, but also presenting an opportunity of 
testing whether the underlying model is reasonable. The 2 X 2 X 2 contingenoy 
table: 
Biorn. J. 31 (1989) 5 
sequence 
score = -1 I 1 2 score = + 1 
sequence 
1 2 
pattern R I nOlO n~lO pattern R nuo n~lO 
type S n001 n~01 type S nm n~01 
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could be analysed using a log-linear model in which terms for sequences, scores 
and patterns are fitted. Since conditional probabilities (1) and (3), and (2) 
and (4) above are identical, it is clear that the model is specifying that there will 
be no three-factor interaction or interaction between patterns and scores. Testing 
for these interactions is thus a test of the underlying model. If c = 0 the conditional 
probabilities (1), (2), (3) and (4) are all equal, and there is no interaction between 
patterns and sequences, so testing for this interaction gives a test of carry-over. 
It is possible to obtain an estimate of c by equating the expressions for the prob-
abilities in equations (1) to (4) with the corresponding observed relative frequen-
cies. Since the expressions in (1) and (3) and in (2) and (4) are identical the two 
relative frequencies should be combined in some way. The ideal would be to 
weight them by the inverse of their standard errors, but this is not possible as the 
standard errors contain the parameters being estimated, so a more ad hoc method 
must be used. The two obvious possibilities are to average the two relative fre-
quencies, or to add the numerators and denominators. The latter method results in 
a simpler expression for the estimate of c, and seems the more preferable, giving 
n010+n110 e"'+c 
as an estimate of 
nOlO + nOO1 + 11 110 + n 101 el.,+c +e-I.,-I..-c 
and 
, , 
nOl0+ n 110 




cA,+c + e A'-A' c e,h-c + e-A'-A'+C 
L l-M 4c 
it is easy to see that 1-L ~ =e so that the required estimate of cis 
A _.: I {nolO + nUO . n~01 + n~01} 
c- n " 4 n001 + n101 nOlO + nuo 
From table 1 it can be seen that apart from the normaliSing constant, the term 
for treatment effect in the model appears in the probabilities for the patterns in 
which there is just one success: 010, 001,100; and in the pattern giving a score of 
-2 (011). The term also appears in the probability for the 111 pattern, but this 
information about lJ is difficult to retrieve. Concentrating on those patterns with 
just one success, we have the conditional probabilitities: AI+6 
for sequence 1 : p (success in period 1 / 1 success) = ,_-:--:e-:--_--:--:--~ 
e"IH + eA,-HC + e-AI-A,-6-C 
for sequence 2: p (success in period 1 /1 success) 
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Clearly these conditional probabilities are equal if lJ and c are both zero so that 
testing the equality of these would test whether lJ = 0 if the previous test showed 
that c = O. However, it would be preferable to obtain a test of lJ = 0 allowing for 
the effect of first-order carry-over. 
The maximum likelihood estimators of the above conditional probabilities will 
be the observed relative frequencies . 
, 
nlOO nlOO 
and, I I 
nlOO + nOlO + nODI nlOO + nOlO + nOOI 
if these estimators are equated with the expressions for the conditional probabili-
ties that they estimate, an algebraic simplification can be made yielding: 
nOlO + nOOI "I+oJ 
e . 
nlOO 
dividing these gives 
(5) 
Similarly, if the patterns giving exactly two successes, or just one failure, are 
considered, we can obtain the conditional probabilities: 
e-).1-26 
for sequence 1: p (failure in period 1 )1 failure) = -,1.1-26 + AI+AI+C + -AI-C 
e e e 
e-).1+26 
for sequence 2: p (failure in period 1 )1 failure) = e-.l.t+26 +eAIH2-C +e-,1.2+C 
Again, equating these to the observed relative frequencies which estimate them 
and simplifying gives: 
for sequence 1: nno+nlOI e-).1-26 =eA1 (e).2+C +e-AI-A2-C) 
non 
, I 
for sequenoe 2: nllO ;-n101 e-AI+2"=e.l.t(eA2-C+e-AI-A2+C) 
nOll 
dividing these gives: 
(6) e-46 (nno + nlOI ) n~ll = e).'+o + e-).I-A2-
C 
n~IO + n~Ol nOll eAa- C + e-.l.t-A2+C 
If 6=0 the L.R.S. of equation (5) is equal to the R.H.S. of equation (6), implying 
that: 
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The equality of these ratios is therefore a test of ~ = O. This can be tested by 
testing the three-way interaction in the 2X2X2 table: 
1 success 
sequence 
1 2 1 failure 
sequence 
1 2 
, I , , 
in per no nOlO + nOOl nOlO + nOOl in per no nlOl + nllO nlOI + nllo 
1 ~ yes nlOO n~oo 1 ~ yes nOll n~ll 
Note also that the period X sequence interaction is also a test of ~ = 0 if there is 
no first-order carry-over effect i.e. c = O. 
An estimate of ~ can be obtained from the expressions (5) and (6) above. From 
equation (5) 
e46 = {e}'2+C + e-;"-;'l-C} -:- {n~lO + n~Ol . n~oo} 
eAl-C+e-At Al+C nOlO+nOOl nlOO 
while equation (6) gives 
3. Example 
The ease with which these tests can be applied can be seen by conSidering their 
use with a set of data. The data used here are the expected frequencies, rounded to 
the nearest integer, obtained by using the linear model for the logits given above 
with parameter values A1=0.2, "'2=0.3, ~=0.5 and c=0.6, and assuming N= 
=N'=20. 
response 000 
observed seq. 1 (ABB) 5 
freq. seq. 2 (BAA) 4 
100 010 001 
430 




101 011 111 
111 
243 
Note that if the usual two-period crossover had been undertaken the following 
responses would have been observed: 
response I 00 01 10 11 
observed seq. 1 (AB) 





Gart's tests would then give: 
for treatment effects 
x2=O.9 (not sig) 
success per. 1 





seq. 1 (AB) 
5 
4 
seq. 2 (BA) 
3 
6 
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for period effect 
X2=0.23 (not sig). 
seq. 1 (AB) seq. 2 (BA) 
success treat A 5 
on treat B 4 
6 
3 
It is of particular interest that Gart's test fails to detect "the difference in 
treatments. 
Using the proposed new tests with the data from all three periods, the first 
2 X 2 X 2 contingency table to be considered is 
score = -1 
pattern R 
8 
seq. 1 seq. 2 
3 2 
o 3 
score = + 1 
pattern R 
8 





This was analysed using a log-linear model fitted by GLIM with the three fac-
tors sequence (Q), score (8) and Pattern (P). This gives the following scaled devian-
ces: 
3 - factor interaction = 0.56453 
pattern x score interaction = 0.3435 
i.e. 0.90805 on 2 dJ. (not sig) 
Recall that the non-significance of these two interactions is a test of the model, 
which in this case is known to be approPJiate as the data was generated from it. 
The test of carryover is based on the pattern X sequence interaction which has a 
scaled deviance of 5.21 on 1 d.f. (sig at 5%). Thus the test correctly detects the 
presence of carryover. 
The estimate of the carryover effect e is 
-In --'-- =0.6476 1 {3+5 3+2} 
4 0+1 2+1 
This may seem a rather poor estimate of the true value of 0.6, but it must be 
remembered that the true expected frequencies have been rounded to the nearest 
integer, which causes the inaccuracy. 
The second 2 X 2 X 2 contingency table is as follows: 
sequence sequence 
1 success 1 2 1 failure I 1 2 
in per no 3 5 in per no I~ 3 1? yes 4 1 1? yes 4 
This has again been analysed by fitting a log-linear model using GLIM in which 
the three factors sequence (Q), success/failure (8), and period (P) are used. 
The three-factor interaction is a test of treatments and the scaled deviance for 
this is 5.279 on 1 d.f. (sig. at 5%) so that the test again correctly detects the pre-
sence of a treatment effect. 
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The estimate of the treatment effect 8 is • 
1 {(5+1) 4} {(3+0) I} ~ln (1+2)·1 7 (2+3) ·4 =0.497 
gratifyingly near to the true value of.0.5 in spite of the innaccuracies introduced by 
rounding the expected frequencies. 
4. Discussion 
In this paper, Gart's logistic model for the two-period crossover has been extended 
to the three-period crossover. Gart's model has individual subject parameters {h, 
which will accommodate any dependency between the observations on the same 
subject, whereas a recent paper by KENWARD & JONES [1987] uses a parameterisa-
tion with specific terms in the model to describe the within-subject dependency 
structure. This latter type of model could be used for the three-period design, but 
it was felt that Gart's parameterisation, was more intuitive. 
The drawback with Gart's model for the two-period crossover and to some ex-
tent the design itself is that no test of carry-over is possible, although it is well-
known that any test of treatments is invalid if difference in carry-over exists. 
HILLS and ARMITAGE [1979] do give a test for carry-over for the two-period cross-
over with binary data, and although no formal justification of the test is given, 
KENWARD & JONES [1987] have subsequently shown that it does test for differ-
ence in carry -over in the two groups. HILLS & ARMITAGE reason that carry -over will 
tend to alter the average number of successes in the two groups, and hence the 
relative proportions of subjects giving responses 00 and 11. This is also the basis 
for the corresponding test with continuous response variables, which is known to 
lack power (BROWN [1980]), so that the test for binary data is also likely to be 
weak. More important is the fact that the test for carry-over is essentially a pre-test 
which must give a nonsignificant result if the test for treatments is to be valid. The 
three-period crossover avoids this difficulty, allowing a test for treatments which 
, is valid even if there is a difference in first-order carry-over, and hence is tp be 
preferred. It is hoped that, by showing that tests for the three-period design can be 
simply performed using log-linear models, this paper will encourage the use of the 
three-period design. 
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